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The loss and dysfunction of selected populations of synapses is characteristic of 
mammalian brain ageing and alterations in these receptive compartments are 
considered to underpin age-related cognitive decline. Discrete neuroanatomical 
regions of the cortical architecture harbour disparate populations of synapses that 
demonstrate significant heterogeneity with regards to advancing age. Of particular 
interest is the hippocampus, which is selectively vulnerable during ageing. The 
hippocampal synaptic architecture exhibits subtle structural and biophysical 
alterations, which are considered to promote the manifestation of cognitive 
symptoms in aged patients. This notion of “selective synaptic vulnerability” has been 
the focal point of a multitude of morphological studies investigating age-related 
cognitive decline, which have often provided tentative conclusions as to how this 
phenomenon may be regulated. The molecular correlates bolstering the reported age-
dependent morphological and functional shift remain elusive and studies are only 
now beginning to unravel how discrete organelles, proteins and signalling cascades 
may hierarchically or synergistically attenuate synaptic function. Until there is 
considerable comprehension of how functional mediators drive the biochemical 
substrates regulating age-related cognitive decline, there are limited strategic avenues 
for the development of efficacious therapeutic interventions that promote successful 
ageing.  
To address the phenomenon of selective synaptic vulnerability, we have utilised an 
unbiased combinatorial approach, including quantitative proteomic analyses coupled 
with in vivo candidate assessments in lower order animals (Drosophila), to 
temporally profile regional synapse and synaptic mitochondrial biochemistry during 
normal healthy ageing. We begin by demonstrating that cortical mitochondria 
located at the synaptic terminal are morphologically distinct from non-synaptic 
mitochondria in adult rodents and human patients. Biochemical isolation and 
purification of discrete mitochondrial subpopulations from control adult rat forebrain 
enabled generation of synaptic and non-synaptic mitochondrial molecular 
fingerprints using quantitative proteomics, which revealed that expression of the 
mitochondrial proteome is highly dependent on subcellular localisation. We 
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subsequently demonstrate that the molecular differences observed between 
mitochondrial sub-populations are capable of selectively influencing synaptic 
morphology in-vivo. Next, we sought to examine how the synaptic mitochondrial 
proteome was dynamically and temporally regulated throughout ageing to determine 
whether protein expression changes within the mitochondrial milieu are actively 
regulating the age-dependent vulnerability of the synaptic compartment. Proteomic 
profiling of wild-type mouse cortical synaptic and non-synaptic mitochondria across 
the lifespan revealed significant age-dependent heterogeneity between mitochondrial 
subpopulations, with aged organelles exhibiting unique protein expression profiles. 
Recapitulation of aged synaptic mitochondrial protein expression at the Drosophila 
neuromuscular junction has the propensity to perturb the synaptic architecture, 
demonstrating that temporal regulation of the mitochondrial proteome may directly 
modulate the stability of the synapse in vivo.  
 
Although we had comprehensively characterised the temporal regulation of rodent 
cortical mitochondrial subpopulations, providing a number of novel candidates that 
may be mediating synaptic vulnerability during ageing, we sought to establish 
whether similar alterations were occurring in the primate brain. Using synaptic 
isolates from neuroanatomically distinct age-resistant (occipital cortex) and age-
vulnerable (hippocampus) regions, we demonstrate that synaptic ageing is brain-
region dependent and that discrete populations of synapses significantly differ at a 
biochemical level in the healthy human and non-human primate brain. Recapitulation 
of aged hippocampal protein expression with genetic manipulation in vivo revealed 
numerous novel candidates that have the propensity to significantly modulate 
multiple morphological parameters at the synapse. Furthermore, we demonstrate that 
several of these candidates sit downstream of TGFβ1 and activation of the TGFβ1 
signalling cascade in hippocampal synaptic populations drives the aberrant 
expression of selected candidates during ageing. Finally, we show that selective 
pharmacological inhibition of this pathway rescues synaptic phenotypes in multiple 
candidate lines. The data affirmed that activation of the TGFβ1 transduction pathway 
modulates synaptic stability and thus may contribute to the selective vulnerability of 
hippocampal synapses during ageing.  
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Lay Summary 
Ageing is a natural and inevitable part of life, and our society is currently shifting 
towards an aged population. While ageing affects all cells in the body, its 
advancement can vary significantly between individuals and even differently within 
organs. Although many of the cellular changes that occur throughout the lifespan are 
considered normal, they also represent a major risk factor for disease. It is well 
established that aged individuals are more vulnerable to the development of disease 
but basic questions remain unanswered. For example, it is unclear what triggers the 
development of disease and how age may change our vulnerability to these 
processes. There is therefore a vital need to understand what distinguishes ‘normal 
healthy’ from ‘pathological’ ageing.  
 
The brain is organized into many different regions, containing billions of highly 
interconnected nerve cells, called neurons. As we age, the brain loses some of the 
connections between cells, or synapses, which compromises neuronal function.  
Importantly, the loss or alteration of synapses occurs more frequently in certain brain 
regions as we age. For example, in aged individuals there appear to be large numbers 
of changes in synapses that populate a brain region called the hippocampus. This 
area is a major site of memory storage and synaptic alterations in the hippocampus 
often underlie age-related memory changes. However, there is little understanding as 
to why particular populations of synapses are vulnerable to age-related changes.   
 
To address the question of synaptic vulnerability, we characterised the molecular 
changes occurring in synapses during normal healthy ageing. The study made use of 
both rodent brain tissue and archived, frozen non-human primate brain samples, from 
young adult, middle-aged and old healthy control animals. Non-human primate 
tissues were used due to the close genetic relationship to humans, which might 
provide results more relevant to human ageing. By isolating synapses from specific 
brain regions we were able to track particular molecular trends that may be 
associated with normal healthy aging or increased vulnerability to disease. With the 
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use of computer tools, we were able to identify candidate protein molecules that may 
be contributing to synaptic vulnerability during ageing.  
 
In order to actively test the role of candidate protein molecules that change with age 
and affect synaptic vulnerability, we took advantage of the fruit fly model, as the 
basic structure of synapses is present in the nervous system of all animals. By using 
fruit flies as a convenient experimental tool, we could quickly establish whether 
changing the amount of specific proteins we identified from our rodent and non-
human primate experiments can directly influence synapse form or function. By 
using this variety of techniques, our study has identified several new molecules that 
may affect the vulnerability of synapses during aging.  
 
These findings provide new insights into how synapses age and how changes in the 
amount of specific proteins can influence the vulnerability of the synapse. This may 
be important for the early detection of degenerative disease and open up new 
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Chapter 1. Introduction 
 
1.1 Ageing: a global epidemic? 
 
Population ageing has become a twenty-first century global phenomenon. There has 
been a dramatic demographic shift worldwide and recent reports have highlighted 
that the number of individuals aged 80 years or over has increased by 76% since the 
year 2000 (1). Although this increase in lifespan may be deemed somewhat 
triumphant, reflecting superior healthcare strategies, technological advancements and 
innovative scientific discoveries, the prevalence of dementia and age-related 
cognitive decline is irrepressibly escalating. The significant surge in individuals 
afflicted with alterations in cognitive capacity poses an enormous societal, emotional 
and economic burden, accruing care costs upwards of $8 billion per year in the UK 
alone (2). This is projected to increase by up to 300% in the upcoming decade 
indicating an impending public health crisis (1, 2). With substantial healthcare 
challenges imminently approaching there is an urgent requirement for efficacious 
treatments that promote successful ageing.  
Advancing age is the single largest risk factor for the development and diagnosis of a 
neurodegenerative disease. How the dichotomous pathways regulating normative 
ageing and pathogenic ageing intersect remains elusive, however investigating 
spatiotemporal changes in the “normal” central nervous system (CNS) milieu may 
reveal molecular pathogenic precursors that have the propensity to significantly 
perturb neuronal structure and function. As humans age, the brain exhibits subtle 
cellular and molecular alterations that progressively impair neuronal receptivity to 
novel stimuli and enhance susceptibility to pathogenicity. These physiological 
modifications manifest as a selective decline in multiple cognitive faculties, 
particularly those regulated by the hippocampus e.g. executive function, short-term 
memory capacity and retention of novel information (3-5), causing patients 
significant concern. Until recently, age-related cognitive decline was purportedly an 
inevitable component of normative ageing, however emerging evidence suggests that 
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the trajectory of ageing displays significant malleability (6-8). The advent of 
genomic, transcriptomic and proteomic technologies has enabled the identification of 
discrete signalling cascades, effector molecules and genetic transcripts that alter 
during the lifespan suggesting cognitive preservation via the manipulation of 
molecular mediators may be a tangible possibility. Although an auspicious notion, 
investigations have detected exceptionally few functional mediators capable of 
modulating or ameliorating age-related cognitive decline in vivo (7). Identification of 
such functional mediators is a critical junction that must be resolutely attained in 
order to provide mechanistic insights into the disrupted molecular pathways that may 
be constitutively promoting age-dependent cognitive decline and/or pathogenic 
neurodegenerative cascades. Until there is considerable comprehension of how 
functional mediators hierarchically or synergistically drive the biochemical 
substrates regulating age-related cognitive decline, there are limited strategic avenues 
















1.2 The synapse 
 
1.2.1 Synaptic morphology  
The brain is a highly complex and sophisticated structure composed of vast 
interconnected circuitries that regulate all aspects of learning, memory, emotion, 
perception and behaviour. Studies estimate that the human brain harbours over a 
trillion neurons (1012) and in excess of a quadrillion synapses (1015 (9)), reflecting 
the architectural intricacy of the central nervous system milieu. The ultrastructural 
morphometric conformation of the neuropil is incredibly diverse, often indicating 
specialised functional roles (i.e. brain region or structure specific) and adaptive 
plastic alterations accrued throughout the duration of the lifespan (10-12). Of the 
neuropil compartments, synapses are perhaps the most fascinating structures owing 
to their dynamic roles in electrochemical neurotransmission, activity-dependent 
plasticity and the pathogenesis of numerous neurodegenerative diseases (13, 14). 
Synapses, in the simplest sense, are structurally and biochemically unique bulbous 
swellings located at the distal ends of axons or on branched dendritic segments (15, 
16). The synapse requires two functional partner domains: the presynaptic 
compartment and the postsynaptic terminal, which form of an intercellular adhesive 
junction (∼20nm wide) facilitating rapid and synchronous transmission of the action 
potential between neurons (10, 15). Signal transduction involves the Ca2+-dependent 
fusion and exocytosis of neurotransmitter-rich vesicles from the presynaptic plasma 
membrane into the synaptic cleft, which bind and activate corresponding receptors 
expressed on the postsynaptic membrane. This highly efficient signalling cascade is 
strictly regulated by the presynaptic active zone – a dense filamentous matrix 
contiguous to the plasma membrane that orchestrates vesicular endocytosis, docking, 
priming and mobilisation in preparation for release (9, 16-19). The active zone is 
situated in close apposition to the postsynaptic density (PSD), which harbours 
myriad receptors, ion channels, scaffolding proteins and effector molecules (20), 




Ultrastructurally, synapses demonstrate distinct morphological markers revealing 
disparate cardinal functions. Excitatory (asymmetric) synapses are typically located 
on dendritic spines and exhibit an extensive and illustrious PSD, comprising 
ionotropic (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), N-
methyl-D-aspartate (NMDA), kainate) and metabotropic glutamatergic receptors, 
PDZ-domain proteins (PSD-95, Discs-large, Zona occludens-1), adhesion molecules 
and cytoplasmic signalling proteins (20, 21). The unique morphological properties of 
excitatory synapses enables activation of numerous synergistic inter- and 
intracellular glutamate-dependent signalling cascades, which have the propensity to 
instigate dynamic alterations in synaptic transmission efficacy via the induction of 
long-term potentiation (LTP) or long-term depression (LTD) – processes crucial to 
learning and memory formation ((22, 23) discussed in further detail in section 1.2.4). 
Conversely, inhibitory (symmetric) synapses differ in morphometry and 
neurotransmission signalling cascades. These synapses appear to primarily occupy 
the dendritic shaft and inputs surrounding the axonal cell body and demonstrate a 
significantly less dense PSD coupled with smaller ovoid presynaptic vesicles (10, 
21). Despite the PSD expressing scaffolding and adhesion molecules homologous to 
excitatory synapses, the inherent receptor subtypes anchored to the postsynaptic 
membrane are functionally regulated by the neurotransmitters gamma-aminobutyric 
acid (GABA) and glycine (21). Signal transmission by either GABA or glycine does 
not appear to stimulate analogous LTP- or LTD-dependent synaptic alterations 
observed at glutamatergic synapses however, evidence suggests these synapses 
demonstrate a discrete form of inhibitory plasticity mediated by varied ion channels 
(e.g. Cl- channels), substrates (e.g. endocannabinoids, nitric oxide) and molecular 
mechanisms (this will not be discussed in further detail but for a comprehensive 
review see: Castillo et al (24)).  
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Figure 1: Electron microscopy images demonstrating the unique morphology of 
excitatory and inhibitory cortical synapses. A. Example image of an excitatory 
(asymmetric) synapse in the wild-type (WT) mouse cortex. The electron dense PSD is 
indicated by the white arrow. Note the presence of clear spherical vesicles in the pre-
synaptic compartment. B. Example image of an inhibitory (symmetric) synapse in the WT 
mouse cortex. The white arrow denotes the PSD, which is visibly less dense than the 
analogous structure located on the excitatory synapse. The pre-synaptic terminal harbours 




1.2.2 Regulation of the synaptic milieu  
Diversity in synaptic structure is strongly indicative of function and the two must 
demonstrate considerable synergy to promote synaptic and neuronal homeostasis. 
The functionality of both excitatory and inhibitory synapses is profoundly affected 
by the structural architecture and morphology of the synaptic milieu and aberrant 
regulation of this spatial organisation through a wide range of insults may result in 
synaptic demise (see section 1.3). Although there are a plethora of converging 
cascades mediating trophic factors essential for synaptic stability, the longevity of 
neurons poses considerable challenges for the maintenance of an intracellular 
equilibrium. Unlike peripheral cells, which display significant regenerative 
capacities, the majority of neurons present in the CNS subsist throughout the 
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duration of the lifespan, requiring proficient synaptic function for decades (25). The 
average synaptic terminal boasts approximately 300,000 functional proteins (26), 
comprising multiple copies of those that are essential for compartmental stability, 
neurotransmission, vesicular-recycling and signalling cascades. Accordingly, this 
synaptic protein compendium must be dynamically and strictly regulated to ensure 
optimal functional capacity persists throughout the lifetime of the organism. 
Although the synaptic compartment demonstrates considerable resilience to intense 
electrochemical activity, the intracellular environment is often hostile, with regular 
and significant increases in free Ca2+ ions, protons and reactive species that have the 
propensity to promote protein damage and dysfunction (27). Failure to remove and 
replenish defective proteins may result in the accumulation of dysfunctional 
organelles, machinery and macromolecular complexes promoting synaptic 
destabilisation and concomitant perturbations in the neuronal milieu. Thus, to sustain 
long-term synaptic structure, function and viability, neurons have developed multiple 
strategies for the synthesis, delivery and removal of proteins to promote proteostasis 
in discrete neuronal compartments (25, 27, 28).  
 
1.2.2.1 Axonal transport and local protein synthesis 
Regulation of the synaptic proteome is a complex event due to the vast distances 
(often >100 µm, but up to 1 metre) between synaptic terminals and the protein 
synthesis machinery located in the cell body (28). A large number of synaptic-
specific proteins and compartmental constituents (e.g. mitochondria and vesicles) are 
pre-assembled in the cell body (29) and transported along the length of the axon to 
support continuous replenishment of the protein pool and dynamic functional 
adaptations of the synapse in response to external stimuli (30). Termed “axonal 
transport”, this active delivery system enables the binding of molecular cargo to 
motor protein complexes that travel along two types of polarised cytoskeletal 
structures: microtubules and actin filaments. Microtubules typically facilitate long-
distance transport of synaptic cargoes to and from the dendritic shaft via two families 
of motor proteins: kinesins - which regulate anterograde movement and dyneins - 
which facilitate retrograde movement (31). Conversely, actin filaments utilise 
myosin complexes for short-range trafficking and local delivery of cargo to dendritic 
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spines, where microtubular networks are sparse. The localised expression of the 
microtubule and actin networks promotes synergistic proteostatic regulation of the 
synaptic milieu at the spino-dendritic interface, which supports important 
compartmental functional cascades such as stability, activity and plasticity (31, 32).  
 
Although modulation of the synaptic proteome by axonal transport is an important 
mechanistic pathway for the delivery of cargo to synapses, the morphological 
expanse of individual neurons suggests that conveyance of all molecular material 
would be unfeasible. Axonal transport is a relatively slow process moving at 
approximately 1.2 µm/second (30), meaning that the duration between the 
requirement and delivery of essential proteins involved in the dynamic adaptation of 
the synaptic compartment may be hours, or even days. In conjunction, multiple 
synaptic proteins display transient half-lives, which suggests that long-range 
transport would be an unsustainable mechanism for the delivery of functional 
proteins (30). Thus, it seems probable that synaptic compartments require additional 
machinery for autonomous regulation of dynamic protein turnover. Indeed, it is now 
widely recognised that axons and synapses are capable of local protein translation, 
providing rapid activity-dependent spatial and temporal regulation of proteostasis 
within the synaptic compartment (25, 27, 28, 33). Axonal segments in apposition to 
synapses harbour local protein translation machinery, including ribosomes (34) and 
elongation factors (35), in addition to mRNA transcripts for large numbers of 
presynaptic proteins (36, 37), which enables near-instantaneous protein expression in 
response to synaptic activity. Interestingly, discrete populations of synapses from 
anatomically distinct cortical regions demonstrate varied levels of local translational 
machinery (33, 38) suggesting that there may be differential mechanistic regulation 
of the synaptic proteome throughout the cortical architecture dependent on synapse 
localisation. Although not thoroughly explored, this may have vast implications for 
the modulation of synaptic proteostasis in ageing and disease states, particularly with 
regard to selective synaptic vulnerability (discussed further in section 1.3.1). Whilst 
the underlying mechanisms of local synaptic protein translation remain unresolved, 
questions persist as to whether synapses also harbour local protein degradative 
cascades to enable rapid equilibration of intracellular protein concentrations.  
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1.2.2.2 Protein degradation pathways 
Alongside protein synthesis cascades, neurons also possess two major protein 
degradation pathways – the ubiquitin-proteasome system (UPS) and the autophagic-
lysosomal system – for selective removal of damaged cellular components and 
maintenance of synaptic health ((39, 40) Fig. 2). Although inter-dependent 
configurations (39), each exhibits discrete functional roles and divergent mechanistic 
cascades to facilitate targeting of proteins and organelles to the appropriate 
proteolytic machinery. The UPS typically degrades the majority of short-lived 
soluble intracellular proteins found at synaptic terminals by selectively tagging and 
transporting substrates to the 26S proteasome (40, 41). This occurs through a 
succession of enzymatic reactions regulated by activation (E1), conjugation (E2) and 
ligase (E3) enzymes, resulting in covalent modification of the target protein via the 
conjugation of a polyubiquitin chain to acceptor lysine residues (41-43). Once 
polyubiquitinated, E3 ligases and associated chaperone molecules shuttle the proteins 
to the proteasome where protein unfolding, proteolysis and deubiquitination 
pathways yield constituent peptides and free ubiquitin molecules, which are recycled 
by the neuron ((41, 43, 44) Fig. 2A&B). Although the ubiquitination of proteins is 
traditionally associated with the UPS catabolic cascade, recent evidence has 
suggested that ubiquitinated substrates may also be selectively targeted to and 
degraded by the lysosome (39, 45). Lysosomal-mediated autophagy is the primary 
macroautophagic mechanism employed by the neuron for the degradation of large 
structural molecules, insoluble proteins (misfolded, oligomerised, aggregated) and 
cellular organelles, such as mitochondria (41, 44, 46). The canonical autophagic 
cascade involves the sequestration of cytoplasmic substrates into a dynamic double-
membrane bound vesicle termed an autophagosome, which then fuses with the 
lysosome for acidic hydrolysis of the engulfed contents ((27, 41, 44) Fig. 2C). The 
resulting amino acid products are subsequently trafficked from the lysosome to the 
intracellular amino acid pool for de novo protein synthesis (27), mediated by the 
cascades described in section 1.2.2.1. Appropriate targeted degradation of local 
substrates by autophagy is a vital mechanism preventing the accumulation of 
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synaptotoxic proteinaceous inclusions characteristic of pathological 
neurodegenerative conditions.  
 
Although the notion of local synaptic degradation has traditionally been a 
contentious issue, recent evidence has reported the presence of biochemically and 
functionally unique proteolytic machinery at synaptic terminals (27, 41, 47). 
Multiple investigations have demonstrated that coordinated proteolysis is a 
fundamental mechanism facilitating plasticity at cortical synapses (see section 1.2.4) 
via alterations in the pre- and postsynaptic protein complement (Fig. 2D). Indeed, 
studies examining the role of the UPS in the regulation of synaptic transmission 
report activity-dependent translocation of the proteasome to the postsynaptic 
compartment mediated by the binding of glutamate to NMDA receptors. The 
proteasome locally acts to promote the ubiquitination and internalisation of 
transmembrane AMPA receptors (48), which concomitantly modulates synaptic 
efficacy by inducing LTD cascades ((41, 48, 49) discussed in section 1.2.4). 
Internalisation of AMPA receptors and induction of LTD may be modulated by 
application of proteasome inhibitors (49), suggesting that the UPS is actively 
regulating the strength of synaptic transmission via the ubiqutination of intracellular 
and transmembrane substrates ((41) Fig. 2D). Similarly, acute neurotransmission 
activity also facilitates the transient upregulation of autophagosomes and lysosomes 
in the pre- and postsynaptic compartments, which promotes the rapid engulfment of 
selected internalised AMPA receptors (27, 48, 50) and rejuvenation of the active 
zone vesicular pool (27, 42). Application of autophagy inhibitors to neurons in vivo 
elicits reductions in synaptic vesicle number, neurotransmission and induction of 
plasticity cascades (42, 51), suggesting that local autophagic regulation of the 
synapse is a fundamental cascade bolstering synaptic activity and function (Fig. 2D).  
 
The resolute equilibration of synaptic protein synthesis and degradation is critical for 
the maintenance of synaptic health. Investigations have demonstrated that 
autonomous temporal and spatial modulation of the synaptic proteome by local 
machinery facilitates alterations in synaptic structure, function and efficacy, which 
may synergistically regulate the molecular mechanisms mediating memory 
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formation. However, how these cascades are autonomously regulated or how 





Figure 2: Protein degradation pathways regulating synaptic stability. A. Schematic 
representing the UPS cascade. Ubiquitin monomers are activated and conjugated to the 
target substrate through a series of reversible enzymatic reactions (enzymes shown in blue). 
The polyubiquitinated substrate is either degraded by the 26S proteasome, yielding 
constituent peptides or deubiquitylated to prevent the proteolytic process. B. Schematic 
indicates varied types of protein ubiquitination. Left panel demonstrates monoubiquitination: 
a single ubiquitin monomer is conjugated to a single lysine acceptor molecule; middle panel 
displays multiple monoubiquitination: numerous lysine molecules on a single protein are 
covalently modified by the addition of ubiquitin; right panel illustrates polyubiquitination: a 
single lysine acceptor molecule harbours a ubiquitin chain. C. Schematic represents 
lysosomal-mediated autophagy. Large substrates are enveloped in a double membrane-bound 
phagopore, which seals to form an autophagosome. The autophagosome fuses with the 
lysosome and acidic hydrolases degrade the contents, providing amino acids for synthesis of 
new proteins. See key in black box for information. D. Diagram illustrating how the UPS and 
lysosomal cascades synergistically maintain synaptic proteostasis. Presynaptic cell: vesicular 
fusion and release of neurotransmitter stimulates the vesicular recycling cascade. The 
proteasome and lysosome remove damaged vesicles from the vesicle pool to promote 
functional synaptic transmission. Postsynaptic cell: glutamatergic neurotransmission induces 
an increase in intracellular Ca2+, which promotes translocation of the 26S proteasome and the 
lysosome to the synaptic compartment. The presence of UPS machinery enables 
ubiquitination of transmembrane AMPA receptors, which are internalised and engulfed by 
the autophagosome and lysosome. Other damaged cellular materials e.g. mitochondria are 
also enveloped by autophagosomes before being transferred to the lysosome. The lysosome 
may locally degrade contents or traffic to the cell body via the cytoskeletal microtubular 
network. See key in black box for information. 2A&B adapted from Hedge, 2004 (48); 2D 
adapted from Bingol & Sheng, 2011 (41). 
 
 
1.2.3 Synaptic mitochondria 
Mitochondria are present in nearly every mammalian cell and numbers range from 
several hundred to >1000 dependent upon cellular type and basic functional 
requirements (52, 53). Although typically believed to be symmetric ovoid organelles, 
mitochondria exhibit significantly varied morphologies dependent upon tissue, 
subcellular localization and the biochemical properties of the intracellular milieu (54, 
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55) in order to functionally promote homeostatic equilibration. Despite the varied 
shape and size of the organelles, the configuration of the membranous structures 
encompassing the intrinsic molecular machinery remains relatively consistent. 
Mitochondria harbor a double-membrane arrangement, which forms four 
biochemically discrete compartments: the outer-membrane, the inter-membrane 
space, the inner membrane and the matrix (52, 53, 55). Of central importance is the 
inner membrane, which houses the enzymatic complexes (I-V) of the respiratory 
chain (52, 53, 55) and enables the generation of adenosine triphosphate (ATP) via 
the process of oxidative phosphorylation to fuel virtually every cellular process (Fig. 
3). The respiratory chain is a structurally and biochemically sophisticated network 
under dual genetic control from nuclear (nDNA) and mitochondrial DNA (mtDNA) 
(52, 56), which promotes the systematic assembly of the complexes via integration of 
the 13 mtDNA encoded proteins and >100 nDNA polypeptides critical for function. 
Through this arrangement, the proteins act synergistically to generate a proton 
motive force across the inner membrane by the sequential reduction of electrons in 
complexes I-IV, promoting a net accumulation of protons outside the inner 
membrane (57). The flow of protons back into the mitochondria via the F1/F0 ATP-
synthase (complex V) drives the synthesis of ATP (52, 53), which is transported to 
the cytosol by ADP/ATP carriers (58). The synthesis and dissemination of ATP by 
the mitochondrial machinery supports a multitude of functions in the CNS including 
neurotransmission cascades, synaptic vesicle endocytosis and release, trafficking of 
intracellular cargo and maintenance of essential signaling pathways (59, 60). 
 
 
Figure 3: The mitochondrial respiratory chain. Image adapted from Sazanov, 2016 (61). 
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Mitochondria are incredibly dynamic organelles and exhibit continuous bi-
directional trafficking along the neuronal cytoskeleton via actin cables and 
microtubule motors (60). Binding of mitochondria of the appropriate size and shape 
to the cytoskeleton (facilitated by fission and fusion proteins) is achieved through the 
motor-adaptor-receptor complexes kinesin (KIF5) and dynein, which regulate 
anterograde and retrograde motility and ensure targeted trafficking of the 
mitochondria in response to biochemical fluctuations in the intracellular milieu (54, 
60, 62). The transport of mitochondria appears to be regulated by synaptic activity 
and the organelles are rapidly redistributed to the pre- and postsynaptic 
compartments in response to two signals: ATP depletion and elevations in 
intracellular Ca2+ (60, 62). Accordingly, recruitment and docking of mitochondria to 
the synapse enables replenishment of the ATP pool and clearance of free Ca2+ ions - 
processes required for homeostatic control and the induction of synaptic plasticity 
(59, 62). Interestingly, mitochondria localized to the synaptic compartment are 
biochemically distinguishable from those organelles located in the axonal milieu 
(63). Investigations document that the synaptic mitochondrial subpopulation displays 
unique enzymatic (63), calcium buffering (64, 65) and antioxidant properties (66), 
which are considered to occur in response to the environmental conditions at the 
synapse. Of particular interest are reports that there is significant subcellular 
heterogeneity with regards to calcium handling mechanisms. Synaptic mitochondria 
exhibit increased susceptibility to progressive Ca2+ overload versus non-synaptic 
mitochondria and rapidly initiate the catastrophic permeability transition pore, which 
promotes loss of mitochondrial membrane potential, rupture of the outer membrane 
and ultimately mitochondrial demise (64). Although experimentally undetermined, 
the limited Ca2+ buffering capacities of synaptic mitochondria may facilitate 
perturbations in synaptic stability during ageing and disease, as the functional 
demands of the active synapse are not being met. The cause of such heterogeneity 
remains elusive, however various studies have suggested that the maladaptive 
properties of synaptic mitochondria may occur due to the failure of retrograde 
transport (66), promoting “ageing” of the synaptic mitochondrial subpool and 
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concomitant dysfunction (64, 67). Despite this, the mechanistic pathways mediating 
such events have not been well characterised.  
 
Recently, in vitro investigations have begun to examine subcellular heterogeneity in 
the mitochondrial proteome. Indeed, there are reports of synaptic mitochondria 
harbouring discrete proteomes, with varied expression of the proteins comprising the 
respiratory complexes, fission and fusion, Ca2+ buffering and mtDNA maintenance 
(68), providing insights into the differential regulation of unique mitochondrial 
populations. Although these data are indubitably important with regards to 
biochemical adaptation of discrete mitochondrial populations, the use of cell lines 
may not faithfully recapitulate a biological system. As illustrated throughout this 
section, it is well established that mitochondria are highly dynamic organelles, 
consistently altering their morphological and functional parameters, as well as their 
protein complement, to adapt to the surrounding cellular milieu. Thus, the expression 
of the synaptic and non-synaptic mitochondrial proteomes will likely be highly 
responsive to the in vitro environment. The current knowledge concerning 
differential mitochondrial protein expression in the mammalian CNS remains in its 
infancy despite numerous efforts to elucidate the biochemical composition of 
discrete organellar subpopulations. Although it is probable that synaptic 
mitochondria contribute to adverse age-dependent alterations, further studies are 
required to delineate the functional implications of differential mitochondrial protein 
expression in vivo, particularly upon the synaptic architecture. 
 
 
1.2.4 Synaptic Plasticity 
As alluded to in sections 1.2.1 and 1.2.2, synaptic plasticity is the putative biological 
substrate underpinning the neural basis of learning and memory. It has been well 
established that glutamatergic synapses, particularly those resident to the 
hippocampus, demonstrate activity-dependent modifications in synaptic transmission 
efficacy (22, 23). This “plasticity” is capable of promoting the strengthening (long-
term potentiation (LTP)) or weakening (long-term depression (LTD)) of synaptic 
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connections - effects dictated by the parameters of neural stimulation, voltage-
dependent activation of the NMDA receptor and calcium-mediated signalling.  
 
LTP and LTD are incredibly sophisticated molecular cascades, which remain 
somewhat equivocal with regards to the biochemical mechanisms governing specific 
mnemonic processes. Although a holistic mechanistic model of synaptic plasticity 
has not yet been established, genetic and pharmacological investigations have 
confirmed that a number of properties must be satisfied for the induction, expression 
and maintenance of LTP and LTD (23, 69-71). Crucially, to induce plastic 
modifications at the synapse, the voltage-gated NMDA receptor channel must be 
opened to allow the permeation of Ca2+ ions into the postsynaptic terminal, 
promoting signal transduction, functional changes in channel conductance and 
sustained alterations in synaptic strength. Although both LTP and LTD are mediated 
by the NMDA receptor, it is the amplitude of the arriving action potential that 
dictates whether potentiation or depression of the synapse occurs (22, 23, 69, 72). 
LTP induction typically commands high frequency tetanic stimulation for opening of 
the NMDA receptor pore and the subsequent strengthening of synaptic connections 
(22). At resting membrane potentials, the NMDA receptor harbours a Mg2+ ion 
blockade, preventing the permeation of cations through the channel, however the 
arrival of a depolarising stimulus of sufficient amplitude is capable of surmounting 
the blockade, expelling the Mg2+ ions from the NMDA pore and enabling maximal 
influx of Ca2+ ions into the postsynaptic terminal (73).  Thus, the NMDA receptor is 
often referred to as a molecular coincidence detector as opening of the pore and 
induction of LTP requires two events to occur concurrently: i) the release and 
binding of glutamate to postsynaptic receptors and ii) strong depolarisation of the 
postsynaptic membrane to enable expulsion of blockading Mg2+ ions from the 
NMDA receptor pore and permeation of Ca2+ ions (23, 73). Similarly, LTD 
induction also requires an increase in postsynaptic Ca2+ concentration, however this 
is typically achieved by repeated low frequency stimulation of the presynaptic 
neuron (69-72). The NMDA receptor Mg2+ ion blockade is not absolute, even at 
resting membrane potentials, and modest activation of the receptors invoked by a 
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low amplitude depolarising stimulus promotes sufficient influx of Ca2+ ions for 
transduction of the LTD signal without necessitating Mg2+ expulsion (74).  
 
Although LTP and LTD are mutually exclusive events, occurring on a divergent 
spectrum of synaptic plasticity, both demonstrate calcium-dependent signal 
transduction mechanisms that facilitate enduring modifications in synaptic efficacy 
(75, 76). Cyclic AMP (cAMP), calcium calmodulin-dependent kinase 2 (CaMKII), 
protein phosphatase 1 (PP1) and calcineurin have all been championed as 
fundamental regulators of plasticity owing to their prevailing role in various 
mechanistic phosphorylation cascades within the pre- and postsynaptic milieu (77-
79). cAMP and CaMKII mediate the Ca2+-dependent phosphorylation of AMPA 
receptors, promoting enhanced receptor trafficking and insertion at the postsynaptic 
membrane in addition to increased single channel conductance (80), which supports 
the long-term maintenance of synaptic potentiation. Conversely, lower 
concentrations of intracellular Ca2+ activate the phosphatases PP1 and calcineurin, 
which dephosphorylate AMPA receptors promoting receptor internalisation, reduced 
channel efficacy and depotentiation of the synapse (78, 79). In conjunction with post-
translational modifications at AMPA receptors, sustained activation of LTP/LTD 
signalling cascades promotes cAMP to function as a mediator between the synaptic 
and nuclear compartments, initiating alterations in gene transcription and local 
protein synthesis and degradation via the cascades discussed in section 1.2.2 (23, 69). 
The assimilation of these events and the corresponding morphological alterations 
occurring at the pre- and postsynaptic specialisations (i.e. changes in spine and active 
zone density and numbers (81)), are considered to orchestrate the mechanisms of 
memory storage and longevity. How the biophysical properties of the pre- and 
postsynaptic terminals alter during advancing age and contribute to impairments in 







1.3 The ageing cortical synapse 
 
Widespread neuronal loss was traditionally considered to be the anatomical correlate 
of age-related cognitive-decline. Early investigations into mammalian cortical ageing 
reported significant reductions in brain weight and neuronal density (82-85) resulting 
in a broad consensus that the degeneration of neuronal populations was an inevitable 
component of normal ageing. However, this hypothesis has since been refuted owing 
to the application of modern stereological techniques (86-88). It is now widely 
accepted that typical age-related alterations in cognitive capacity are associated with 
subtle vicissitudes in the synaptic milieu as opposed to gross cellular loss, which is 
characteristic of pathological conditions (4). Studies increasingly report that 
perturbations in various dendritic modalities, including arborisation, spine number, 
volume, density and stability (4, 5, 89, 90), alterations in synaptic firing patterns (4, 
5) and increases in free radicals (91, 92) systematically encumber cognition during 
advancing age. Despite this, the molecular precursors bolstering the documented age-
dependent morphological and functional shift remain elusive and studies are only 
now beginning to unravel how discrete organelles, proteins and signalling cascades 
may hierarchically or synergistically attenuate synaptic function.  
 
 
1.3.1 Brain regional vulnerability of discrete synaptic populations 
Discrete neuroanatomical regions of the cortical architecture harbour disparate 
populations of synapses that demonstrate significant heterogeneity with regards to 
advancing age (3-5, 93, 94). This notion of “selective synaptic vulnerability” has 
been the focal point of a multitude of morphological studies investigating age-related 
cognitive decline (94-98), which have often provided tentative conclusions as to how 
this phenomenon may be mediated. Despite this, the data have enabled a thorough 
structural characterisation of specific subsets of synapses that appear to demonstrate 
heightened susceptibility or resistance to age-related alterations and/or loss. Of 
particular interest are the prefrontal cortex (PFC) and hippocampus, which are 
reportedly the most vulnerable brain regions during ageing, and the occipital cortex, 
which demonstrates relative resistance to age-dependent synaptic alterations ((3, 94, 
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99) the PFC will not be discussed in detail here - please refer to Morrison & Baxter, 
2012 (4) for an extensive review).  
 
1.3.1.1 Morphological alterations in ageing hippocampal synapses 
Anatomical studies in human patients (100), rhesus macaques (101) and rodents 
(102) consistently describe significant age-dependent morphometric alterations in 
hippocampal synaptic number and density, which appear to correlate with cognitive 
function (4, 13). The perforant path – projecting from the entorhinal cortex to the 
outer molecular layer of the dentate gyrus (Fig. 4A) – is exceedingly vulnerable to 
age-related alterations (103-105) and exhibits complex changes in multiple 
morphological parameters, including pre- and postsynaptic coupling, in the ageing 
rhesus macaque (4, 103, 104). Light and electron microscopy studies examining the 
perforant path have reported a significant age-dependent preferential loss of 
axodendritic synapses from the outer molecular layer of the non-human primate 
(NHP) dentate gyrus, but preservation of the ultrastructurally distinct axospinous 
synapses from the same region (95). Despite this, reductions in total numbers of 
axodendritic synapses do not correlate with hippocampal-mediated cognitive 
impairments (106). Instead, it has now been proposed that subtle alterations in the 
properties the excitatory axospinous synapses furnishing the outer molecular layer 
facilitate age-related reductions in cognitive capacity. Indeed, investigations 
characterising pre- and postsynaptic terminal coupling in young and old NHPs 
describe a 100% increase in synaptic terminal dissociation (resulting in non-synaptic 
boutons) in addition to a decrease in the number of perforated synapses and multi-
synaptic boutons in the aged macaque ((106) Fig. 4B). This morphological shift is 
indicative of spine retraction, or, alternatively, a reduction in long-term spine 
retention, suggesting that the aged hippocampus may not be capable of adequately 
maintaining a significant volume of synaptic connections. Interestingly, the number 
of non-synaptic boutons robustly correlates with cognitive impairment on 
hippocampal-dependent behavioural tasks (106), indicating that the stability of pre-
established complex synaptic connections in the outer molecular layer, and other 
sub-regions of the dentate gyrus, supports the maintenance of cognitive capacity 
(Fig. 4C).   
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The anatomical organisation of the primate hippocampus is relatively well preserved 
in rodents (Fig. 4A) and reports consistently document that rats, like humans and 
NHPs, exhibit hippocampal-dependent cognitive impairments. Investigations 
examining the morphological correlates associated with alterations in rodent 
cognition have identified perturbed synaptic structures in homologous regions to the 
NHP – primarily, an age-dependent selective loss of synapses from the outer 
molecular layers of the dentate gyrus (4, 107). Although the loss of these 
axodendritic synapses in the NHP does not correlate with cognitive capacity, aged 
rats demonstrate significant memory impairments, likely mediated by the loss of both 
axodendritic and axospinous synaptic subtypes (102, 107). Further evidence utilising 
immunolabelling techniques coupled with electron microscopy indicates that aged 
rats also harbour significant reductions in the number of synaptic terminals in the 
hippocampal CA3 circuitry versus younger animals and, strikingly, the loss of these 
distinct synapses directly correlates with spatial learning deficits (108, 109). 
Moreover, despite morphological preservation of the CA1 circuitry in aged humans 
and NHPs, rats display subtle vicissitudes in the synaptic milieu comprising the 
regional CA1 architecture. Analyses report significant reductions in postsynaptic 
density area on perforated synapses (an approximate 27-44% loss), which appears to 
mediate spatial learning deficits (110). Although perturbations in the human CA1 
synaptic population is indicative of pathogenesis, the natural age-dependent 
deterioration of this circuitry in the rat may provide insight into conserved cognitive 




Figure 4: Alterations in hippocampal synaptic morphology correlate with age-related 
cognitive impairment. A. Age-dependent changes in the hippocampus. Schematics depict 
hippocampal circuitry and alterations in the density of perforant path spines between young 
and aged animals (EC = entorhinal cortex; DG = dentate gyrus). B. Schematics illustrating 
age-dependent morphological alterations in hippocampal synaptic subtypes. Aged animals 
display an increase in the number of non-synaptic boutons and reductions in multi-synaptic 
boutons versus young. C. A significant inverse correlation exists between the percentage of 
detectable non-synaptic boutons in the dentate gyrus and the average accuracy on the 
hippocampal-dependent delayed non-matching-to-sample (DNMS) cognitive test. SSB = 
single synaptic bouton; NSB = non-synaptic bouton; MSB = multi-synaptic bouton. Panel A 
adapted from Fan et al, 2017 (7); panels B & C adapted from Morrison & Baxter, 2012 (4). 
 
 
The age-dependent selective vulnerability of the hippocampal synaptic milieu 
evidently bolsters reductions in cognitive capacity. Although it is now well 
established that morphological alterations in complex synapses associated, including 
a decline in multi-synaptic boutons and previously potentiated perforated synapses 
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(4), promote impairments in memory storage, retention and retrieval, the molecular 
mediators orchestrating this preferential loss remain elusive. There is a substantial 
requirement for well-executed biochemical investigations to examine the temporal 
alterations occurring in hippocampal synapses and determine how molecular 
networks may be promoting perturbed structure and function. Such studies may 
enable the development of therapeutic strategies promoting the stability of these 
receptive compartments, which is of paramount importance for preservation of 
cognitive capacity during advancing age. 
 
1.3.1.2 Morphological alterations in ageing occipital cortex synapses 
Although there has been significant scientific focus on the selective synaptic 
vulnerability of the hippocampal formation, few studies have investigated the age-
dependent trajectory of occipital cortex synapses despite the reported preservation of 
structural and functional stability throughout the duration of the lifespan (3, 94, 99). 
Indeed, studies examining temporal alterations in the NHP occipital cortex synaptic 
milieu report no age-dependent morphological changes (Fig. 5B&C), including 
preservation of synaptic number, spine density and dendritic arborisation (3, 94, 99, 
111). In addition, gross anatomical investigations utilising magnetic resonance 
imaging (MRI) document no significant volumetric changes associated with 
advancing age in the occipital cortex, with area and cortical thickness displaying 
quantitatively similar measurements in both young and old humans (Fig. 6), as well 
as rhesus macaques (94, 112, 113). Coupled with the outlined stereological studies, 
there is also recent behavioural evidence describing that performance on visual 
discrimination tasks is consistent throughout the lifespan in the rhesus macaque, 
which suggests functional preservation of the region during ageing (99). 
Furthermore, there are extraordinary reports documenting that even in patients with 
advanced neurodegenerative conditions such as AD, the occipital lobes remain 
relatively unaffected, with sparse pathological tau inclusions (114, 115) and 





Figure 5: Morphological preservation of the occipital cortex during ageing. A. Asterisks 
mark the anterior margin of the occipital cortex in the rhesus macaque brain. B&C. 
Unbiased stereologic analyses demonstrate preservation of total cortical volume and total 
neuronal number in the occipital cortex during ageing. Scale bar = 1cm. Image adapted from 
Hof et al, 2002 (94). 
 
 
The age-dependent resistance of the synaptic populations furnishing the occipital 
cortex is certainly intriguing and, to our knowledge, there have been no 
investigations examining the biochemical cascades orchestrating this inherent 
neuroprotection. Despite this, a recent study has begun computationally 
characterising the dendritic differences between vulnerable PFC neurons and 
resistant occipital cortex neurons (122). Interestingly, the occipital cortex exhibits 
significantly reduced dendritic complexity, with fewer spines, smaller dendritic 
arbours and conserved cortical connectivity (99, 122), which may promote resistance 
to age-dependent alterations via functional mechanisms yet to be determined. 
Elucidating the morphological and molecular correlates of occipital synaptic 
protection may be fundamental in understanding the selective vulnerability of 
discrete populations of synapses and recapitulation of such physiological cascades 
may provide a therapeutic strategy to ameliorate adverse synaptic alterations in the 




Figure 6: Differentially vulnerable brain regions demonstrate discrete volumetric 
alterations during ageing in human patients. Each point indicates the calculated volume 
of the occipital cortex (A.) or the hippocampus (B.) in a single patient from MRI images. 
The hippocampus exhibits volumetric decreases after 60 years of age whereas the occipital 




1.3.2 Synaptic plasticity in the ageing brain 
As previously discussed, synaptic structure and function are intricately intertwined, 
exhibiting significant synergy to promote compartmental stability. It is well 
established that selected hippocampal synapses display morphometric shifts during 
ageing (see section 1.3.1.1), which is highly suggestive of concomitant modifications 
in functional plasticity cascades. Indeed, investigations examining the molecular 
mediators of hippocampal plasticity have documented a plethora of age-dependent 
changes in critical properties believed to modulate cognition including Ca2+ 
homeostasis, NMDA receptor expression and LTP induction threshold (5, 103, 123). 
Although numerous electrophysiological properties remain constant through the 
duration of the lifespan (e.g. resting membrane potential, action potential threshold 
(5)), a salient feature of rodent hippocampal ageing is an increase in Ca2+ 
conductance in the CA3 and CA1 circuitry, promoting K+-mediated increases in the 
magnitude of the after-hyperpolarising (AHP) phase of the action potential (5, 123, 
124). The amplification and extended duration of the AHP in selected hippocampal 
neurons impedes cell excitability and synaptic plasticity by preventing the 
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subsequent generation of an action potential and attenuating firing frequency of the 
synapse (4, 5, 123). This phenomenon is believed to be mechanistically regulated by 
age-dependent elevations in intracellular Ca2+ via increased expression of L-type 
Ca2+ channels and alterations in Ca2+ buffering and extrusion machinery (this is 
briefly discussed in section 1.2.3). Disruptions in intracellular Ca2+ homeostasis 
during advancing age have been widely reported and are frequently associated with 
perturbations in the induction of LTP and LTD cascades. As outlined in section 
1.2.4, the potentiation and depression of synaptic compartments is Ca2+-dependent 
and alterations in ion equilibration may diminish neuronal capacity to induce such 
plastic modifications. Indeed, elevations in postsynaptic intracellular Ca2+ 
concentrations in the aged rat dentate gyrus and CA3 promote a functional shift in 
plasticity, with neurons preferentially inducing LTD over LTP due to Ca2+-
dependent modifications of the synaptic potentiation threshold (125, 126). 
Additionally, moderate increases in intracellular Ca2+ levels are reported to promote 
LTD in aged animals by stimulating calcineurin activity, which inhibits NMDA 
receptor opening via dephosphorylation cascades (127). Further reports of age-
related reductions in LTP document the preferential loss (30%) of an essential 
NMDA receptor subunit (NR1) in the NHP perforant path (specifically the outer 
molecular layer of the dentate gyrus), which has been suggested to mediate cognitive 
deficits during advancing age due to disruptions in LTP-dependent learning and 





Figure 7: Age-dependent alterations in the synaptic potentiation threshold. Graph 
depicts stimulation frequency and induction of LTP and LTD in young and aged rats (young 
= purple circles; old = orange triangles; dashed line = LTP induction threshold). Aged rats 
exhibit a lower LTD threshold resulting in an extended range of frequencies upon which 
LTD can be induced. Additionally, old animals demonstrate a plateau preventing synaptic 
potentiation at these frequencies. Induction of LTP in aged animals requires significantly 
higher frequency stimulation to overcome the prolonged Ca2+-dependent AHP. Image 
adapted from Kumar & Foster, 2007 (123). 
 
 
Collectively, evidence supports the notion that focal disruptions in Ca2+ homeostasis 
promote perturbations in synaptic plasticity and cognitive capacity by 
mechanistically altering cell excitability via the neuronal AHP and potentiation 
threshold. Investigations have begun to describe that restoration of “young” 
intracellular Ca2+ concentrations in old animals facilitates learning and memory 
through modulation of the AHP and activation of LTP cascades (128, 129), 
suggesting that age-related cognitive decline is, in part, due to alterations in the 
plastic properties of the synapse. Despite this, the molecular mediators triggering the 
initial dysfunction in Ca2+ homeostasis remain unresolved. Temporal examinations 
of Ca2+ sequestration and extrusion properties up- and downstream of 
neurotransmission cascades may elucidate the molecular machinery contributing to 
the age-dependent vulnerability of the synaptic milieu. Furthermore, investigations 
exploring how alterations in functional plasticity pathways may be hierarchically or 
synergistically driving morphological changes in selected synaptic populations are 




1.3.3 Temporal regulation of the synaptic proteome 
Though the studies described have provided comprehensive insights into age-
dependent modifications in synapse morphology and reductions in synaptic efficacy, 
few have examined the global molecular alterations that may be bolstering these 
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events. Investigations are now beginning to utilise unbiased quantitative “–omic” 
approaches to discern how dynamic modulations in transcript or protein expression 
may mechanistically mediate structural and functional perturbations in the aged 
synaptic milieu. Indeed, studies characterising temporal expression changes in the rat 
hippocampal synaptic proteome using two-dimensional difference gel 
electrophoresis (2D-DIGE) and MS/MS techniques, report significant and 
synchronous reductions in a multitude of proteins regulating synaptic transmission 
and vesicle dynamics during advancing age (130, 131). Furthermore, microarray 
investigations assessing the expression of 340 selected synaptic transcripts describe 
an age-dependent downregulation of genes mediating neurotransmission cascades, 
PSD scaffolding and cell adhesion in multiple cortical regions (132). Together, the 
data suggest that the progressive loss of critical proteins regulating the properties of 
neurotransmission during ageing likely modulates the reported alterations in 
electrophysiological properties and thus may represent a molecular precursor to 
perturbed plasticity and concomitant cognitive impairment. 
  
However, despite the outlined “–omic” studies providing protein expression data 
consistent with reported alterations in synaptic transmission efficacy, the use of out-
dated methods (2D-DIGE) has hindered the number of protein identifications and 
quantitation of low-abundance proteins (some of which may play a fundamental role 
in regulating synaptic stability and/or vulnerability during ageing). The application 
of modern mass spectrometry techniques to isolated regional synaptic compartments 
will be fundamental in ascertaining the global temporal changes associated with 
selective alterations in structure, function and stability of the synapse. Improved 
methodologies and optimised workflows will promote examination of the dynamic 
processes facilitating age-dependent cognitive impairment and enable identification 







1.4 Models of ageing 
 
1.4.1 Non-human primates 
Modelling human ageing is a complex and challenging notion. Ageing research has 
been somewhat hindered by the lack of reliable models that faithfully recapitulate the 
array of physiological alterations occurring in the aged human patient. Numerous 
investigations have adopted rodent models in an attempt to decipher the biochemical 
substrates bolstering neuronal instability, however this approach often lacks 
sufficient translational impact due to the documented differences in fundamental 
processes considered relevant to the ageing trajectory. Rodents possess limited 
lifespans and thus the natural development of common age-related comorbidities 
(e.g. diabetes, sarcopenia, atherosclerosis) does not appear to occur (133). Although 
this may be convenient for a laboratory study, a multitude of recent investigations 
have provided evidence that the presence of a comorbid disorder may attenuate 
neuronal and synaptic stability, contributing to the development of age-related 
cognitive decline in non-human primates and human patients (134-137). 
Furthermore, evolutionary divergence of the primate cortex has promoted functional 
neuronal alterations that are uniquely primate (4) and studies documenting rodent 
biological brain ageing are not necessarily representative of the complex processes 
occurring in the human patient, particularly with regards to selective synaptic 
vulnerability (138). Thus, in order to tease apart human age-related cognitive decline, 
non-human primates provide some advantages. Non-human primates are 
phylogenetically closer to humans and possess distinctly primate morphological, 
endocrine, behavioural, and cognitive traits (4, 94), in addition to an increased 
lifespan (Fig. 8), which may provide data uniquely relevant to human ageing.  
 
Of particular importance is the rhesus macaque (macaca mulatta) – an old world 
monkey demonstrating an estimated 93% genetic similarity with humans (139). 
Rhesus macaques are the most widely utilised NHP in ageing research due to their 
practical size (5-10kg), protracted captive lifespan of 25-30 years (Fig. 8) and 
capacity for extensive cognitive testing (3, 94, 133). Importantly, laboratory rhesus 
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macaques are outbred, offering biologically relevant genetic diversity between 
animals, which is akin to that of humans (140). Indeed, morphological and 
behavioural studies in macaques demonstrate that age-dependent neuronal alterations 
and concomitant cognitive impairments occur in only a subset of animals, mirroring 
the epidemiological incidence of such impairments in the human population (103, 
141, 142). However, unlike humans, environmental, dietary and social interactions 
may be controlled (133), providing a structured platform with which to dissect the 
physical and physiological mechanisms governing the effect of advancing age on the 
neuronal milieu.  
 
Despite ageing rhesus macaques exhibiting cellular and behavioural alterations 
analogous to human patients, including selective synaptic loss, alterations in 
neuronal biophysical properties and impairments in short-term memory and 
executive function ((3, 4) see section 1.3), NHPs do not suffer from age-related 
neurodegenerative diseases (e.g. AD (3, 94, 103)). Although the aged macaque 
displays varying levels of β-amyloid (Aβ-40) deposits throughout the brain 
accompanied by dystrophic phenotypes in the surrounding neuronal architecture, the 
localisation and frequency of plaques correlates solely with increasing age, not 
cognitive status (3). Interestingly, neurofibrillary tangles - the pathological drivers of 
cognitive dysfunction in AD (116) - appear to be uniquely human, with no reports of 
such substrates in even the oldest macaque brains, despite the expression of 
homologous tau protein (3).  
 
NHPs provide a uniquely relevant model to assess how the trajectory of human 
cortical ageing may be mediated. Although the age-dependent structural alterations 
occurring in the neuronal milieu and concomitant behavioural changes have been 
extensively characterised in the rhesus macaque, the molecular substrates governing 
these morphological adaptations remain elusive. Biochemical investigations 
examining the mechanistic cascades regulating such events in the NHP will harbour 
numerous benefits, as the effect of age may be assessed independently of the 




Figure 8: Rhesus macaque survival curve. Graph depicts survival of animals in captivity 
and the reported stages of ageing. Onset of cognitive decline typically appears between ages 
18-22. Data obtained from Moss et al, 1999 (143). 
 
 
1.4.2 Drosophila melanogaster  
Though the use of NHP tissues in ageing studies provides invaluable data regarding 
the molecular mechanisms orchestrating human synaptic ageing, the generation of 
such models is often timely and requires significant laboratory space as well as 
expertly trained individuals. Thus, alternate models of ageing, such as Drosophila 
melanogaster, may offer additional insights into the spatiotemporal regulation of 
synaptic biochemistry during advancing age. The development of sophisticated tools 
for use in Drosophila melanogaster models has offered pioneering strategies 
enabling the characterization of a multitude of genes, proteins and biochemical 
cascades regulating the stability of the nervous system. Although from an 
evolutionary perspective Drosophila may appear to display significant phylogenetic 
distance from humans, numerous fundamental mammalian biological and 
neurological pathways have been shown to demonstrate conservation in the fruit fly 
(144). Additionally, sequencing of both the primate and Drosophila genomes has 
indicated that up to 75% of human disease related genes exhibit a functional ortholog 
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in the fly (145, 146), thus providing a reliable model that rapidly and faithfully 
recapitulates aspects of mammalian pathologies.  
 
The use of Drosophila models in the research environment is an attractive prospect – 
not only for the documented mammalian genetic homology, but also for the arsenal 
of innovative tools, stereotyped organization of the nervous system and timely 
genesis of adult flies. The Drosophila life cycle is a dynamic 10-day event consisting 
of several ephemeral developmental stages, resulting in larval metamorphosis and 
the eclosion of adult flies (Fig. 9). Adult females have the ability to lay hundreds of 
fertilized eggs over the duration of several days (146, 147), with first instar larva 
hatching from the egg after completion of embryogenesis. Maturation of the larva 
continues through the second and third instar stages before the animals pupariate for 
the initiation of histolytic processes (147), which concomitantly stimulates the 
generation of adult anatomical structures. Once complete, adult flies eclose from the 
pupal casing in a circadian-rhythm dependent manner (148), allowing the life cycle 




Figure 9: The Drosophila life cycle. Image obtained from Creative Diagnostics. 
 
 
The swift generation of flies provides obvious advantages with regards to the 
collection of experimental data and many Drosophila based laboratories selectively 
utilize high throughput genetic screens to delineate the functions of hundreds of 
genes over relatively short time frames. Primarily, research focuses on two methods 
of manipulation to examine genetic function: loss of function (LOF) and gain of 
function (GOF). Suitably named, loss of function studies serve to partially or wholly 
abolish candidate function primarily by introducing LOF mutant alleles or RNA 
interference (RNAi) constructs (147). Conversely, investigations interrogating gain 
of function properties typically employ GOF mutant alleles or targeted over-
expression constructs to assess hypermorphic effects of the candidate (147). 
Fortunately, nearly every Drosophila gene may be manipulated to provide targeted 
LOF and/or GOF genotypes through the insertion of P-element transposons into the 
fly genome during embryogenesis. Although the classification of P-element lines is 
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vast, two particular collections are of relevance to this project: Gal4/Upstream 
Activating Sequence (UAS) and RNAi.  
 
The Gal4/UAS system has become an indispensable tool for elucidating gene 
function since its introduction in 1993 by Brand & Perrimon (149). The sophisticated 
genetic approach allows directed expression of target genes in a tissue and cell-
specific manner by utilizing a bipartite arrangement consisting of driver (Gal4) and 
target (UAS) elements maintained on discrete parental lines (147, 149, 150). 
Importantly, the Gal4 and UAS constructs remain transcriptionally silent in the parent 
lines (149), due to the presence of solely the driver or target elements, which 
supports the sustained viability of the organisms. It is only with generation of 
offspring by crossing these two lines that spatiotemporal activation of the target gene 
occurs, as the progeny harbour both the Gal4 driver and UAS target elements (Fig. 
10). The use of UAS-RNAi strategies has become a prevailing approach employed 
by laboratories to assess genetic loss of function. UAS-RNAi constructs are available 
for almost every Drosophila gene (147), promoting targeted Gal4-dependent knock-
down of selected candidates in particular tissues for examination of mechanistic 
cascades regulating phenotypic presentations in vivo. Although Drosophila and 
numerous other organisms do not inherently express the endogenous saccharomyces 
cerevisiae protein Gal4 (149, 150), transgenic insertion of the gene into selected 
tissues or cells provides functional expression in vivo, allowing meticulous control of 
UAS-linked gene activation and delineation of genetic function. Superfluous to the 
elegance of the Brand & Perrimon’s system (149) was the identification of 
temperature-dependent activity of Gal4, which allows for increased versatility with 
use of the approach, including tailored expression of the target transgene through 




Figure 10: Schematic depicting the Gal4/UAS system. The driver (Gal4) and target (UAS-
Gene X) lines are maintained separately. Crossing of the lines generates offspring 
harbouring both components of the Gal4/UAS system promoting tissue-specific transcription 
of the gene of interest. Image adapted from Brand & Perrimon, 1993 (149) and Roote & 
Prokop, 2013 (147). 
 
 
Application of the tools described to study the mechanistic regulation of the 
Drosophila nervous system has provided fundamental insights into the molecular 
arrangement and function of the mammalian neuronal milieu. Much of the 
knowledge concerning biochemical modulation the nervous system has been derived 
from studies utilizing the third instar larva neuromuscular junction ((NMJ) Fig. 
11A). The larval NMJ is an excellent model system to unravel the molecular 
mechanisms underpinning synaptic structure, function and plasticity (151) due to its 
simple stereotypic morphology, easily accessible musculature and distinguishable 
subtypes of synapses ((152) Fig. 11). The body wall musculature contains 32 motor 
neurons in each abdominal hemisegment (152) with each exhibiting distinct 
arborisation patterns and variations in expression of type Ib, Is II and III synaptic 
boutons. The majority of these boutons are glutamatergic and harbour contiguous 
invaginated post-synaptic membranes (sub-synaptic reticulum (SSR)) (153, 154), 
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which display significant homology to those found in the mammalian central nervous 
system. Neurotransmission between these connections has the propensity to invoke 
plastic modifications (151, 153, 155), providing physiologically relevant mechanistic 
insights into proteins regulating the structure and function of the synapse in 
mammalian cognition (155). 
 
 
Figure 11: The larval body wall musculature and synaptic bouton subtypes. A. Left 
panel: larval fillet preparation displaying the body wall musculature at 4x. Right panel: 
schematic illustrating the stereotypic morphology of larval abdominal hemisegment A3. The 
frequently examined muscle 12 and 13 NMJ is highlighted in red. B. Panel exhibits 
morphometry of discrete subtypes of synaptic boutons expressed at larval NMJs. SSR – sub-










1.5 Experimental Aims 
1.5.1 Overarching aims  
i) Devise a reliable and replicable unbiased quantitative methodological 
workflow for examination of the spatiotemporal molecular alterations 
occurring in the synaptic milieu  
ii) Utilise the methodological workflow to establish species-specific synaptic 
signatures during advancing age 
iii) Identify proteins, pathways and biochemical cascades that may have the 
propensity to alter synaptic stability  
iv) Determine if identified candidates modulate the synaptic architecture in 
vivo 
v) Assess the similitude of spatiotemporal molecular alterations occurring 
between species to determine whether analogous biochemical cascades 
regulate synaptic ageing in the rodent, non-human primate and human 
patient  
 
1.5.2 Chapter aims 
Chapter 3: Characterise the proteomes of rodent mitochondria derived from discrete 
subcellular compartments and demonstrate how varied protein expression may 
modulate the stability of the synaptic milieu. 
Chapter 4: Examine the temporal alterations occurring in the rodent synaptic and 
non-synaptic mitochondrial proteomes and identify candidates capable of promoting 
synaptic vulnerability during advancing age. 
Chapter 5: Isolate and examine the temporal proteomic profiles of synapses derived 
from two differentially vulnerable NHP brain regions and demonstrate how age-
dependent preferential synaptic loss may be mechanistically regulated. 
Chapter 6: Utilise synapses purified from analogous human patient brain regions to 
describe dynamic alterations in the synaptic proteome and how these may dictate 
age-dependent vulnerability of the hippocampal synapse. 
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Chapter 2. Materials and Methods 
This section describes the general methodologies utilised in Chapters 3-6. For 
detailed experimental procedures please refer to the specific methodological sub-
sections associated with each chapter. 
2.1 Methodological workflow development 
As outlined in the overarching aims (chapter 1, section 1.5.1), the development of a 
reliable and replicable workflow was essential to enable direct comparisons of the 
spatiotemporal molecular alterations occurring in synaptic isolates derived from 
varied species. The methodological model was established in years 1 and 2 and 
utilises a combinatorial approach, encompassing quantitative proteomics, in silico 
analyses and molecular genetics. The workflow was designed to be applicable to any 
spatiotemporal analysis, utilising any tissues, species or disease model of choice, to 
promote consistency between “-omic” experiments. For more information please 
refer to appendix 1 where my recommendations for experimental design and 
implementation of such workflows is documented in a published manuscript (Expert 
Review of Proteomics, 2016).   
 
2.2 Ethics 
In compliance with the 3Rs, no animals were bred specifically for this project. All 
tissue samples used in this thesis were derived from existing archived brains or 
harvested alongside other ongoing experiments. The University of Edinburgh 
internal ethics committee approved all animal experiments. 
 
2.3 Human Patient Samples 
Human patient samples were obtained from the Edinburgh Brain Bank in 
collaboration with Prof. Colin Smith. All tissues were classified as “controls” due to 
the absence of gross pathological hallmarks and neurological disease. Use of human 
tissue for post-mortem studies was reviewed and approved by the Edinburgh Brain 
Bank ethics committee. The Edinburgh Brain Bank is a Medical Research Council 
funded facility with research ethics committee approval (11/ES/0022).  
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2.4 Synaptosomal Preparations 
Brain tissue samples were homogenised in an ice-cold isotonic sucrose solution (0.32 
M sucrose, 1 mM EDTA, 5 mM Tris-HCl, pH 7.4).  Homogenates were centrifuged 
in a fixed-angle rotor at 900 g for 10 min and the supernatant (S1) was 
collected.  The pellet (P1) was resuspended in sucrose solution and centrifuged again 
at 900 g for 10 min. Supernatants were combined and centrifuged in a fixed angle 
rotor at 20,000 g for 15 min. The remaining pellets (P2) contained the synaptosomes. 
Such synaptosomal isolates are predominantly pre-synaptic in terms of content and 
demonstrate adequate purity for our experimental needs as previously demonstrated 
(156-158). 
 
2.5 Mitochondrial Preparations 
For a comprehensive overview of the methodology employed, see Lai et al, 1977 
(63) and Fig. 12. This traditional approach was adopted due to the methodological 
technique resulting in samples with demonstrated organelle purity and conserved 
biochemical activity. All procedures were carried out at 4°C. Forebrains were 
homogenized by hand in isolation medium (0.32M sucrose, 1mM K-EDTA, 10mM, 
Tris HCl) to give a 1:10 homogenate. The homogenates were centrifuged at 1,300g 
for 3 minutes and the resulting pellets were manually resuspended in 15ml isolation 
medium before recentrifugation using the same parameters. Supernatants were 
pooled and centrifuged at 17,000g for 10 minutes to give the crude mitochondrial 
pellet (CM). The CM pellet was resuspended in 15ml isolation medium and 5ml of 
the suspension was layered into 3 tubes containing 7ml of 7.5% Ficoll-sucrose 
medium (7% Ficoll, 0.32M sucrose, 50µM K-EDTA, 10mM Tris HCl) on top of 7ml 
of 10% Ficoll-sucrose medium (10% Ficoll, 0.32M sucrose, 50µM K-EDTA, 10mM 
Tris HCl) and centrifuged at 99,000g for 30 minutes on a swing-out Beckman 
ultracentrifuge. This resulted in a myelin (My) fraction banded at the top, a 
synaptosomal (Syn) fraction at the second interphase and a ‘free’ (non-synaptic) 
mitochondrial pellet (M) at the bottom. The myelin fraction was aspirated and the 
synaptic fraction collected, without disturbing the pellet. This was then diluted in 3x 
isolation medium and centrifuged at 18,500g for 10 minutes. The non-synaptic 
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mitochondrial pellet was frozen immediately on dry ice before storage at -80°C. The 
resulting synaptosomal pellet was lysed and resuspended in 30ml 6mM Tris-HCl (pH 
8.1) and centrifuged at 11,800g for 10 minutes. The supernatant was removed and 
the pellet was again resuspended in 10ml of 6mM Tris-HCl (pH 8.1) and 
recentrifuged at 8,300g for 10 minutes. The supernatant was discarded and the pellet 
resuspended in 10ml of 3% Ficoll medium (3% Ficoll, 0.12M mannitol, 30mM 
sucrose, 25µM K-EDTA, 5mM Tris-HCl). One third of this suspension was layered 
into 3 tubes containing 5ml 4.5% Ficoll medium (4.5% Ficoll, 0.24M mannitol, 
60mM sucrose, 50µM K-EDTA, 10mM Tris-HCl) on top of 10ml 6% Ficoll (6% 
Ficoll, 0.24M mannitol, 60mM sucrose, 50µM K-EDTA, 10mM Tris-HCl) and 
centrifuged at 11,300g for 30 minutes in a swing-out Beckman ultracentrifuge. After 
centrifugation, the top band was removed and the intermediate band decanted and 
diluted with an equal volume of isolation medium. This lysate was then centrifuged 
at 17,000g for 10 minutes providing synaptosomally derived mitochondria (SM 
population) and an SM2 fraction (pellet). The SM and SM2 fractions were pooled to 
give a greater yield for proteomic experiments and validation, frozen on dry ice and 
stored at -80°C. 
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Figure 12: Method of mitochondrial neuronal subpopulation isolation from cortical 
tissue. Image adapted from Lai et al. Abbreviations: Syn – synaptosomal, M – non-synaptic, 
SM – ‘light’ fraction, SM2 – ‘heavy’ fraction.  
 
2.6 Protein Concentration Assay 
Samples were homogenized in label-free or RIPA buffer + 1% protease cocktail 
inhibitor (Thermo Scientific). After homogenisation, samples were centrifuged at 
20,000g for 20 minutes at 4°C. The supernatant containing the solubilised protein 
was removed and pellets discarded. Protein concentration of samples was determined 
using a Pierce Micro BCA assay kit according to the manufacturers instructions. 
 
2.7 Label-free Proteomics 
All mass spectrometry analyses were performed by FingerPrints proteomic facility at 
the University of Dundee unless otherwise specified. I was afforded the opportunity 
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to implement the following methodology during a 7-day training course alongside 
Amy Tavendale and Douglas Lamont at the facility during my PhD studies. Samples 
were extracted in SDT lysis buffer containing 100 mM Tris-HCl (pH 7.6), 4% (W/V) 
Sodium dodecyl sulfate (VWR) and 0.1 M d/l-dithiothreitol (Sigma). For efficient 
protein extraction, lysates were freeze–thawed and homogenized in SDT buffer 
several times. Protein concentration was then determined using a micro BCA assay 
(see section 2.5).  
 
Aliquots of each preparation were processed through FASP (filter-aided sample 
preparation) prior to a double digestion with trypsin (Roche, sequencing grade), 
initially for 4 hours, then overnight at 30 °C. Trypsin-digested peptides were 
separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system. 
Using an ESI Easy Spray source at 50 °C, technical replicates of each sample were 
loaded with a constant flow onto an Acclaim PepMap100 nanoViper C18 trap 
column (ThermoScientific). After trap enrichment, peptides were eluted onto an 
Acclaim PepMap RSLC nanoViper, C18 column (ThermoScientific). The HPLC 
system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-
Orbitrap Velos Pro, Thermo Scientific) via a nanoelectrospray ion source (Thermo 
Scientific). Full-scan MS survey spectra in profile mode were acquired in the 
Orbitrap. Data were acquired using the Xcalibur software. 
 
All further analyses were performed by Laura Graham at the Roslin Institute. Raw 
proteomic data were imported into Progenesis for characterization and analysis of 
relative ion abundance. 2D representations of MS/MS output were created for each 
sample and these were aligned to determine similar features. Following alignment, 
data was filtered by retention time to correct for elution variability. The runs were 
grouped according to the experimental paradigm and Statistical P values were 
automatically generated in Progenesis software through a one-way ANOVA on the 
ArcSinh transform of the normalized data. 
 
Peptides were filtered by the following criteria: power <0.8, fold change >1.2, 
p>0.05 and the remaining data were exported from Progenesis for identification of 
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individual peptide sequences using the Mascot Search Engine (V2.3.2). Identified 
proteins were re-imported into Progenesis for further processing. Proteins were 
subject to stringent filtering parameters to eliminate those which had <2 unique 
peptides, <1.2 fold change and p>0.05 to obtain the proteins which demonstrated the 
largest significant variation in expression between experimental conditions.  
 
2.8 Biolayout Express3D  
Proteomic data was dissected using the complex pattern recognition software, 
Biolayout Express3D (159). The software allows visualization of molecular networks 
by applying Markov clustering algorithms to raw proteomic data (MCL 2.2). All 
graphs were clustered using a Pearson correlation value specific to the input data.  
 
2.9 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) experiments were performed as previously 
described (157), with the interaction data limited as follows: direct and indirect 
interactions; experimentally observed data only; 35 molecules per network; 10 
networks per dataset. Prediction activation scores (z-score) were calculated in IPA. 
The z-score is a statistical measure of the match between an expected relationship 
direction and the observed protein expression. Positive z-scores indicate activation 
(orange) and negative z-scores indicate inhibition (blue) (160). 
 
2.10 Quantitative Fluorescent Western Blotting 
Quantitative fluorescent western blotting was performed as previously described 
(161). Samples were diluted to provide desired protein concentration. 4-15µg protein 




4-12% Bis Tris mini-gels (Life 
Technologies) and transferred to PVDF membranes using an iBlot®
 
and Invitrogen 
gel transfer stacks. Membranes were incubated in primary antibodies at 4°C and 
secondary antibodies at room temperature (concentrations according to 
manufacturers instructions) and washed in 1x PBS before imaging on Li-COR 
Odyssey infrared scanner (see Tables 1 & 2 for antibody details). Protein expression 
was quantified utilising Odyssey software (Li-COR Biosciences).  
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Table 1: Primary antibodies utilized for western blotting experiments. 
Primary antibody Source Catalogue number 
βIII-tubulin Abcam ab18207 
Telomerase Abcam ab32020  
VDAC1 Abcam ab14734  
CoxIV Abcam ab16056 
Hibch Abcam ab101672 
Ogdh ProteinTech 15212-1-AP 
Citrate synthase OriGene  TA310356 
Beta-actin ProteinTech 20536-1-AP 
Ndufs5 ProteinTech 15224-1-AP 
Rcn2 ProteinTech 10193-2-AP 
Cdh2 ProteinTech  22018-1-AP 
Rock2 Abcam ab71598 
 
 
Table 2: Secondary antibodies used for western blotting. 
Secondary antibody Source Catalogue number 
Goat anti-rabbit IRDye 680 Odyssey P/N 925-68071 
Donkey anti-mouse IRDye 680 Odyssey P/N 925-68072 
 
 
2.11 Drosophila Stocks 
Drosophila husbandry, genetics and phenotypic assessment skills were initially 
acquired whilst hosted in the Pennetta laboratory for a period of 9 months at the 
University of Edinburgh. Outside advice on experimental paradigms was sought 
from Dr. Marc Freeman (University of Massachusetts/Oregon Health and Sciences 
University), Dr. Lukas Neukomm (University of Massachusetts), Dr. Mary Logan 
(Oregon Health and Sciences University) and Prof. Richard Ribchester (University 
of Edinburgh) where appropriate. All Drosophila stocks utilised are listed in Table 3. 
Stocks were obtained from the Vienna Drosophila Research Centre (VDRC), 
Austria; FlyORF, Switzerland and Bloomington Drosophila Stock Center (BDSC), 
University of Indiana, USA. Flies were raised on standard cornmeal food in a 
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temperature-controlled laboratory (average room temperature 22°C). Mammalian 
genetic homology to Drosophila ortholog lines was determined by input of genes 
into DIOPT (DRSC Integrative Ortholog Prediction Tool (162): see Table 3). The 
elav-Gal4 driver strain was used for all experiments described (see Table 4). Crosses 
were maintained at 22°C for 24 hours before removal of adults and embryos were 
incubated at 30°C to increase levels and activity of the Gal4 proteins.  
 
 
Table 3: Drosophila lines utilized throughout the project. DIOPT score indicates 
mammalian genetic homology to ortholog lines. Higher scores denote increased 
candidate homology. Maximum score of 11. 
Gene Source Annotation symbol Drosophila stock ID DIOPT score 
Ndufb8 VDRC CG3192 v30413 8 
Vdac1 VDRC CG6647 v101336 7 
Mitofilin VDRC CG6455 v47615 6 
Aldh1 VDRC CG3752 v21707 5 
Mcu BDSC CG18769 42580 9 
Rab31 BDSC CG3870 9837 2 
Rhog BDSC CG8556 26650 3 
Cyc1 VDRC CG1659 v9180 11 
Uqcrc1 VDRC CG3731 v40466 7 
Wdr1 VDRC CG10724 v22851 11 
Rock2 BDSC CG9774 28797 10 
Capza2 VDRC CG10540 v100773 10 
Ogdh BDSC CG33791 34101 6 
Rcn2 VDRC CG31650 v30690 10 
Cdh2 VDRC CG42829 v36166 2 
 
 
Table 4: Drosophila driver and control lines. 
Drosophila Line Source Description 
Canton-S BDSC Wild-type  




Wandering third instar larva were selected and dissected in PBS (n=8). The dissected 
larval neuromuscular junctions (NMJs) were fixed in Bouin’s fixative (15:5:1 picric 
acid, 37% formaldehyde and acetic acid) for 10 minutes and washed thoroughly in 
PBT (PBS + 0.1% TritonX-100). Preparations were blocked in PBT + 10% normal 
goat serum for 2 hours then incubated in primary antibody overnight at 4°C. NMJs 
were again washed extensively in PBT and incubated in secondary antibody at room 
temperature for 2 hours (see Tables 5 & 6 for antibody details). Samples were 
mounted on microscope slides using Vectashield mounting medium (Vector 
Laboratories) and imaged on a Zeiss confocal microscope. All quantification was 
performed in ImageJ using a standardised protocol for NMJ analyses (163).  
 
 
Table 5: Primary antibodies employed for Drosophila immunohistochemistry 
experiments. 
Primary antibody Source Catalogue number 
Horse Radish Peroxidase 
(HRP) Jackson ImmunoResearch 323-005-021 
Discs Large 1 (DLG) Developmental Studies Hybridoma Bank 
4F3 anti-discs 
large 
Bruchpilot Developmental Studies Hybridoma Bank nc82-s 
 
 
Table 6: Secondary antibodies utilised for Drosophila immunohistochemistry 
experiments.  
Secondary antibody Source Catalogue number 










2.13 Statistical Analyses 
Data were collected in Microsoft Excel and statistical tests were performed in 
GraphPad Prism 6 software. For all analyses p<0.05 was considered significant. 























Chapter 3. Proteomic profiling of neuronal 
mitochondria reveals modulators of the synaptic 
architecture 
I confirm that I have authored the following work and that this 
chapter is currently under review at Molecular Neurodegeneration 
(August 2017). 
3.1 Introduction 
Ageing is a fundamental risk factor for the development of a large range of 
neurodegenerative diseases, which are characterized by the selective death of 
neuronal subpopulations (52, 164). Neurons are highly polarized cells consisting of 3 
distinct functional domains: the cell body, axon and the synapse. Previously, it was 
believed that the clinical phenotypes of neurodegenerative diseases were caused by 
the loss of entire neurons (165), however it has  recently become apparent that these 
neuronal sub-compartments can degenerate independently of one another (166, 167), 
with synapses being particularly vulnerable to a broad range of stimuli. Whilst the 
properties of the potential differential degenerative mechanisms remain largely 
unknown, numerous themes have consistently appeared in the literature, suggesting 
that proteins regulating the ubiquitin-proteasome system (14, 168, 169), oxidative 
stress (62, 66, 170, 171) and mitochondria (14, 52, 59, 60, 66, 171, 172) may all play 
a role in regulating the stability of the synaptic compartment. 
Synaptic compartments constantly demand ATP to maintain ionic gradients and 
neurotransmission events (173). In addition synapses also demonstrate a substantial 
need for calcium buffering machinery (172). Accordingly, sub-populations of 
mitochondria are enriched pre- and post-synaptically (14, 52, 66). Such synaptic 
mitochondria are reportedly distinguishable from non-synaptic mitochondria, 
displaying unique enzymatic (63), calcium buffering (64, 65) and antioxidant 
properties (66). However, if and how these distinctive subpopulations of synaptic 
mitochondria influence the vulnerability of synaptic compartments remains largely 
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unknown. 
In an attempt to address this, we have used label-free proteomics to characterise the 
proteomes of synaptic and non-synaptic mitochondria following established 
biochemical isolation methods (63). By utilizing this methodology, we have 
generated proteomic profiles that reveal consistent molecular fingerprints for 
synaptic and non-synaptic mitochondria. Quantitative fluorescent western blotting 
was used to confirm these proteomic and fractionation data in a range of species, 
including rat and ovine tissues.  These results were consistent with the existence of 
distinct mitochondrial sub-populations containing patterns of relative protein 
abundances that are conserved between different mammalian species. To determine 
if the molecular differences between these mitochondrial subpopulations may be 
capable of influencing the vulnerability of synapses, we manipulated the expression 
of mitochondrial candidates in vivo to assess synaptic stability in the Drosophila 
neuromuscular system. Our data demonstrate that selective knock-down of intrinsic 
mitochondrial proteins identified in this manner have the potential to alter synaptic 
morphology and the area of the presynaptic active zone in vivo. Thus, changes in 
mitochondrial protein expression may contribute to increased synaptic vulnerability 
and dysfunctional neurotransmission in early molecular pathological processes 









In compliance with the 3Rs, no animals were bred specifically for this project. 
Where possible all tissue samples used in this current study were derived from 
existing archived brains or harvested alongside other ongoing experiments. All 
animal experiments were approved by the University of Edinburgh Animal Welfare 
and Ethical Review Body and performed in accordance with the UK Animal 
(Scientific Procedures) Act, 1986. Use of human tissue for post-mortem studies was 
reviewed and approved by the Edinburgh Brain Bank ethics committee. The 
Edinburgh Brain Bank is a Medical Research Council funded facility with research 
ethics committee approval (11/ES/0022).  
 
3.2.2 Rats 
Nine male wild-type Sprague Dawley rats aged ca. 24 weeks (actual range 168-171 
days) were used. Rats were group housed (3-4 per cage) in a SPF facility in open-top 
cages and maintained on a 12-12h light-dark cycle (lights on at 07:00h), under 
controlled temperature (22±2°C) and humidity (55±5%) with free access to drinking 
water and standard 14% protein rodent diet (Harlan Teklad). Rats were killed by 
conscious decapitation and brains were immediately excised. Brain stem and 
cerebellum were removed and discarded. Fresh forebrains were weighed and pooled 
for homogenization before mitochondrial preparations. 
 
3.2.3 Sheep 
Three Scottish blackface female sheep aged 5 years were utilized. Sheep were 
sacrificed at the Farm Animal Teaching Hospital, Royal (Dick) School of Veterinary 
Studies, University of Edinburgh by anaesthetisation and exsanguination. Brains 
were excised, bisected at the sagittal midline and the brain stem and cerebellum were 
removed and discarded. Tissues were submerged in ice cold high magnesium 
artificial cerebral spinal fluid (NaCl 125mM; NaHCO3 26mM; glucose 25mM; KCl 
2.5mM; NaH2PO4(2H2O) 1.25mM; CaCl2 1mM;  MgCl2 4mM) to maintain brain 
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structural integrity before cortical mitochondrial preparations. 
 
3.2.4 Mitochondrial preparations 
For a comprehensive methodological outline see chapter 2, section 2.5 and Lai et al, 
1977 (63). Synaptic and non-synaptic mitochondrial populations were isolated from 
the rat and sheep tissues described in sections 3.2.1 and 3.2.2. Protein concentrations 
of each sample was determine using the methods outlines in chapter 2, section 2.6. 
 
3.2.5 Label-free proteomics 
Synaptic and non-synaptic mitochondrial preparations were extracted in SDT lysis 
buffer containing 100 mM Tris-HCl (pH 7.6), 4% (W/V) sodium dodecyl sulfate 
(VWR) and 0.1 M d/l-dithiothreitol (Sigma). For efficient protein extraction, lysates 
were freeze–thawed and homogenized in SDT buffer several times. Protein 
concentration was then determined using BCA assay.  
The following mass spectrometry analyses were performed by the FingerPrints 
proteomic facility at the University of Dundee. Aliquots (2mg) of each mitochondrial 
preparation were processed through FASP (filter-aided sample preparation) 
involving buffer exchange to 8 M urea and alkylation with 50 mM iodoacetamide 
prior to a double digestion with trypsin (Roche, sequencing grade), initially 
overnight, then for an additional 5 h at 30oC. Resulting peptides were desalted then 
separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system. 
Using an ESI Easy Spray source at 50 °C, technical replicates (3 × 0.75 µg) of each 
sample were loaded with a constant flow of 5 µL/min onto an Acclaim PepMap100 
nanoViper C18 trap column (100 µm inner diameter, 2 cm length; Thermo 
Scientific). After trap enrichment for 3 min, peptides were eluted onto an Acclaim 
PepMap RSLC nanoViper, C18 column (75 µm, 50 cm; Thermo Scientific) with a 
linear gradient of 2–40% solvent B (80% acetonitrile with 0.08% formic acid) over 
90 min with a constant flow of 300 nL/min. The HPLC system was coupled to a 
linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap Velos Pro, Thermo 
Scientific) via a nanoelectrospray ion source (Thermo Scientific). The spray voltage 
was set to 1.6 kV, and the temperature of the heated capillary was set to 250 °C. Full-
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scan MS survey spectra (m/z 335–1800) in profile mode were acquired in the 
Orbitrap with a resolution of 60"000 after accumulation of 1"000"000 ions. The 15 
most intense peptide ions from the preview scan in the Orbitrap were fragmented by 
collision-induced dissociation (normalized collision energy, 35%; activation Q, 
0.250; and activation time, 10 ms) in the LTQ after the accumulation of 10"000 ions. 
Dynamic exclusion parameters were set as follows: repeat count, 1; repeat duration, 
30 s; exclusion list size, 500; exclusion duration, 45 s; exclusion mass width, 
plus/minus 10 ppm (relative to reference mass). Maximal filling times were 1,000 ms 
for the full scans and 150 ms for the MS/MS scans. Precursor ion charge state 
screening was enabled, and all unassigned charge states as well as singly charged 
species were rejected. The lock mass (445.120"024), option was enabled for survey 
scans to improve mass accuracy. Data were acquired using the Xcalibur software (for 
all raw data see PRIDE project accession: PXD005537).  
 
The following experiments were performed by Laura Graham at the Roslin Institute. 
Raw proteomic data were imported into Progenesis for characterization and analysis 
of relative ion abundance. 2D representations of MS/MS output were created for 
each sample and these were aligned to determine similar features (average alignment 
score >90%). Following alignment, data was filtered by retention time with features 
detected below 5 minutes and above 110 minutes discarded to correct for elution 
variability and peptides with charge state between 2 and 5 only included in the 
search. The runs were grouped according to subcellular localization (synaptic and 
non-synaptic) and Statistical P values were automatically generated in Progenesis 
software through a 1 way ANOVA on the ArcSinh transform of the normalized data. 
Peptides were filtered by the following criteria: power <0.8, fold change >2, p<0.05 
and the remaining data were exported from Progenesis for identification of 
individual peptide sequences using the Uniprot Swall subspecies rattus norvegicus 
via Mascot Search Engine (V2.3.2). Enzyme specificity was set to that of trypsin, 
allowing for cleavage N-terminal to proline residues. Other parameters used were as 
follows. (i) Variable modifications: methionine oxidation, methionine dioxidation, 
protein N-acetylation, gln → pyro-glu. (ii) Fixed modifications: cysteine 
carbamidomethylation. (iii) MS/MS tolerance: FTMS- 10 ppm, ITMS- 0.6 Da. (iv) 
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Maximum missed cleavages: 2. (vi) False Discovery Rate: 1%. A cutoff score of >29 
was used based on Mascot probability threshold of 0.05 that the observed hit is a 
random event. As an indication of identification certainty, the false discovery rate for 
peptide matches above identity threshold was set at 1%. Identified proteins were re-
imported into Progenesis for further processing. Proteins were subject to stringent 
filtering parameters to eliminate those which had <2 unique peptides, <2-fold change 
between subpopulations and p>0.05 to obtain the proteins which demonstrated the 
largest significant variation in expression between synaptic and non-synaptic 
mitochondria. 
 
3.2.6 Quantitative Fluorescent Western Blotting 
For a comprehensive methodological outline see chapter 2, section 2.10 and Eaton et 
al, 2013 (161). Western blotting was performed on synaptic and non-synaptic 
mitochondrial isolates derived from both the rat and sheep cortical tissues. All 
antibodies details are listed in Tables 1 & 2. 
 
3.2.7 Transmission Electron Microscopy 
Control mixed sex human patient brain samples (n=4) were prepared for electron 
microscopy as previously outlined in detail (174). Briefly, fresh post-mortem 
samples, stored in 0.1 M PB were trimmed into small cortical blocks and fixed in 
4 % paraformaldehyde and 2.5 % glutaraldehyde in 0.1 M PB for 48 h. Mouse brain 
samples were prepared as follows: anesthetized WT male C57BL/6J mice ((n=4) 
intraperitoneal injection of Ketanest (100 mg/kg) and Rompun (5 mg/kg)) were 
killed by perfusion fixation with 0.1M phosphate buffer containing 4% 
paraformaldehyde and 2.5% glutaraldehyde before removing the brain and 
immersing it in fixative for a further 12 h. Following fixation, both human and 
mouse brain samples were washed in 0.1 m phosphate buffer before cutting free 
floating 70-µm-thick coronal sections on a Vibratome. Sections were postfixed in 1% 
osmium tetroxide in 0.1 m phosphate buffer for 45 min. Following dehydration 
through an ascending series of ethanol solutions and propylene oxide, all sections 
were embedded on glass slides in Durcupan resin. Regions of interest were glued 
onto a resin block for sectioning. Ultrathin sections (60–70 nm) were cut and 
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collected on Formvar-coated grids (Agar Scientific), stained with uranyl acetate and 
lead citrate in an LKB “Ultrostainer”, and then quantitatively assessed in a Philips 
CM12 transmission electron microscope. Negatives taken in the microscope were 
scanned into an Apple Macintosh G5 computer using an Epson 4870 Photo flat-bed 
scanner at 600dpi and subsequently processed using Adobe Photoshop. Images were 
analysed using ImageJ. Prof. Tom Gillingwater performed the electron microscopy 
experiments and provided control human patient and WT mouse cortical images for 
analysis. 
 
3.2.8 Ingenuity Pathway Analysis 
Please refer to chapter 2, section 2.9 for a detailed overview of the methodological 
parameters employed for pathway analysis.  
 
3.2.9 Drosophila Stocks 
Drosophila stocks were obtained from the VDRC (IDs: 21707, 47615, 101336, 
30413) and Bloomington Drosophila stock center (Canton-S). For more information 
on the stocks utilised and homology of the Drosophila ortholog with regards to the 
mammalian gene please refer to Tables 3 & 4. Off-target effects of candidate lines 
were assessed using E-RNAi software (175). Candidate lines exhibited no off-target 
effects based on genetic mapping data and all displayed 97.21-100% efficiency for 
targeting the intended gene (Ndufb8 = 97.75%; mitofilin = 97.21%; Vdac1 = 100%; 
Aldh = 100%). The Drosophila experiments described in this chapter were 
performed in conjunction with Dr. Giuseppa Pennetta. 
 
3.2.10 Statistical Analysis 
Data were collected in Microsoft Excel and statistical tests were performed in 
GraphPad Prism 6 software. For all analyses p<0.05 was considered statistically 







3.3.1 Mitochondrial subcellular localisation dictates organelle 
morphology in rodents and humans  
Enzymatic activity differences between neuronal mitochondrial sub-populations 
were first comprehensively described in the 1970s (63). However, the molecular 
underpinnings of these biochemical differences and their morphological or 
physiological consequences were never elucidated. We therefore began by 
investigating whether mitochondria residing at the pre-synaptic terminal were 
morphologically different from those in non-synaptic compartments. It has 
previously been suggested that the size of mitochondria may provide indications of 
biochemical processes as well as neuronal integrity and survival. Numerous studies 
have begun to describe mitochondrial morphology in the cell body (66, 176-178) but 
few demonstrate characterisation of those organelles in the axon and synapse – the 
compartments that show heightened vulnerability to degenerative insult. To establish 
whether size differences existed between synaptic and non-synaptic mitochondria, 
we examined transmission electron microscopy images from human and mouse 
cortical tissue. Mitochondria were classified as ‘synaptic’ if they were <1µm from 
the post-synaptic density and vesicles were clearly present within the terminal. 
Mitochondria outside of the boutons were classed as non-synaptic; anything 
ambiguous was excluded from the analysis. The results indicate that in both mouse 
and human cortex, non-synaptic mitochondria appear significantly larger than the 
organelles present within synaptic terminals ((Fig. 13) mouse: p<0.0001; human: 
p=0.0099, respectively). Non-synaptic populations in both species demonstrated 
elongation versus that of synaptic mitochondria, which displayed a spherical 
morphology (data not shown). Although these morphological differences between 
mitochondrial sub-populations may solely reflect adaptations to the particular size 
and structure of cellular compartments, we hypothesised that biochemical 
adaptations would also likely exist due to the dynamic interplay between protein 
expression and organelle configuration (see Picard et al, 2013 for a comprehensive 





Figure 13: Synaptic and non-synaptic mitochondria are morphologically distinct in 
both rodent and human brain tissue. A&B. Example EM images of WT mouse and 
human cortical tissue displaying synaptic and non-synaptic mitochondria (S = synaptic, NS = 
non-synaptic). C&D. Scatterplots representing WT mouse (C.) and control human patient 
(D.) cortical synaptic and non-synaptic mitochondrial areas (µm2). C. synaptic n=391, non-
synaptic n=1113 from 4 mice; D. synaptic n=177, non-synaptic n=812 from 4 patients. A 
data point of distinct shape represents each individual animal or patient. Non-synaptic 
mitochondria appear to be significantly larger than synaptic mitochondria in both mouse and 
human cortical tissue. Student’s t-test with Welch correction for unequal sample size: 
****p<0.0001, **p<0.01). Scale bar = 0.5µm. 
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3.3.2 Label-free proteomics reveals significant mitochondrial 
heterogeneity 
To identify molecular differences between mitochondria derived from synaptic and 
non-synaptic neuronal compartments, we performed label-free proteomics on 
mitochondrial-enriched fractions isolated from rat forebrain. Quantitative label-free 
proteomic analyses identified >1500 proteins associated with both synaptic and non-
synaptic mitochondria, revealing dynamic variations in protein expression dependent 
upon subcellular localisation (Fig. 14A&B). Strikingly, over 400 proteins were 
altered by greater than 2-fold between mitochondrial subpopulations (Fig. 14C), 












Figure 14: Identification of the mitochondrial proteome. A. 2-way clustering of 1511 
proteins identified in both synaptic (S) and non-synaptic (NS) mitochondrial samples. Each 
column represents a single LC-MS/MS run, based on log-transformed data. Proteins (rows) 
and samples (columns) are clustered by similarities in protein expression intensity, 
represented by the colour range: dark blue = least abundant, to dark red = most abundant. 
Dendrogram indicates protein expression differences between synaptic and non-synaptic 
mitochondrial sub-populations in addition to grouping of individual proteins that 
demonstrate similar intensity profiles. B. Graph represents expression of all 1511 identified 
proteins with 2 or more unique peptides, independent of magnitude. C. Graph displays the 
411 proteins which have a >2 fold change between populations, p<0.05 and were identified 
with >1 unique peptide. The expression profile demonstrates 2 clear trends of differential 
protein expression between the sub-populations of mitochondria: proteins that are more 
abundant in synaptic mitochondria and less abundant in non-synaptic, and vice-versa. D&E. 
Principal components analyses of the unfiltered (D.) and filtered (E.) proteomic data. Pink 
data points denote non-synaptic mitochondrial samples and blue data points indicate synaptic 
mitochondrial samples. Samples are clustered by subcellular localization in both the filtered 
and unfiltered datasets with little technical variation. Grey displays identified proteins by 
accession number. 
 
Relative purity of mitochondrial isolates was assessed using bioinformatics 
enrichment analyses (Table 7) and quantitative fluorescent western blotting (QFWB) 
on ovine forebrain. The mitochondrial yield obtained from rat forebrain was not 
sufficient for validation purposes (see methods). The mitochondrial markers VDAC1 
and COXIV indicated significant enrichment in synaptic and non-synaptic 
mitochondrial fractions versus whole brain lysate suggesting purification of the 
mitochondria from their respective subcellular compartments (Fig. 15A). In addition 
to demonstrating purification of mitochondrial subpopulations, we again employed 
QFWB to determine the veracity of the proteomic data. We observed corresponding 
protein expression trends in each tissue preparation, as indicated by the proteomics, 
for multiple proteins (Fig. 15C-E). Taken together, these results indicate the relative 
purity of the mitochondrial isolates and suggest the proteomic data is representative 
of the molecular alterations occurring in the tissue samples. Furthermore, the data 
indicate that the observed heterogeneity in mitochondrial protein expression may be 
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conserved between mammalian species.  
 
 
Figure 15: Purification of distinct mitochondrial subpopulations and validation of 
proteomic data. A. Quantitative fluorescent western blots demonstrating relative abundance 
of the mitochondrial markers COXIV and VDAC1 and the nuclear marker telomerase in 
whole brain lysate and mitochondrial samples. Mitochondrial samples display little nuclear 
contamination and enrichment of COXIV and VDAC1. B. Quantification of the beta-tubulin 
loading control signal. C. Left bar chart displays the proteomic average normalised 
expression values of proteins in synaptic and non-synaptic mitochondria. Right bar chart 
demonstrates sample protein expression quantified by fluorescent western blots. Proteomic 
and sample expression of all proteins (HIBCH, OGDH and citrate synthase) follow the same 
trend thereby providing validation of the proteomic data. Statistical analysis was performed 
using an unpaired two-tailed Student’s t-test, n=3. 
 
 
Table 7: DAVID 6.7 (NIAID/NIH) enrichment analysis of synaptic and non-synaptic 
mitochondrial samples. Table comprises the top gene ontology (GO) terms associated with 
1511 proteins identified in synaptic and non-synaptic mitochondrial samples. The analysis 
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3.3.3 Expression profiling highlights bioenergetic alterations 
between synaptic and non-synaptic mitochondrial proteomes  
Having confirmed the veracity of the proteomic data, we next sought to further 
dissect the proteomic data using Biolayout Express3D (159). The software applies 
unbiased Markov clustering algorithms to the input data and groups proteins 
displaying similar expression trends. This allows visualisation of spatial profiles 
promoting the identification of physiological cascades altered within the dataset. The 
nodes, shown as spheres with identical dimensions, signify individual proteins and 
the edges, represented by connecting lines, are indicative of the correlation of protein 
expression within the data. Graphs were constructed in 3D space utilizing the 1511 
identified proteins from the mitochondrial proteomic analysis (see Fig. 14B&C), 
generating 10 protein clusters. In agreement with the principal component analysis 
correlation graphs (Fig. 14D&E), network clustering of the data displayed similar 
trends with regards to fragmentation of the graph into two localisation-dependent 
networks (Fig. 16).  The fragmentation of the dataset into 2 distinct groups suggests 
that significant heterogeneity in protein expression exists between the mitochondrial 
populations derived from discrete neuronal sub-compartments. Indeed, with further 
examination we exhibited that proteins with increased abundance in synaptic 
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mitochondria cluster into the distinct network on the left of the graph whereas those 
with increased abundance in non-synaptic mitochondria are observed in the right 
network (Fig. 16). To identify the functional cascades associated that appear to 
demonstrate differential expression between the two mitochondrial subpopulations, 
the top 3 protein clusters were entered into Database for Annotation, Visualization 
and Integrated Discovery (DAVID) v6.7 to determine the basic functions of the 
clustered proteins (Fig. 16). Interestingly, the proteins that exhibit upregulation in 
synaptic mitochondria (clusters 1 and 2) are associated with the inner membrane 
bioenergetic complexes, which suggests that distinct synaptic and non-synaptic 
mitochondrial protein expression may reflect altered local requirements for energetic 
expenditure. Interestingly, these data correlate with the original biochemical study by 
Lai et al (63), which reported variations in mitochondrial enzymatic activities 
dependent upon the subcellular localisation of the organelles. Here, we can account 
for approximately 35% of those reported enzymatic activity alterations, which are 
likely due to the differing abundance of particular enzymes in the discrete sub-pools 
of mitochondria.  
 
 
Figure 16: Expression profile clustering identifies alterations associated with 
bioenergetic control. Nodes (spheres) represent individual proteins and edges (lines) reflect 
the strength of correlation of expression between proteins. The schematic displays 2 distinct 
protein networks – proteins displaying increased abundance in synaptic mitochondria on the 
left and those exhibiting enhanced expression in non-synaptic mitochondria on the right. 
Coloured nodes represent protein clusters based on expression profile and each cluster 
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3.3.4 Pathway analysis highlights mitochondrial complex I 
expression differences as potentially conserved regulators in a range 
of neurodegenerative conditions.  
In order to determine how differential protein expression in mitochondrial 
subpopulations may synergistically regulate downstream molecular pathways and 
cellular processes, we performed an in silico analysis using Ingenuity Pathway 
Analysis (IPA) software. The software promotes the identification of statistically 
significant functional groups of proteins, based on known protein interactions and 
biological functions reported in the published literature (157). Functional networks 
generated by IPA software are statistically ranked according to a score calculated via 
a right-tailed Fischer's exact test, taking into account the number of original input 
proteins and the size of the resulting network. With input of the 411 differentially 
expressed proteins from the mitochondrial proteomic data (>2-fold change), the 
analysis revealed that 154 (37%) candidates have previously been associated with 
neurological diseases in the published literature (Fig. 17A), suggesting that a 
multitude of these proteins may play a role in regulating synaptic stability.  
 
Further examination into the molecular cascades that may be associated the 
pathogenesis of neurodegenerative diseases highlights that mitochondrial complex I 
is an upstream regulator of degenerative processes (Fig. 17B). The particular 
expression of proteins downstream of complex I in synaptic, but not non-synaptic, 
mitochondria have previously been implicated in numerous neurodegenerative 
diseases including Huntington’s disease, Parkinson’s disease and Lewy body 
dementia - all of which demonstrate synaptic perturbations early during pathogenesis 
(for a comprehensive review see (52)). These results suggest that modulation of the 
synaptic mitochondrial proteome may synergistically drive the demise of the synapse 
in age-related neuropathologies.  In conjunction, assessment of the downstream 
physiological cascades modulated by synaptic mitochondrial protein expression 
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identified significant inhibition of synaptic transmission cascades (Fig 17C). The 
increased expression of alpha-synuclein, GAD1, SH3GL1, SH3GL2, S100B PPP3R1 
and SYT1 in the non-synaptic mitochondrial proteome appears to indirectly inhibit 
synaptic transmission. Conversely, the enhanced expression of SNPH, PRNP, 
GNAI1 and GNAI2 in synaptic mitochondria inhibits neurotransmission cascades in 
the synaptic compartment. This suggests that heterogeneity in discrete mitochondrial 
proteomes and their associated downstream pathways has the propensity to promote 





Figure 17: Pathway analysis highlights mitochondrial alterations associated with 
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altered synaptic function and a broad range of neurodegenerative diseases, mediated 
by complex 1. A. 411 differentially expressed mitochondrial proteins are implicated in the 
literature as contributors to neurological disease, psychological disorders and skeletal and 
muscular disorders. B. Mitochondrial complex 1 is central to the network of interactions 
(highlighted in light blue) and features a number of intrinsic mitochondrial proteins and 2 
protein families. Expression of the synaptic mitochondrial proteome is associated with 
perturbed synaptic structure and function. C. The significant differential expression of 
proteins in synaptic and non-synaptic compartments appears to inhibit downstream pathways 
associated with synaptic transmission. Solid lines indicate direct interactions; dashed lines 
represent indirect interactions; proteins highlighted in pink are those which are more 
abundant in synaptic mitochondria; proteins in green are those which are more abundant in 
non-synaptic mitochondria; dark blue represents predicted pathway inhibition. Shapes are 
indicative of protein function: diamond = enzyme; rectangle = GPCR; square =cytokine; 
trapezoid = transporter; circle = other. 
 
 
3.3.5 Mitochondrial proteins regulate synaptic morphology in vivo 
Although we had generated a compendium of the molecular differences present 
between synaptic and non-synaptic mitochondrial populations, it remained unclear if 
any of the identified proteins were capable of actively modulating synaptic stability 
in vivo. To assess this, we employed a molecular genetic approach using the 
Drosophila larval neuromuscular junction (NMJ) to screen individual proteins to 
examine their potential role in regulating synaptic morphology. The larval NMJ is an 
excellent model system to unravel the molecular mechanisms underpinning synaptic 
structure, function and plasticity (151). Fundamental mammalian biological and 
neurological pathways demonstrate conservation in Drosophila and recent evidence 
has indicated that up to 75% of human disease related genes exhibit a functional 
orthologue in the fruit fly (145). Larval NMJs harbour glutamatergic synaptic 
boutons with contiguous invaginated post-synaptic membranes (153, 154), which 
display significant homology to those found in the mammalian central nervous 
system. Neurotransmission between these connections has the propensity to invoke 
plastic modifications (151, 153, 155), providing physiologically relevant mechanistic 
insights into proteins regulating the structure and function of the synapse in 
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mammalian cognition (155). 
 
In order to assess whether the expression of particular proteins in synaptic 
mitochondria may be regulating the morphology of the synapse, we utilised the 
Drosophila UAS/Gal4 system, which allows tissue specific expression of a particular 
transgene with use of selected drivers. We selected candidates based on magnitude of 
change, mitochondrial localisation and availability of Drosophila orthologues (see 
Table 2). Interestingly, the short-listed candidates displayed increased protein 
expression in synaptic versus non-synaptic mitochondria. Thus, we aimed to 
selectively knock-down the expression of these mitochondrial proteins in third instar 
larva neurons for assessment of associated phenotypes. Pan-neural expression of the 
RNAi constructs (v30413; v47616; v10136; v21707) under control of the elav-Gal4 
driver resulted in viable larva from all crosses. To assess synaptic morphology and 
potential mitochondrial-dependent alterations in synaptic transmission, we examined 
the larval muscle 12/13 NMJ by immunohistochemistry with antibodies against the 
presynaptic marker horseradish peroxidase (HRP) and active zone marker bruchpilot 
(BRP). Here, we found that the selective RNAi-mediated knock-down of single 
candidates produced striking synaptic phenotypes at the NMJ (Fig. 18). NDUFB8, 
mitofilin, VDAC1 and ALDH demonstrated varied phenotypes at the NMJ with 
alterations in distinct synaptic parameters including bouton diameter and total bouton 
area (Fig. 18). The most severe phenotype was associated with selective knock-down 
of aldehyde dehydrogenase (ALDH), which promoted significant reductions 
(p<0.05) in synaptic bouton area with concomitant loss of distinguishable Ib and Is 
boutons (Fig. 18A). In conjunction, there was a significant decrease (p<0.0001) in 
synaptic bouton active zone staining (Fig. 19A) relative to control NMJs. Similarly, 
knock-down of neuronal NDUFB8 expression promoted aberrant NMJ morphology 
(Fig. 18A&B) with significant increases in bouton diameter. Despite this, the NMJs 
demonstrated a corresponding reduction in active zone area (p<0.0001) versus 
controls (Fig. 19A&C). Interestingly, we did not observe any obvious perturbations 
in axonal branching or morphology in our elav-Gal4/RNAi lines (Fig. 18F&G), 
suggesting that selective knock-down of these candidates promotes selective 
alterations in synaptic morphology, mediated by mitochondrial protein expression. 
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Significant reductions in the area of active zone staining in both the ALDH and 
NDUFB8 RNAi lines suggests that mitochondria may have a direct functional 
impact on vesicular release and bouton firing properties. Although the mechanistic 
pathways modulating these alterations remain elusive, regulation of the 
mitochondrial proteome appears to be significant mediator of synaptic-specific 
structural and biochemical properties.  
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Figure 18: Mitochondrial candidates modulate synaptic morphology in vivo. A. 
Representative image of WT muscle 12 NMJ in abdominal segment A3 (n=8) 
immunostained with anti-HRP. B-E. Top panel displays representative images of muscle 12 
NMJ, hemisegment A3 bouton morphology with candidate knock-down. Middle panel 
demonstrates masks utilized for quantification of HRP staining in ImageJ. Lower panel 
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shows a section of axon. Scale bar = 10um for synaptic HRP and mask layers, 5um for 
axons. B. elav-GAL4/Ndufb8RNAi; C. elav-GAL4/MitofilinRNAi; D. elav-
GAL4/Vdac1RNAi; E. elav-GAL4/AldhRNAi. Arrows represent loss or alteration of 
boutons and/or fragmentation of dendritic branches. A variety of phenotypes exist. All NMJs 
immunostained with anti-HRP and imaged at 63x (n=8). F. Quantification of axon diameter 
in candidate lines versus control (Ndufb8 p=0.4095; Mitofilin p=0.169; Vdac1 p=0.1427; 
Aldh p=0.3138). G. Quantification of number of NMJ branches in candidate lines versus 
control (Ndufb8 p=0.1161; Mitofilin p=0.117; Vdac1 p=0.2722; Aldh p=0.0522). H. 
Quantification of the synaptic bouton diameter in candidate lines versus control (Ndufb8 
p=0.0003; Mitofilin p=0.5759; Vdac1 p=0.0003; Aldh p=0.5291). I. Quantification of the 
total bouton area in candidate versus control lines (NDUFB8 p=0.4246; Mitofilin p=0.0078; 
Vdac1 p=0.6083; Aldh p=0.0337). All quantification used students t-test; * = p<0.05, ** = 
p<0.01, *** = p<0.001, **** = p<0.0001. 
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Figure 19: Manipulation of the mitochondrial proteome modulates active zone 
expression. A. Representative images of WT, NDUFB8 and ALDH muscle 12 NMJs from 
abdominal segment A3 (n=8) immunostained with anti-HRP and anti-bruchpilot. Bottom 
panel displays ImageJ quantification mask utilized for analysis of HRP staining. B. 
Quantification of total bouton area in NDUFB8 and ALDH RNAi lines. C. Quantification of 
total NMJ active zone area in NDUFB8 and ALDH RNAi lines. All quantification used 




The current study has demonstrated novel insights into how a ‘top-down’ approach 
may be utilised for identifying individual proteins that may modulate the stability of 
synaptic compartments in vivo. By using a range of techniques we have shown that 
neuronal mitochondria derived from synaptic and non-synaptic cellular 
compartments display significant morphological and biochemical differences. 
Electron microscopy analyses from mouse and human cortical tissue suggest that 
non-synaptic mitochondria are significantly larger than those found in the synaptic 
terminal. Alongside these morphological alterations, we have also demonstrated that 
upwards of 400 mitochondrial associated proteins identified from our label-free 
proteomic experiments display a ≥2-fold expression difference between sub-
populations. Using molecular genetic tools at the Drosophila neuromuscular 
junction, we were able to manipulate the expression of 4 of the identified candidates 
that displayed increased abundance in synaptic mitochondria, resulting in selective 
alterations in synaptic, but not obvious axonal morphology in vivo. Our data promote 
further understanding of the basic biology of the mitochondria and how these 
organelles may regulate the vulnerability of the synapse in a physiologically relevant 
model. In addition, the results presented may provide increased insight into how 
mitochondrial perturbations influence the synaptic alterations commonly occurring 
during ageing and disease.  
Our initial proteomic screen revealed a remarkably large and heterogeneous list of 
candidates that significantly differed in expression dependent upon mitochondrial 
subcellular localisation. Despite this heterogeneity, upon further analysis of the data 
utilising in silico tools, it became apparent that many of these proteins have 
previously been associated with perturbations in synaptic transmission. Experimental 
manipulation of 4 of these candidates produced varied synaptic phenotypes. The 
differing morphological phenotypes likely reflect the functional specificities, 
biological roles and downstream cascades associated with the proteins. NDUFB8, a 
mitochondrial complex I subunit, produced a relatively mild phenotype at the NMJ 
with morphological overgrowth but retention of branching patterns seen in controls. 
The preservation of numerous morphological characteristics despite NDUFB8 
! 91!
knock-down may reflect a compensatory mechanism occurring within the elaborate 
multi-subunit complex I. Conversely, reductions in ALDH expression resulted in the 
most severe phenotype, with significant alterations in synaptic bouton morphology 
and striking alterations within the NMJ architecture. This is likely due to its primary 
role in protecting mitochondria from endogenous aldehydes generated by lipid 
peroxidation (179). With reductions in ALDH, it is probable that an accumulation of 
noxious metabolites occurs, resulting in cytotoxicity. In support of our observations, 
a previous study from our laboratory (158) reported that Drosophila harbouring 
mutant ALDH displayed spontaneous degeneration of axons in the olfactory receptor 
neuron, however the presence of a synaptic phenotype was not morphologically 
assessed in that system. Furthermore, there have been several recent reports 
documenting a potential detoxification role for ALDH specifically in populations of 
dopaminergic neurons (180). Notably, sub-populations of dopaminergic cells from 
the brains of Parkinson’s disease patients demonstrated a significant reduction in 
ALDH (181), which may contribute to alterations in synaptic stability resulting in the 
activation of degenerative cascades.  
Despite NDUFB8 and ALDH demonstrating varied synaptic bouton phenotypes, 
both candidates promoted a significant reduction in the active zone area. 
Mitochondrial morphology and function has been associated with alterations in the 
efficacy of the presynaptic active zone in numerous investigations, however the 
molecular mediators regulating such events remain elusive. Synaptic transmission is 
a bioenergetically demanding process requiring the persistent aerobic production of 
ATP and buffering of intracellular Ca2+ concentrations. Evidence indicates that 
mitochondria redistribute and bind to the active zone in response to synaptic 
transmission for homeostatic regulation at the synapse (182, 183), promoting the 
controlled exocytosis underpinning neurotransmission. Disruptions in the 
mitochondrial proteome may have the propensity to alter the functional organisation 
and stability of the active zone by reductions in calcium buffering, ATP availability 
and/or vesicular endocytosis. Although we directly manipulated the expression of 
NDUFB8 and ALDH, it is likely that the NMJ mitochondria harboured further 
disruptions to the proteome that were hierarchically driven by alterations in the 
candidates, which may have synergistically promoted aberrations at the active zone.  
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Although a conventional RNAi screen would require multiple RNAi and point 
mutations to be certain of the importance of specific candidates, we have presented 
several novel synaptic specific phenotypes with selective knock-down of single 
mitochondrial candidates. However, it is unlikely that the expression of these 
proteins solely regulate synaptic morphology and stability. Instead, it is probable that 
multiple cellular and molecular pathways, up-and downstream of the mitochondria, 
converge to modulate compartmental stability in mammalian systems. Despite this, 
protein expression within the mitochondria, as well as the subcellular localisation of 
the organelle, are clearly important variables that must be considered when 
characterising cascades negatively affecting synaptic morphology, transmission and 
physiology. 
A next logical step in determining how the mitochondrial proteome may be 
contributing to synaptic vulnerability in vivo, is to perform an ageing study using the 
same tools and techniques presented in the current investigation. It has been well 
documented that mitochondria dynamically alter dependent on their environment 
(63-66), and we have provided further evidence for this hypothesis here. However, 
few studies have attempted to investigate how the synaptic mitochondrial proteome 
alters during ageing and how variations in protein expression may impact on the 
function and architecture of the synapse in a physiologically relevant model. An 
examination of such processes provides scope to potentially identify mitochondrial 
proteins that may be contributing to synaptic demise during normal healthy and 
pathological ageing. Furthermore, these data may indicate why such large disparities 
appear to exist with regards to the vulnerability of synaptic and neuronal populations 
with different pathogenic insults. 
Although the use of label-free proteomics has provided a fairly comprehensive 
coverage of the mitochondrial proteome (this study yields the highest identification 
of mitochondrial proteins in a single in vivo analysis to date (1511)), for improved 
detection of low molecular weight proteins other techniques such as tandem mass 
tagging with high fractionation may be employed for future experiments. It is highly 
likely that numerous mitochondrial proteins that were not detected or removed from 
the data due to stringent filtering parameters, may influence synaptic stability in vivo. 
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Despite this, it is abundantly clear that proteomics and molecular genetics are 
powerful tools to identify candidates that may impact upon synaptic structure and 
function. 
The current study has demonstrated novel insights into how a ‘top-down’ approach 
may be utilised for identifying novel candidates that may modulate the stability of 
synaptic compartments in vivo. Our investigation has established that the 
morphological and biochemical properties of synaptic and non-synaptic 
mitochondria differ significantly across a multitude of mammalian species. Using 
molecular genetic tools at the Drosophila neuromuscular junction, manipulation in 
the expression several candidates that displayed increased abundance in synaptic 
mitochondria, resulted in selective alterations in synaptic, but not axonal morphology 
in vivo. Thus changes in mitochondrial protein expression may contribute to 
increased synaptic vulnerability in early molecular pathological processes during 














Chapter 4. The ageing mitochondrial proteome and 
regulation of the synaptic milieu 
4.1 Introduction 
As alluded to in Chapter 3, mitochondria are incredibly dynamic and heterogeneous 
organelles that have the propensity to directly modulate the morphology of the 
synaptic architecture. Although mitochondria have long been considered a 
biochemical substrate significantly contributing to the dysfunction of neuronal 
compartments during advancing age (184), the mechanisms orchestrating such events 
and how these may impact upon cognitive function remain poorly understood. 
Traditional theories of age-dependent mitochondrial dysfunction, such as the free 
radical theory of ageing (92) - which suggests that mitochondrial reactive species 
cumulatively promote cellular damage during the lifespan - are now beginning to be 
revised due to novel experimental evidence languishing numerous facets of the 
model (184, 185). In recent years, a wealth of innovative studies has promoted the 
development of an alternative multi-factorial model of mitochondrial ageing 
suggesting that alterations in reactive species detoxification (186), bioenergetics 
(187), Ca2+ buffering capacity (188), mtDNA integrity (189) and organelle dynamics 
(190) synergistically facilitate changes in neuronal receptivity during advancing age.  
As previously discussed, synapses are particularly susceptible to the effects of 
advancing age, however the biochemical cascades governing this compartmental 
vulnerability remain elusive. Accordingly, recent investigations have begun to 
delineate how temporal alterations in mitochondrial subpopulations may be 
contributing to perturbations in the synaptic milieu and facilitating concomitant 
cognitive decline. Indeed, morphometric analyses of mitochondria using 3D electron 
microscopy techniques in young and aged rhesus macaques revealed significant age-
dependent morphological alterations in organelles within cortical presynaptic 
terminals, which robustly correlates with cognitive capacity (190). Young animals 
exhibited stereotypical spherical and tubular mitochondria, whereas old animals 
appeared to harbour numerous “donut” shaped organelles, which are considered to be 
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indicative of mitochondrial dysfunction. Intriguingly, the number of “donut” 
mitochondria directly correlated with the size of the presynaptic active zone and 
number of synaptic vesicles, in addition to the severity of cognitive impairment, 
suggesting that divergent mitochondrial morphologies may unequivocally modulate 
synaptic transmission, plasticity and stability during advancing age (190, 191). In 
agreement with this, investigations examining synaptic mitochondrial motility have 
reported that the presence of mitochondria within the presynaptic compartment 
dictates the strength of transmission (192). Retrograde trafficking of mitochondria 
away from the presynaptic terminal mediates reductions in synaptic strength, 
whereas the presence of the organelles in apposition to the active zone promotes 
sustained neurotransmitter release and plastic modifications within the synaptic 
terminal (192). Together, these data indicate that synaptic mitochondria play a 
fundamental role in regulating a multitude of properties at the synapse (191) and 
dynamic temporal modifications of this discrete population of organelles may 
significantly impact upon the structure and function of the compartment, promoting 
alterations in cognitive capacity.  
The outlined studies documenting the dynamic intersection between mitochondrial 
morphology and synaptic function during ageing are particularly compelling, 
highlighting the influence of mitochondria on cognition. Molecular investigations 
attempting to unravel the causal and/or concomitant temporal biochemical alterations 
regulating this shift in synaptic mitochondrial morphometry however, demonstrate 
significantly variable results, with reports describing conflicting changes in 
important modulatory processes such as respiratory capacity (187, 193-196) and the 
fission/fusion balance (194, 196, 197). Indeed, it is well established that the dynamic 
regulation of mitochondrial morphology by fission and fusion events mediates 
mtDNA integrity, respiration and free radical generation, and equilibration of these 
processes appears critical during ageing (198, 199). Notably, numerous studies report 
reductions in the expression of fission proteins in aged cells (200, 201), shifting the 
fission/fusion equilibrium. Fission enables the segregation and sequestration of 
damaged organelles via autophagy pathways, promoting the maintenance of a 
healthy pool of functional mitochondria (60). Age-dependent decreases in proteins 
regulating fission are associated with “giant” and “donut” dysfunctional 
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mitochondria (198), in addition to reduced numbers of organelles within synaptic 
terminals, which mitigate synaptic vesicle mobilisation during neurotransmission 
(60, 190). Reductions in fission events have also been directly associated with 
attenuated autophagy, suggesting that modifications in neuronal mitochondrial 
morphology may directly modulate proteostasis (201). Despite this, conflicting 
studies have indicated that age-dependent increases in mitochondrial fission may also 
be detrimental to the synapse. Investigations modelling numerous age-related 
neurodegenerative diseases in vitro report excessive fission-mediated mitochondrial 
fragmentation as an early pathogenic event (202), promoting organellar and cellular 
dysfunction and damage. 
Of course, mitochondrial morphology and function are not mutually exclusive and a 
reciprocal effect exists upon physiological alteration of either parameter (203). Thus, 
investigations have begun to examine whether the respiratory capacities of synaptic 
and non-synaptic mitochondria alter with advancing age and identify how these 
changes may bolster compartmental vulnerability. Indeed, a recent proteomic study 
examining the temporal alterations occurring in the mouse synaptic mitochondrial 
proteome reported that increased age promoted the progressive downregulation of 
mitochondrial electron transport chain subunits, however, this appeared to have no 
functional impact on the bioenergetic capacity of isolated synaptic mitochondria 
(194). Despite this, there are now a number of studies disputing these results and 
investigations employing similar biochemical methodologies reveal that synaptic 
mitochondrial respiratory capacity is diminished with advancing age (187, 193, 204). 
Although, the reported respiratory data is not in agreement with the literature, the 
investigation also documented an accumulation of synaptic mitochondrial mtDNA 
damage, increases in reactive species and reductions in the expression of fission 
proteins (194), which appear to closely coincide with the studies highlighted above 
(186, 189, 200, 201). Although the adoption of proteomic methodologies to track the 
molecular spatiotemporal alterations occurring in synaptic mitochondria is an 
admirable approach, the authors did not include a non-synaptic mitochondrial 
population for proteomic comparison, thus preventing delineation of how 
subpopulation-specific biochemical alterations may be modulating compartmental 
vulnerability during ageing. It is imperative that future studies address the subcellular 
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divergence in temporal mitochondrial protein expression to enable identification of 
functional mediators that may be promoting perturbations in the synaptic 
compartment during advancing age.  
Mitochondria unequivocally exhibit subcellular heterogeneity in morphology and 
protein expression (refer to Chapter 3) and studies are now beginning to demonstrate 
that the synaptic mitochondrial proteome may be dynamically altered during ageing 
(194). However, the presence of discrepancies regarding the temporal regulation of 
mitochondrial properties in the literature has hampered the identification of 
functional mitochondrial mediators that may be modulating synaptic stability and 
cognitive decline during advancing age. There is significant demand for well-
executed, physiologically relevant studies that characterise the spatiotemporal 
molecular alterations occurring in both synaptic and non-synaptic mitochondria to 
enable the identification of biochemical cascades that may be promoting age-
dependent vulnerability of the synaptic compartment.  
In order to address this, here we employ an unbiased combinatorial approach, 
including quantitative proteomics coupled with in vivo phenotypic assessments, to 
temporally profile the biochemical alterations occurring in mitochondrial 
subpopulations throughout normal healthy ageing in the rodent cortex. We 
demonstrate that mitochondrial ageing is highly heterogeneous and subcellular 
localisation dictates the biochemical composition of discrete mitochondrial 
populations throughout the lifespan. Strikingly, we reveal that over 1000 proteins are 
temporally altered by greater than 20% in both synaptic and non-synaptic 
mitochondrial populations, demonstrating significant age-dependent modifications at 
the proteome level. Interestingly, aged synaptic mitochondria exhibit significant 
divergence in global protein expression, which may contribute to the enhanced 
vulnerability of cortical synapses at this particular age. Recapitulation of aged 
synaptic mitochondrial protein expression using molecular genetic tools in vivo 
revealed several novel functional mediators that have the propensity to significantly 
modulate multiple morphological parameters at the synapse. We suggest that 
selective alterations in the synaptic mitochondrial proteome may contribute to the 
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documented structural and functional perturbations occurring at synaptic terminals 



















In compliance with the 3Rs, no animals were bred specifically for this project. All 
tissue samples used in the current study were derived from existing archived brains 
or harvested alongside other ongoing experiments. The University of Edinburgh 
internal ethics committee approved all animal experiments. 
 
4.2.2 Animals 
12 wild-type C57BL/6 mice of differing sexes and ages were utilized for the studies 
described. Animals were assigned to the young (mean age = 4 weeks), mid-age 
(mean age = 6 months) or old age (mean age = 24 months) group, with 4 animals per 
time point. Animals were killed by conscious decapitation and brains were 
immediately excised. Brain stem and cerebellum were removed and discarded and 
the remaining forebrains were frozen slowly in an insulated container at -80°C to 
preserve morphological integrity. Immediately before mitochondrial isolations, 
forebrains were rapidly thawed by immersion in a water bath at 37°C (for further 
information on slow-freeze/rapid thaw methodology please refer to Hardy et al, 1983 
(205)). Samples were weighed and pooled by age group for homogenization and 
mitochondrial preparations.  
 
4.2.3 Mitochondrial isolations 
For a comprehensive methodological outline see chapter 2, section 2.5 and Lai et al, 
1977 (63). Laura Graham performed all subcellular fractionation procedures. 
Synaptic and non-synaptic mitochondrial populations were isolated from the young, 
mid-age and old mouse tissues described in section 4.2.2. Protein concentrations of 
all samples were determined utilizing the methods outlined in section 2.6. 
 
4.2.4 Label-free proteomics 
Mass spectrometry was performed by Amy Tavendale, Samantha Kosto and Douglas 
Lamont at the University of Dundee. Synaptic and non-synaptic mitochondrial 
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preparations were extracted in SDT lysis buffer containing 100 mM Tris-HCl (pH 
7.6), 4% (W/V) Sodium dodecyl sulfate (VWR) and 0.1 M d/l-dithiothreitol (Sigma). 
For efficient protein extraction, lysates were freeze–thawed and homogenized in 
SDT buffer several times. Protein concentration was then determined using BCA 
assay. Aliquots (200 µg) of each preparation were processed through FASP (filter-
aided sample preparation) involving buffer exchange to 8 M urea and alkylation with 
50 mM iodoacetamide prior to a double digestion with trypsin (Roche, sequencing 
grade), initially for 4 h, then overnight at 30 °C. Trypsin-digested peptides were 
separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system 
with the column oven set to 35 °C. Technical replicates (3 × ∼1 µg) of each sample 
were loaded at a constant flow of 5 µL/min onto a trapping cartridge (PepMap100, 
C18, 5µm, 100Å 0.3 x  5 mm; (Thermo Scientific, San Jose, CA) using 2% 
Acetonitrile, 0.1 % formic acid. After trap enrichment, peptides were separated on a 
peptide CSH, 1.7µm, 130Å, 75µm x 250mm C18 column (Waters Corp, Milford, 
MA) with the following gradient: t=0 min, 2 % B; t=6, 2 % B; t=20, 8 % B; t=110, 
24 % B; t=135, 37 % B where solvent A is water with 0.1 % formic acid and solvent 
B is 80% acetonitrile with 0.1% formic acid, with a constant flow of 260 nL/min. 
The HPLC system was coupled to a linear ion trap Orbitrap hybrid mass 
spectrometer (LTQ-Orbitrap Velos Pro, Thermo Scientific) via a nanoelectrospray 
ion source (Thermo Scientific). The spray voltage was set to 2.2 kV, and the 
temperature of the heated capillary was set to 200 °C. Full-scan MS survey spectra 
(m/z 335–1800) in profile mode were acquired in the Orbitrap with a resolution of 
60#000 after accumulation of 1#000#000 ions. A lock mass of 445.120#024 was 
enabled for survey scans to improve mass accuracy. The 15 most intense peptide ions 
from the preview scan in the Orbitrap were fragmented by collision-induced 
dissociation (normalized collision energy, 35%; activation Q, 0.250; and activation 
time, 10 ms) in the LTQ after the accumulation of 10#000 ions. Dynamic exclusion 
parameters were set as follows: repeat count, 1; repeat duration, 30 s; exclusion list 
size, 500; exclusion duration, 45 s; exclusion mass width, plus/minus 10 ppm 
(relative to reference mass). Maximal filling times were 10 ms for the full scans and 
100 ms for the MS/MS scans. Precursor ion charge state screening was enabled, and 
all unassigned charge states as well as singly charged species were rejected. Data 
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were acquired using Xcalibur software. 
 
The following analyses described were performed by Laura Graham at the Roslin 
Institute. Raw proteomic data were imported into Progenesis for characterization and 
analysis of relative ion abundance. 2D representations of MS/MS output were 
created for each sample and these were aligned to determine similar features 
(average alignment score >80%). Following alignment, data was filtered by retention 
time with features detected below 12.16 minutes and above 133.78 minutes 
discarded to correct for elution variability. The runs were grouped according to age 
and mitochondrial subcellular localization and Statistical P values were 
automatically generated in Progenesis software through a 1-way ANOVA on the 
ArcSinh transform of the normalized data. 
 
Peptides were filtered by the following criteria: power <0.8, fold change >1.2, 
p>0.05 and the remaining data were exported from Progenesis for identification of 
individual peptide sequences using the IPI-mus musculus database via Mascot Search 
Engine (V2.3.2). Enzyme specificity was set to that of trypsin, allowing for cleavage 
N-terminal to proline residues and between aspartic acid and proline residues. Other 
parameters used were as follows. (i) Variable modifications: methionine oxidation, 
methionine dioxidation, protein N-acetylation, gln → pyro-glu. (ii) Fixed 
modifications: cysteine carbamidomethylation. (iii) MS/MS tolerance: FTMS- 10 
ppm, ITMS- 0.6 Da. (iv) Minimum peptide length: 6. (v) Maximum missed 
cleavages: 2. (vi) False discovery rate: 1%. A cutoff score of >34 was used based on 
Mascot probability threshold of 0.05 that the observed hit is a random event. As an 
indication of identification certainty, the false discovery rate for peptide matches 
above identity threshold was set at 1%.  
 
Identified proteins were re-imported into Progenesis for further processing. Proteins 
were subject to stringent filtering parameters to eliminate those which had <2 unique 
peptides and p>0.05 to obtain the proteins which demonstrated statistically 




4.2.5 Biolayout Express3D 
Proteomic data was dissected using the complex pattern recognition software, 
Biolayout Express3D (159). The software allows visualization of molecular networks 
by applying Markov clustering algorithms to raw proteomic data (MCL 2.2). All 
graphs were clustered using Pearson correlation r=0.96. Clusters of interest 
indicating age-dependent alterations included those that demonstrated a steady up- or 
down-regulation or a late stage up- or late stage down-regulation during the 
timecourse of ageing. Proteins from clusters with analogous expression profiles 
underwent a subtractive process – candidates appearing in both the synaptic and non-
synaptic clusters, altered in the same manner, were unlikely to regulate synaptic 
stability during ageing and were eliminated from further analyses.  
 
4.2.6 Drosophila Stocks 
See methods section 2.11 for a comprehensive overview. All stocks lines used for 
experiments were obtained from the BDSC: 9837, 26650, 42580 (see Table 3). Flies 
were raised on standard cornmeal food at room temperature. Homology of mouse 
gene of interest and Drosophila ortholog was determined by input into DIOPT 
(DRSC Integrative Ortholog Prediction Tool (162): see Table 3). The elav-Gal4 
driver strain was used for all experiments (see Table 4). Immunohistochemistry 








4.3.1 Spatiotemporal characterisation of discrete mitochondrial 
proteomes. 
To determine age-dependent molecular alterations occurring in discrete neuronal 
compartments of the rodent brain, we purified and characterised isolated 
mitochondria from cortical synaptic and non-synaptic compartments at 3 time points 
(young adult, mid-age, old). Quantitative label-free proteomic analyses identified 
>1800 common proteins common to each subpopulation across the time-course (Fig. 
20A&B), revealing dynamic variations in synaptic protein expression. Markedly, 
over 1000 proteins were altered by greater than 20% in each discrete mitochondrial 
population, demonstrating significant age-dependent modifications at the proteome 
level. To assess the purity of mitochondrial preparations, PANTHER Gene Ontology 
bioinformatics software was employed. Input of the 1857 identified proteins from the 
proteomic data indicated enrichment of the ATP synthase complex and the 




Figure 20: Spatiotemporal characterisation of the mitochondrial proteome. A & B. 
Venn diagrams demonstrating identification of synaptic and non-synaptic mitochondrial 
proteins. Proteins were identified and filtered in Progenesis software using the criteria 
p>0.05 and 1 unique peptide. 1857 common proteins were identified in both the synaptic and 
non-synaptic mitochondrial datasets and these were utilized for all further analyses. C. 
PANTHER GO-Slim cellular component enrichment analysis of the synaptic and non-
synaptic mitochondrial raw data. Table indicates enrichment of the mitochondrial ATP 
synthase complex and mitochondrial inner membrane suggesting relative purity of 




4.3.2 Mitochondrial ageing demonstrates subcellular heterogeneity.  
To address whether dynamic variations in the mitochondrial proteome may be 
contributing to age-dependent synaptic vulnerability, we sought to determine if 
organelles from discrete subcellular compartments aged in a similar manner. Using 
the objective network visualisation software Biolayout Express3D ((159) 
www.biolayout.org), we generated synaptic and non-synaptic mitochondria principal 
component analysis (PCA) correlation graphs demonstrating relative age-dependent 
similarities (Fig. 21A&B). Examination of these networks confirmed distinct 
compartment-dependent clustering profiles. Non-synaptic mitochondria display a 
single network suggesting a degree of homogeneity between young, mid-age and old 
samples (Fig. 21B). Though the old and young mitochondria appear to demonstrate 
reduced equivalence – represented by the distance between population nodes – the 
data suggest that there are fewer significant temporal alterations occurring in the 
non-synaptic versus the synaptic organelles. Conversely, the synaptic mitochondria 
demonstrate increased heterogeneity between sample populations. Fragmentation of 
the graph indicates that the aged synaptic mitochondrial population possesses 
discrete protein expression profiles (Fig. 21A), which may contribute to the 
enhanced vulnerability of cortical synapses at this particular age. Thus, there are 
indications that isolated mitochondrial populations derived from discrete subcellular 
compartments age heterogeneously and the unique alterations occurring in synaptic 
mitochondria may dictate the potential vulnerability of synapses.   
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Figure 21: Mitochondrial ageing demonstrates subcellular heterogeneity. Unbiased 
sample-sample correlation analysis generated from BioLayout Express3D software. Nodes 
signify individual samples and edges reflect the strength of correlation of expression. YS – 
young synaptic mitochondria; MS – mid-age synaptic mitochondria; OS – old synaptic 
mitochondria; YNS – young non-synaptic mitochondria; MNS – mid-age non-synaptic 




4.3.3 Temporal protein profiling of discrete mitochondrial 
populations reveals protein expression trends correlating with 
synaptic vulnerability. 
In conjunction with the principal component analyses, to examine compartment-
specific temporal mitochondrial alterations further, we generated network graphs of 
the synaptic and non-synaptic mitochondrial timecourse proteomic data, again 
utilising Biolayout Express3D (159). The software applies unbiased Markov 
clustering algorithms to the input data and groups proteins displaying similar 
expression trends, allowing visualisation of spatiotemporal profiles and identification 
of discrete biochemical cascades altered within the dataset.  
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Synaptic and non-synaptic mitochondrial graphs were constructed utilizing the 1857 
commonly identified proteins through the timecourse of ageing (see Fig. 20A&B), 
providing 35-45 clusters per subpopulation. Interestingly, in contrast to the principal 
component analyses, the synaptic mitochondrial timecourse exhibited one large 
interconnected network whereas the non-synaptic displayed fragmentation into a 
multitude of smaller arrangements (Fig. 22A&B). Although the fragmentation of the 
non-synaptic mitochondrial protein timecourse may be postulated to be due to 
heterogeneity between the young, mid-age and old sample populations, this is 
incongruous with the PCA. Instead, the fragmentation is likely occurring due to the 
variability in individual protein expression. Numerous individual proteins harbor 
unique expression profiles throughout the timecourse, which prevents assignment to 
a cluster and reduces the connectivity between nodes (Fig. 22B). Conversely, the 
synaptic mitochondria timecourse displays a multitude of proteins that exhibit similar 
expression profiles, despite the heterogeneity between age groups, thus enhancing 
the number of candidates assigned to clusters and connectivity between nodes (Fig. 
22A).  
 
Figure 22: Ageing mitochondrial subpopulations exhibit distinct protein clustering 
patterns. Protein-protein correlation networks displaying protein expression through the 
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timecourse of ageing in mitochondrial subpopulations. Nodes signify individual proteins and 
edges reflect the strength of correlation of expression. Colours represent clusters of proteins 




By utilising two mitochondrial subpopulations demonstrating disparate profiles of 
ageing, we aimed to identify potential mitochondrial regulators of synaptic 
vulnerability with comparison of analogous protein expression profiles. Clusters 
displaying particular expression trends of interest were selected from both the 
synaptic and non-synaptic mitochondrial timecourse network graphs generated in 
Biolayout Express3D (Fig. 22A&B). Those clusters exhibiting steady up- or down-
regulation protein expression profiles during the timecourse were considered as 
potential biomarkers of normal healthy ageing due to the predictable age-dependent 
tractability of those candidates (Fig. 23A). Conversely, proteins displaying late-stage 
increases or decreases in expression were regarded as potential biomarkers of 
synaptic and/or organelle vulnerability as the abrupt expression changes observed in 
the old synaptic and non-synaptic populations likely reflected acute alterations 
disrupting mitochondrial homeostasis (Fig. 23B). In order to identify mitochondrial 
candidates that may be regulating cortical synaptic vulnerability during ageing, 
proteins from synaptic and non-synaptic mitochondrial clusters with analogous 
expression profiles were subject to a subtractive process. Proteins demonstrating 
equivalent spatiotemporal profiles in both synaptic and non-synaptic mitochondrial 
populations were not considered to be regulators of cortical synaptic vulnerability 
and filtered from the data prior to further analysis (Fig. 23C&D). This provided 451 
differentially expressed mitochondrial proteins that may be associated with age-






















Figure 23: Temporal profiling of distinct mitochondrial subpopulations reveals 
biomarkers of organelle ageing and vulnerability. A. Biomarkers of ageing: example 
temporal expression profiles of proteins demonstrating a steady up- or down-regulation 
during ageing. B. Biomarkers of vulnerability: example clusters displaying late stage 
increases or decreases in temporal protein expression. All graphs were generated in 
BioLayout Express3D (r=0.96) and display the mean protein expression across the 
timecourse in mitochondrial samples. C&D. Venn diagrams indicating subtraction of 
candidates. Proteins demonstrating equivalent spatiotemporal profiles in both synaptic and 
non-synaptic mitochondria (shown at intersection) were not considered to be regulators of 
synaptic vulnerability and were subtracted from further analysis.  
 
 
4.3.4 Temporal regulation of the synaptic mitochondrial proteome 
modulates synaptic morphology 
Despite characterizing the global spatiotemporal changes occurring in discrete 
mitochondrial subpopulations, it remained unclear whether divergence in expression 
of individual mitochondrial candidate proteins may be capable of actively regulating 
synaptic vulnerability. To elucidate mitochondrial regulators of synaptic stability, we 
initially mapped the individual temporal expression profiles of the 451 candidates 
identified by the Biolayout Express3D analyses using Python Jupyter Notebook (see 
Appendix 2). Upon examination of the protein expression trends, we hypothesized 
that candidates likely capable of modulating synaptic stability would exhibit 
unequivocal temporal profiles across mitochondrial subpopulations, with 
considerable divergence at old age. Thus, proteins with corresponding expression at 
the young and mid-age time-points in both synaptic and non-synaptic mitochondria, 
followed by a significant demarcation in expression at old age were selected as 
potential regulators of synaptic vulnerability. These particular expression profiles 
correlate with previous reports of significant age-dependent alterations in 
mitochondrial morphology (206), bioenergetics (187) and calcium buffering 




Following the identification of 243 proteins demonstrating the archetypal 
spatiotemporal expression profile (Fig. 24B), we further refined the candidate 
compendium by selecting proteins that exhibited a >2 fold-change in expression 
between synaptic and non-synaptic mitochondria at the old-age time point (Fig. 
24B). The remaining 96 candidates represented potential mitochondrial regulators of 
age-dependent synaptic vulnerability. Interestingly, DAVID enrichment analyses of 
these mitochondrial candidates indicated that alterations in DNA methylation 
cascades may be contributing to synaptic vulnerability during advancing age. To 
examine whether alterations in candidate protein expression in aged synaptic 
mitochondria was contributing to the vulnerability status of synaptic compartments 
in vivo, we utilized a molecular genetic approach at the Drosophila larval NMJ to 




Figure 24: Identification of mitochondrial-associated candidates regulating synaptic 
stability during ageing. A. Heat map displaying average normalized abundance values of 
451 differentially expressed mitochondrial candidates associated with alterations in synaptic 
stability during ageing. Note the divergence in protein expression in the old synaptic 
mitochondria. Blue indicates low expression and red high expression. YS - young synaptic; 
MS – mid-age synaptic; OS – old synaptic; YNS – young non-synaptic; MNS – mid-age non-
synaptic; ONS – old non-synaptic. B. Scatterplot indicating the hierarchical filtering of 
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proteins by stringent parameters for identification of mitochondrial candidates regulating 
synaptic stability. Left panel displays 451 tractable proteins identified from Biolayout 
Express3D analyses. Middle panel represents filtering of 451 candidates by archetypical 
protein expression profile (as illustrated in Appendix 2). Right panel exhibits the 96 
mitochondrial-associated candidates displaying archetypical protein profiles and a 2-fold 
change between mitochondrial subpopulations at the old age time point. Red lines indicate 2-
fold change. C. DAVID enrichment analysis of 96 identified candidates that may have the 
propensity to modulate synaptic stability during ageing. D. Candidate protein expression 
profiles. Graphs represent temporal expression profiles of identified candidates in both 
synaptic and non-synaptic mitochondria. Note the similar expression profiles through young 
and mid-age in both synaptic and non-synaptic mitochondria followed by significant 
divergence in expression at old age. All graphs display the ratio of candidate protein 
expression against the young age. Synaptic mitochondrial temporal protein expression - 
grey; non-synaptic temporal protein expression - black. 
 
Recapitulation of candidate protein expression at the larval NMJ was achieved using 
the UAS/Gal4 system, promoting pan-neuronal expression of the selected transgenes 
under control of the elav-Gal4 driver (see Table 3 for Drosophila orthologs). 
Regulated expression of the constructs (9837, 26650, 42580) resulted in viable 
offspring from all crosses, allowing examination of individual candidate modulatory 
effects on the synaptic architecture. Manipulation of Rab31 (9837), RhoG (26650) 
and Mcu (42580) expression revealed striking synaptic phenotypes at the third instar 
larva muscle 12/13 NMJ in multiple morphological parameters associated with the 
structural and functional stability of the synapse (Fig. 25). Indeed, enhanced 
constitutive expression of the mitochondrial associated vesicular trafficking protein 
Rab31 promoted modest reductions in the total bouton area (p<0.05) in addition to 
concomitant decreases in the active zone punctate size (p<0.0001) versus the control 
line (Fig. 25A-C). Although Rab31 NMJ arborisation appears to demonstrate 
considerable similarity to that of the control, minor reductions in the branching of 
distal processes may be contributing to the observed reductions in total bouton area. 
Conversely, RhoG overexpression promotes marked perturbations in arborisation, 
with NMJs displaying truncated branches and aberrant compacted morphologies 
(Fig. 25A). Correspondingly, significant reductions in bouton volume (p<0.0001) 
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and active zone punctate size (p<0.0001) are observed (Fig. 25A-C), which are likely 
mediated by the role of RhoG in polymerization of the actin cytoskeleton and 
regulation of dendritic differentiation and stabilization during development (209). 
RNAi-mediated knock-down of Mcu expression produced a morphologically distinct 
but quantitatively similar phenotype to that of RhoG manipulation (Fig. 25A). 
Reductions in Mcu activation also appear to attenuate the stereotypic arborisation 
patterns of the NMJ, in addition to facilitating decreases in the total bouton area 
(p<0.0001) and active zone punctate size ((p<0.0001) Fig. 25A-C). Despite all 
candidate lines (Rab31, RhoG and Mcu) demonstrating a significant reduction in 
active zone punctate size, with quantification of total active zone staining per NMJ, 
we report no significant difference versus control lines. Although vesicular dynamics 
may be regulated via biochemical cascades independent of those manipulated here, 
the significant reduction in total bouton area in multiple candidate lines suggests that 
coordinated expression of these particular mitochondrial proteins may be essential 
for the continued maintenance of synaptic-specific structures during advancing age. 
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Figure 25: Recapitulation of candidate protein expression promotes aberrant synaptic 
phenotypes at the Drosophila NMJ. A. Representative confocal images of muscle 12 
NMJs, labelled with anti-HRP and anti-BRP. Overexpression of Rab31 and RhoG and 
RNAi-mediated knock-down of Mcu promote aberrant synaptic phenotypes at the NMJ. 
Lower panel displays masks utilized for quantification of morphological parameters. B. 
Graphs represent quantification of control and candidate line total bouton area (µm). Rab31 
(* p = 0.0376), RhoG (**** p<0.0001) and Mcu (**** p<0.0001) demonstrate significant 
reductions in total bouton area. C. Graphs indicate the average size of active zone punctate 
(µm) in control and candidate lines. Rab31, RhoG and Mcu all display a significant decrease 
in punctate size versus control (**** p<0.0001). D. Graphs display the total area of active 
zone staining in control and candidate lines. Rab31 (p = 0.926), RhoG (p = 0.3574) and Mcu 
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(p = 0.5397) demonstrate no significant difference in active zone area per NMJ. All lines 
used the elav-Gal4 driver system. NMJs imaged at 63x. Scale bar = 10µm, n=5. Statistical 
analyses utilized unpaired two-tailed Student’s t-test (* p = 0.05; ** p = <0.01; *** p = 

























How the spatiotemporal regulation of the mitochondrial proteome and synaptic 
function intersect during advancing age is poorly understood. Here, we indicate that 
selective biochemical alterations in the synaptic mitochondrial proteome may 
promote age-related perturbations in synapse structure and function in vivo. 
Temporal proteomic profiling of distinct subcellular mitochondrial populations from 
the rodent cortex revealed discrete and dynamic alterations in both the synaptic and 
non-synaptic mitochondrial proteomes during normal healthy ageing. Intriguingly, 
aged synaptic mitochondria appeared to harbour a unique proteome, exhibiting 
significant divergence in protein expression. Recapitulation of aged synaptic 
mitochondrial protein expression using molecular genetic tools in vivo revealed 
several novel functional mediators that have the propensity to significantly modulate 
multiple morphological parameters at the synapse, suggesting that the mitochondrial 
proteome and synaptic morphometry are intimately intertwined. The data indicate 
that selective alterations in synaptic mitochondrial protein expression may, in part, 
mediate enhanced vulnerability of the cortical synapse during advancing age.  
 
4.4.1 Mitochondrial candidates modulating synaptic morphology 
The identification of 96 candidates demonstrating a >2 fold change between synaptic 
and non-synaptic mitochondria in a temporal profile associated with increased 
vulnerability of the synapse is highly indicative of the regulatory role the organelles 
may play in modulating synaptic structure and function during ageing. Interestingly, 
the 96 differentially expressed candidates appeared to demonstrate enrichment in 
DNA methylation cascades. Recent evidence has suggested that the methylation of 
mtDNA is age- and brain region dependent (210, 211) and reductions in mtDNA 
methylation promote transcriptional changes associated with senescent phenotypes in 
vitro (212). Furthermore, decreases in mtDNA methylation have also been associated 
with genomic instability, promoting mutagenesis and dysregulation of the respiratory 
complex genes encoded by the mitochondrion (210). Strikingly, the data obtained in 
this study indicate that mtDNA methylation may also demonstrate discrete 
subcellular patterns, which suggests differential regulation of mtDNA integrity in 
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distinct mitochondrial subpopulations. Although global perturbations in mtDNA 
stability have been widely associated with advancing age, few studies have examined 
whether mtDNA integrity differs in ageing synaptic and non-synaptic mitochondria. 
Our results suggest that this may warrant exploration to determine if synaptic 
mitochondria exhibit increased susceptibility to mtDNA mutagenesis, organelle 
dysfunction and concomitant compartmental instability during ageing.  
 
Though we identified 96 candidates that represented potential mitochondrial 
regulators of age-dependent synaptic vulnerability, due to time constraints, we were 
only able to phenotypically assess 3 candidates in vivo. Despite this, we demonstrate 
that recapitulation of Rab31, RhoG and Mcu protein expression at the Drosophila 
larval NMJ promotes aberrant synaptic phenotypes, including reductions in total 
bouton area and decreases in active zone puncta size. Of particular interest is the 
decrease in bouton active zone size in all candidate lines. Indeed, recent evidence 
suggests that the degree of BRP staining present at individual active zone sites 
correlates with the quantity of readily releasable vesicles and thus the probability of 
synaptic vesicle release (213). Accordingly, the results obtained from this study 
indicate that misexpression of selected mitochondrial candidates may promote 
functional alterations in synaptic vesicle recycling and neurotransmission dynamics – 
processes that have been widely associated with age-dependent alterations in 
synaptic stability. Interestingly, these data are in agreement with the Hara et al study 
(refer to section 4.1), which describes age- and mitochondrial-morphology dependent 
decreases in the presynaptic active zone size and the number of synaptic vesicles in 
NHP cortical synapses (190). Though we report significant reductions in the size of 
bouton active zone puncta, quantification of the global active zone area per NMJ 
suggested no differences between control and candidate lines. Although speculative, 
this may represent a compensatory mechanism adopted by the cell to enable the 
maintenance of transmission and plastic properties at the synapse.  
 
The localisation and functional specialisation of the identified candidates is wide-
ranging, likely reflecting the convergence of numerous mitochondrial mechanistic 
pathways required for homeostatic regulation of the synaptic compartment. Rab31 is 
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a small GTP-binding molecule localized to the mitochondrion, golgi and plasma 
membrane and appears to regulate vesicular targeting, mobilization and docking 
(214-216). Though there are relatively few studies documenting the constitutive role 
of the protein and how misexpression may modulate cellular structural and 
functional properties, evidence indicates that Rab31 is a member of the Rab5 
superfamily of Rab GTPases (216). Overexpression of the Rab5 family has been 
directly associated with impairments in synaptic vesicle recycling and 
neurotransmission at the Drosophila NMJ (217, 218), although the mechanism 
governing this impairment remains elusive. Thus, it is probable that the age-
dependent overexpression of Rab31 in synaptic mitochondria may modulate the size 
of the bouton active zone through a corresponding cascade, promoting concomitant 
synaptic dysfunction via alterations in transmission, plasticity and vesicular 
dynamics. Similarly, overexpression of the mitochondrial-associated protein RhoG 
(219) also demonstrated a reduction in bouton active zone size in addition to a highly 
significant reduction in total bouton area. RhoG exhibits involvement in the 
polymerization of the actin cytoskeleton and regulation of dendritic and axonal 
branching and stabilization, particularly during development (210). Previous studies 
examining overexpression of RhoG report reduced axonal and dendritic complexity 
in vivo (220), with significant alterations in arborisation, which appear to correlate 
with the compacted phenotype we present here. To our knowledge, there are 
currently no studies describing the role of RhoG at the synaptic terminal during 
ageing, thus we present novel data demonstrating that temporal increases in synaptic 
mitochondrial RhoG expression, alter multiple morphological parameters associated 
with compartmental function and stability. Though the RhoG and Mcu lines 
exhibited quantitatively and morphologically similar phenotypes at the NMJ, 
divergent mechanisms likely mediate the reported synaptic alterations. Mcu is a 
mitochondrial calcium uniporter that regulates intracellular Ca2+ concentrations via 
uptake of ions into the mitochondrial matrix. Due to the significant fluctuations in 
presynaptic Ca2+ concentrations during neurotransmission events, the mitochondrial 
Mcu has previously been associated with structural and functional perturbations in 
the synaptic milieu during ageing and pathogenesis (221-223); however, 
investigations examining the effects of Mcu knock-down in vitro report conflicting 
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results. There are reports that reductions in Mcu expression diminishes vesicular 
mobility and release, promoting concomitant alterations in short-term synaptic 
plasticity (221), which suggests that regulated Mcu expression facilitates 
neurotransmission properties via presynaptic Ca2+ clearance cascades. However, 
studies examining synaptic vesicle recycling kinetics document no effect of Mcu 
knock-down on presynaptic vesicular exocytosis, total active zone area or 
intracellular Ca2+ levels (222). Though we have not investigated the functional 
properties of the Drosophila NMJs harbouring reductions in Mcu expression, our 
data indicate that Mcu may modulate the size of the bouton active zone, which may 
affect the probability of vesicular release due to a smaller pool of readily releasable 
vesicles. However, whether this is due to elevations in presynaptic intracellular Ca2+, 
reductions in Ca2+-dependent ATP production or alterations in mitochondrial 
dynamics remains undetermined. !
 
4.4.2 Troubleshooting strategies 
Although we have provided a thorough spatiotemporal characterisation of the 
synaptic and non-synaptic mitochondrial proteomes, identifying several biochemical 
substrates that may functionally regulate the stability of the mitochondria and the 
synaptic milieu during advancing age, the investigation initially proved highly 
problematic. We were unable to biochemically validate the purification of the 
mitochondrial preparations or the accuracy of the proteomic data using traditional 
techniques due to the addition of interfering reagents into the label-free sample 
buffer. The presence of 0.1 M d/l-dithiothreitol (DTT) in all samples prevented 
quantitation of total protein concentration despite the use of a number of methods, 
including micro-BCA and Bradford assays. Attempts to precipitate the DTT out of 
the samples were also unsuccessful. Furthermore, we encountered a number of mass 
spectrometry issues, preventing the reliable identification of proteins in the young 
and mid-age synaptic mitochondrial samples (Appendix 3). We suggest that this was 
due to the presence of polymers within the samples, likely caused by transference 
from the tube. Fortunately, reprocessing of the samples and the addition of new 
synaptic and non-synaptic mitochondrial tissues from animals of equivalent ages 
ameliorated the reported mass spectrometry issues and enabled identification and 
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analysis of the proteins from these samples (data shown throughout this chapter). 
Despite this, the duration of time spent attempting to decipher the numerous issues 
highlighted was significant, detracting from the potential collection of additional in 
vivo data, including characterizing the morphologies of synaptic and non-synaptic 




To our knowledge, this is the first study documenting the spatiotemporal alterations 
occurring in both synaptic and non-synaptic mitochondrial populations during 
advancing age. Cumulatively, our data describe that selective alterations in the aged 
synaptic mitochondrial proteome modulate multiple morphological parameters 
associated with synaptic dysfunction in vivo. Further investigations exploring how 
dynamic alterations in the synaptic mitochondrial proteome may attenuate 
neurotransmission, plasticity and vesicular mobility are required to enable 

















Chapter 5. TGFβ1 regulates regional synaptic vulnerability 
during normal healthy ageing 
 
I confirm that I have authored the following text and that the work 
contained within this chapter is currently under consideration at 
Nature Neuroscience (August 2017) 
 
5.1 Introduction 
The loss and dysfunction of selected populations of synapses is characteristic of 
mammalian brain ageing and alterations in these receptive compartments are 
considered to underpin age-related cognitive decline (1-6). It has been well 
established that the hippocampal synaptic architecture displays particular 
vulnerability to a wide range of stimuli during advancing age (1-3), whereas 
populations of synapses resident to the occipital cortex exhibit resistance to age-
related alterations (4-13). Although the synaptic alterations that underlie age-related 
cognitive decline differ from the extensive neuronal loss that leads to dementia and 
Alzheimer’s disease (AD), these alterations may render neurons more vulnerable to 
degeneration during the ageing process (1, 14). An essential area for investigation is 
to determine how synaptic alterations may leave a neuron vulnerable to 
neurodegeneration and the pathological substrates promoting such vulnerability. A 
great deal of our current knowledge concerning the mechanisms of cognitive and 
brain ageing has been provided by rodent studies. Several investigations have 
reported heterogeneous expression of the hippocampal synaptic proteome in ageing 
rodents (15-17), however it has recently been established that relatively few age-
related gene and protein expression alterations demonstrate conservation from mouse 
to man (18). Evolutionary divergence of the primate cortex has promoted functional 
neuronal alterations that are uniquely primate (1) and studies documenting rodent 
biological brain ageing are not necessarily representative of the complex processes 
occurring in the human patient, particularly with regards to selective synaptic 
vulnerability (18). Thus, in order to tease apart human age-related cognitive decline, 
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non-human primates provide some advantages. Non-human primates (NHP) are 
phylogenetically closer to humans and possess distinctly primate morphological, 
endocrine, behavioural, and cognitive traits (1, 6), in addition to an increased 
lifespan, which may provide data uniquely relevant to human ageing. 
 
In what appears to be the first investigation into the regional diversity of the primate 
synaptic proteome during the adult lifespan, we present a comprehensive ‘synaptic 
atlas’ supporting the notion that local biochemical alterations dictate selective 
synaptic vulnerability. Here, we employ an unbiased combinatorial approach, 
including quantitative proteomic analyses coupled with in vivo candidate 
assessments in lower order animals (Drosophila), to temporally profile primate brain 
regional synapse biochemistry during normal healthy ageing. We demonstrate that 
synaptic ageing is brain-region dependent and discrete populations of synapses 
significantly differ at a biochemical level in the healthy human and non-human 
primate brain. Recapitulation of aged hippocampal protein expression with genetic 
manipulation in vivo revealed several novel candidates that have the propensity to 
significantly modulate multiple morphological parameters at the synapse. 
Furthermore, we demonstrate that several of these candidates sit downstream of 
TGFβ1 and activation of the TGFβ1 signalling cascade in hippocampal synaptic 
populations drives the aberrant expression of selected candidates during ageing. 
Finally, we show that selective pharmacological inhibition of this pathway rescues 
synaptic phenotypes in multiple candidate lines. The current investigation has 
affirmed that activation of the TGFβ1 transduction pathway modulates synaptic 
stability and thus may contribute to the selective vulnerability of hippocampal 
synapses during ageing. Additionally, the thorough ‘molecular mapping’ of healthy 
primate brain ageing has provided a dynamic temporal synaptic atlas that we may 
compare disease processes to, allowing elucidation of biochemical alterations that 








In compliance with the 3Rs, no animals were bred specifically for this project. All 
tissue samples used in the current study were derived from existing archived brains 
or harvested alongside other ongoing experiments. The Oregon Health & Sciences 
University Institutional Animal Care and Use Committee at the Oregon National 
Primate Research Center (ONPRC) and the University of Edinburgh internal ethics 
committee approved all animal experiments. 
 
5.2.2 Animals 
12 rhesus macaques (Macaca mulatta) of differing sexes and ages were utilized for 
the studies described. Animals were assigned to the young adult (mean age = 9.5 
years), mid-age (mean age = 15.6 years) or old age (mean age = 23 years) group, 
with 4 animals per time point. All animals were euthanized according to procedures 
recommended by the 2013 Edition of the American Veterinary Medical Association 
Guidelines for the Euthanasia of Animals. Each animal was sedated with ketamine, 
administered pentobarbital (30 mg/kg, i.v.), and exsanguinated by severance of the 
descending aorta. Brains were removed and appropriate regional dissections 
performed before freezing the samples in liquid nitrogen.  
 
5.2.3 Human patient samples 
Human patient samples were obtained from the Edinburgh Brain Bank. All tissues 
were classified as controls due to the absence of gross pathological hallmarks and 
neurological disease. Human tissues were assigned to equivalent age groups: young 
(18-25 years), mid-age (40-50 years) or old age (70+ years), with 4 samples per time 
point. Use of human tissue for post-mortem studies was reviewed and approved by 
the Edinburgh Brain Bank ethics committee. The Edinburgh Brain Bank is a Medical 






5.2.4 Synaptosomal preparations 
All NHP tissue preparations were performed by Laura Graham at Oregon National 
Primate Research Center, Oregon Health and Sciences University, OR, USA 
(September 2014). Regional brain tissue samples were homogenised in an ice-cold 
isotonic sucrose solution (0.32 M sucrose, 1 mM EDTA, 5 mM Tris-HCl, pH 
7.4).  Homogenates were centrifuged in a fixed-angle rotor at 900 g for 10 min and 
the supernatant (S1) was collected.  The pellet (P1) was resuspended in sucrose 
solution and centrifuged again at 900 g for 10 min. Supernatants were combined and 
centrifuged in a fixed angle rotor at 20,000 g for 15 min. The remaining pellets (P2) 
contained the synaptosomes. 
 
5.2.5 Protein concentration assay 
Samples were homogenized in SDT lysis buffer + 1% protease cocktail inhibitor 
(Thermo Scientific). After homogenisation, samples were centrifuged at 20,000g for 
20 minutes at 4°C. The supernatant containing the solubilised protein was removed 
and pellets discarded. Protein concentration of samples was determined using a 
Pierce Micro BCA assay kit according to the manufacturers instructions. 
 
5.2.6 Label-free proteomics 
Mass spectrometry was performed by Dr. Michael Naldrett at the Donald Danforth 
Plant Science Center, St. Louis, Missouri, USA. Regional synaptosomal preparations 
were extracted in SDT lysis buffer containing 100 mM Tris-HCl (pH 7.6) and 4% 
(W/V) Sodium dodecyl sulfate (VWR). For efficient protein extraction, lysates were 
freeze–thawed and homogenized in SDT buffer several times. Protein concentration 
was then determined using BCA assay. Aliquots (200 µg) of each synaptosomal 
preparation were processed through FASP (filter-aided sample preparation) 
involving buffer exchange to 8 M urea and alkylation with 50 mM iodoacetamide 
prior to a double digestion with trypsin (Roche, sequencing grade), initially for 4 h, 
then overnight at 30 °C. Trypsin-digested peptides were separated using an Ultimate 
3000 RSLC (Thermo Scientific) nanoflow LC system with the column oven set to 35 
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°C. Technical replicates (3 × ∼1 µg) of each sample were loaded at a constant flow 
of 5 µL/min onto a trapping cartridge (PepMap100, C18, 5µm, 100Å 0.3 x  5 mm; 
(Thermo Scientific, San Jose, CA) using 2% Acetonitrile, 0.1 % formic acid. After 
trap enrichment, peptides were separated on a peptide CSH, 1.7µm, 130Å, 75µm x 
250mm C18 column (Waters Corp, Milford, MA) with the following gradient: t=0 
min, 2 % B; t=6, 2 % B; t=20, 8 % B; t=110, 24 % B; t=135, 37 % B where solvent 
A is water with 0.1 % formic acid and solvent B is 80% acetonitrile with 0.1% 
formic acid, with a constant flow of 260 nL/min. The HPLC system was coupled to a 
linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap Velos Pro, Thermo 
Scientific) via a nanoelectrospray ion source (Thermo Scientific). The spray voltage 
was set to 2.2 kV, and the temperature of the heated capillary was set to 200 °C. Full-
scan MS survey spectra (m/z 335–1800) in profile mode were acquired in the 
Orbitrap with a resolution of 60$000 after accumulation of 1$000$000 ions. A lock 
mass of 445.120$024 was enabled for survey scans to improve mass accuracy. The 15 
most intense peptide ions from the preview scan in the Orbitrap were fragmented by 
collision-induced dissociation (normalized collision energy, 35%; activation Q, 
0.250; and activation time, 10 ms) in the LTQ after the accumulation of 10$000 ions. 
Dynamic exclusion parameters were set as follows: repeat count, 1; repeat duration, 
30 s; exclusion list size, 500; exclusion duration, 45 s; exclusion mass width, 
plus/minus 10 ppm (relative to reference mass). Maximal filling times were 10 ms 
for the full scans and 100 ms for the MS/MS scans. Precursor ion charge state 
screening was enabled, and all unassigned charge states as well as singly charged 
species were rejected. Data were acquired using Xcalibur software. 
 
The following analyses described were performed by Laura Graham at the Roslin 
Institute. Raw proteomic data were imported into Progenesis for characterization and 
analysis of relative ion abundance. 2D representations of MS/MS output were 
created for each sample and these were aligned to determine similar features 
(average alignment score >80%). Following alignment, data was filtered by retention 
time with features detected below 17 minutes and above 140 minutes discarded to 
correct for elution variability. The runs were grouped according to age and brain 
region and Statistical P values were automatically generated in Progenesis software 
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through a 1 way ANOVA on the ArcSinh transform of the normalized data. 
 
Peptides were filtered by the following criteria: power <0.8, fold change >1.2, 
p>0.05 and the remaining data were exported from Progenesis for identification of 
individual peptide sequences using the IPI-macaca mullata database via Mascot 
Search Engine (V2.3.2). Enzyme specificity was set to that of trypsin, allowing for 
cleavage N-terminal to proline residues and between aspartic acid and proline 
residues. Other parameters used were as follows. (i) Variable modifications: 
methionine oxidation, methionine dioxidation, protein N-acetylation, gln → pyro-
glu. (ii) Fixed modifications: cysteine carbamidomethylation. (iii) MS/MS tolerance: 
FTMS- 10 ppm, ITMS- 0.6 Da. (iv) Minimum peptide length: 6. (v) Maximum 
missed cleavages: 2. (vi) False discovery rate: 1%. A cutoff score of >34 was used 
based on Mascot probability threshold of 0.05 that the observed hit is a random 
event. As an indication of identification certainty, the false discovery rate for peptide 
matches above identity threshold was set at 1%.  
 
Identified proteins were re-imported into Progenesis for further processing. Proteins 
were subject to stringent filtering parameters to eliminate those which had <2 unique 
peptides, <1.2 fold change between age groups and p>0.05 to obtain the proteins 
which demonstrated the largest significant variation in expression over the ageing 
time course in each brain region. 
 
5.2.7 Biolayout Express3D 
Proteomic data was dissected using the complex pattern recognition software, 
Biolayout Express3D (19). The software allows visualization of molecular networks 
by applying Markov clustering algorithms to raw proteomic data (MCL 2.2). All 
graphs were clustered using Pearson correlation r=0.95. Clusters of interest 
indicating age-dependent alterations included those that demonstrated a steady up- or 
down-regulation or a late stage up- or late stage down-regulation during the 
timecourse of ageing. Proteins from clusters with analogous expression profiles 
underwent a subtractive process – candidates appearing in both the resistant and 
vulnerable clusters, altered in the same manner, were unlikely to regulate synaptic 
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vulnerability during ageing. These candidates were eliminated as modulators of 
synaptic vulnerability.  
 
5.2.8 Ingenuity Pathway Analysis 
IPA analyses were performed as previously described (20). See methods section 2.9 
for details on the parameters utilized for experimental analysis.  
 
5.2.9 Quantitative Fluorescent Western Blotting 
All NHP western blots were performed by Laura Graham at Oregon National 
Primate Center (October 2016) as previously described (21). Samples were diluted to 





4-12% Bis Tris mini-gels (Life Technologies) and transferred to 
PVDF membranes using an iBlot®
 
and Invitrogen gel transfer stacks. Membranes 
were incubated in primary antibodies at 4°C and secondary antibodies at room 
temperature (concentrations according to manufacturers instructions) before imaging 
on Li-COR Odyssey infrared scanner. Protein expression was quantified utilising 
Odyssey software (Li-COR Biosciences). All antibodies utilised are listed in Tables 
1 & 2.  
 
5.2.10 Drosophila Stocks 
See methods section 2.11 for a comprehensive overview. Flies were raised on 
standard cornmeal food at room temperature. Homology of rhesus macaque gene of 
interest and Drosophila ortholog was determined by input into DIOPT (DRSC 
Integrative Ortholog Prediction Tool (22): see Table 3). The elav-Gal4 driver strain 
was used for all experiments. Stocks were obtained from the VDRC (v9180; v40466; 
v22851; 28797; v100773; 34101; v30690; v36166) and Bloomington Drosophila 
stock center (Canton-S). For pharmacological experiments, 2mM LY364947 (Tocris, 
cat: 2718) solubilised in 0.3% DMSO (w/v) was added to cornmeal food.  
 
5.2.11 Immunohistochemistry 
Third instar larva were selected and dissected in PBS (n=6). The dissected larval 
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neuromuscular junctions (NMJs) were fixed in Bouin’s fixative (15:5:1 picric acid, 
37% formaldehyde and acetic acid) for 10 minutes and washed thoroughly in PBT 
(PBS + 0.1% TritonX-100). Preparations were blocked in PBT + 10% normal goat 
serum for 2 hours then incubated in primary antibody overnight at 4°C. NMJs were 
again washed extensively in PBT and incubated in secondary antibody at room 
temperature for 2 hours. Samples were mounted on microscope slides using 
Vectashield mounting medium (Vector Laboratories) and imaged on a Zeiss confocal 
microscope. Antibodies used are listed in Table 4 & 5.  
 
 
5.2.12 Statistical Analysis 
Data were collected in Microsoft Excel and statistical tests were performed in 
GraphPad Prism 6 software. For all analyses p<0.05 was considered significant. 


















5.3.1 Characterisation of non-human primate synaptic isolates from 
discrete brain regions. 
Although it has been well documented that discrete neuronal populations 
demonstrate enhanced vulnerability to insult and degeneration during ageing, the 
molecular mechanisms governing such processes remain to be elucidated. To 
determine age-dependent regional molecular alterations occurring in synaptic 
compartments, we purified and characterised crude synaptosomes from differentially 
vulnerable brain regions (cerebellum, temporal cortex, occipital cortex, 
hippocampus) at 3 time points (young adult, mid-age, old). Quantitative label-free 
proteomic analyses identified >1700 proteins in each region across the time-course, 
revealing dynamic variations in synaptic protein expression. Strikingly, over 740 
proteins were altered by greater than 20% in each discrete region (Fig. 26B), 
demonstrating significant age-dependent biochemical adaptations. Purity of regional 
synaptic preparations was verified with quantitative enrichment analyses utilising the 
raw proteomic data. The normalised average abundance of the well-established 
synaptic markers synaptic vesicle glycoprotein 2A (SV2A) and synaptotagmin was 
calculated for each region at the young time point and compared to isolated cortical 
mitochondria of the same age. To ensure parity between the synaptic samples and the 
isolated mitochondria, all preparations were loaded onto the mass spectrometer 
during the same experiment. SV2A and synaptotagmin indicated significant 
enrichment in all respective regions versus isolated cortical mitochondria suggesting 
purification of synaptic compartments (Fig. 26C). In addition to demonstrating 
purification of synaptic fractions, we employed quantitative fluorescent western 
blotting (QFWB) to determine the veracity of the proteomic data. We observed 
corresponding protein expression trends in the tissue preparations as indicated by the 
proteomics for multiple proteins (Fig. 27). Taken together, these results indicate the 
relative purity of the synaptic preparations and suggest the proteomic data is 





Figure 26: Regional characterization of the synaptic proteome. A. Schematic illustrating 
experimental design for comparison of differentially vulnerable brain regions throughout the 
ageing timecourse (HC = hippocampus; OCC = occipital cortex; TC = temporal cortex; CB 
= cerebellum). B. Venn diagrams demonstrating regional characterization of the 
synaptic proteome. Proteins were identified and filtered in Progenesis using the following 
criteria: p>0.05, <1.2 fold change across the timecourse and 1 unique peptide to obtain the 
proteins which demonstrate the largest alterations during ageing. Number of proteins up- or 
down-regulated by >1.2 fold change during ageing, is indicated at the middle intersection. 
These filtered proteins were utilized for all analyses. C. Purity of regional synaptic 
preparations. Purity of regional synaptic isolates was verified with quantitative enrichment 
analyses utilising the raw regional proteomic data and isolated cortical mitochondria. 
Comparative expression of the synaptic markers SV2A and synaptotagmin indicate synaptic 
enrichment of all regional preparations. Statistical analyses utilized unpaired two-tailed 




Figure 27: Validation of regional temporal proteomic data with quantitative 
fluorescent western blotting. A. Actin loading control for pooled hippocampal and 
occipital NHP synaptosomes. Samples were pooled according to age group. Bar charts 
demonstrate there is no significant difference in total protein between ages or regions. B-D. 
Left bar chart displays the proteomic average normalised expression values of proteins in 
regional synapses during ageing. Right bar chart demonstrates sample protein expression 
quantified by fluorescent western blots. Proteomic and sample expression of all proteins 
(hippocampal NDUFS5, hippocampal OGDH and occipital cortex OGDH) follow the same 
trend thereby providing validation of the proteomic data. Statistical analysis was performed 
using an unpaired two-tailed Student’s t-test (* p = <0.05). 
 
 
5.3.2 The synaptic proteome demonstrates regional heterogeneity 
during ageing. 
To address the question of regional vulnerability, we initially sought to determine 
whether synapses from discrete brain regions aged in a similar manner. Using the 
objective network visualisation software Biolayout Express3D (www.biolayout.org), 
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we generated brain regional principal component analysis correlation graphs 
demonstrating relative age-dependent similarities (Fig. 28A-D). Examination of 
these networks confirmed distinct region-dependent clustering profiles. ‘Resistant’ 
synaptic populations (cerebellum, occipital cortex) exhibited single networks 
suggesting congruence between young, mid-age and old samples (Fig. 28A&C). 
Indeed, the cerebellar synapses display significant homogeneity presenting 
equidistant edges within and between sample populations on the correlation graph 
(Fig. 28A). Furthermore, similar trends exist in the occipital cortex, with young and 
mid-age synaptic populations displaying salient similarities. However, the old 
synaptic population appear to demonstrate reduced equivalence with the mid-age 
synapses and enhanced similitude with the young samples (Fig. 28C). Conversely, 
‘vulnerable’ synaptic populations (temporal cortex, hippocampus) display 
fragmentation into 2 smaller networks indicating age-dependent heterogeneity (Fig. 
28B&D). The temporal cortex demonstrates synaptic isolates derived from young 
animals appear inherently different from those of later ages (Fig. 28B). Interestingly, 
the hippocampal correlation graph reveals quite the contrary. Although there appears 
to be a small degree of variability within and between the young and mid-age 
samples, it is evident that the aged synaptic population possesses discrete protein 
expression profiles (Fig. 28D), which may be relevant to the vulnerability status of 
hippocampal synapses at this particular age. Thus, there are indications that isolated 
synaptic populations age in a region-dependent manner and these unique alterations 





Figure 28: Synaptic ageing is regionally heterogeneous. Unbiased sample-sample 
correlation analysis generated from BioLayout Express3D software. Nodes signify individual 
samples and edges reflect the strength of correlation of expression. All graphs clustered 
using Pearson r=0.98. 
  
 
5.3.3 Regional profiling of ageing synapses reveals protein 
expression trends correlating with synaptic vulnerability.  
In conjunction with the principal component analyses, to dissect region-specific age-
dependent synaptic alterations further, we generated network graphs of the regional 
timecourse proteomic data, again utilising Biolayout Express3D (19). The software 
applies unbiased Markov clustering algorithms to the input data and groups proteins 
displaying similar expression trends. This allows visualisation of spatiotemporal 
profiles promoting the identification of physiological cascades altered within the 
dataset. Graphs were constructed utilizing regional differentially expressed proteins 
(altered >20%) through the timecourse of ageing (see Fig. 26A) providing 20-30 
clusters per region. In agreement with the principal component analysis correlation 
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graphs, network clustering of the proteomic data displayed similar trends with 
regards to fragmentation of the graphs representing the vulnerable brain regions 
(temporal cortex, hippocampus), whereas synaptic isolates considered resistant 
during ageing appear as one large network (cerebellum, occipital cortex (Fig. 29A)). 
Remarkably, proteomic data characterising ageing synaptic isolates from human 
post-mortem samples at equivalent ages to the NHP (young, mid-age, old) display 
strikingly similar network clustering profiles (Fig. 29B). There remains significant 
demarcation between the occipital cortex and the hippocampus suggesting resistant 
and vulnerable brain regions are ageing in unique manners in both non-human 
primates and human patients. Furthermore, the results also suggest that the regional 
NHP data may be an accurate reflection of human synaptic ageing with clear 




Figure 29: Distinct clustering patterns are conserved in human patient synapses. 
Regional protein-protein correlation networks displaying proteins significantly altered 
through the timecourse of ageing in NHPs and human patients. Nodes signify individual 
proteins and edges reflect the strength of correlation of expression. Colours represent 
clusters of proteins that are grouped together based on their expression profiles. Correlation 
networks appear to be conserved in synaptosomes from human patients during normal 
healthy ageing. All graphs clustered using Pearson r=0.95. 
 
To avoid ambiguity in the interpretation of complex results, further experimentation 
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focused primarily on a 2-way analysis. Studies documenting neuronal alterations in 
primates demonstrate that the occipital cortex appears to be the least affected brain 
region during ageing, with preservation of total neuronal numbers in NHPs (5) and 
volumetric preservation in aged human patients (23).  Conversely, perturbations in 
the hippocampal architecture are often associated with advancing age due to the 
manifestation of Alzheimer’s disease (AD) in this region (24).  Thus, there appears 
to be a divergent spectrum of synaptic vulnerability upon which the occipital cortex 
opposes the hippocampus. By utilising 2 contrasting brain regions demonstrating 
disparate profiles of ageing, we aimed to identify potential regulators of synaptic 
vulnerability with comparison of analogous protein expression profiles. Clusters 
displaying particular expression trends of interest were selected from both the 
occipital cortex and hippocampus synaptic timecourse using Biolayout Express3D 
(Fig. 30A&B). Those exhibiting steady up- or down-regulation protein expression 
profiles during the timecourse were considered as potential biomarkers of normal 
healthy ageing due to the predictable age-dependent tractability of those candidates 
(Fig. 30A). Conversely, proteins displaying late-stage increases or decreases in 
expression were regarded as potential biomarkers of synaptic vulnerability as the 
abrupt expression changes observed in the old synaptic populations likely reflected 
acute alterations disrupting homeostasis at the synapse (Fig. 30B). In order to 
identify candidates that may be regulating regional synaptic vulnerability during 
ageing, proteins from occipital and hippocampal clusters with analogous expression 
profiles were subject to a subtractive process. Proteins demonstrating equivalent 
spatiotemporal profiles in both occipital cortex and hippocampal synapses were not 
considered to be regulators of differential regional synaptic vulnerability and filtered 
from the data prior to further analysis (Fig. 30C&D). Upon subtraction of proteins 
exhibiting analogous expression profiles, there remained 241 differentially expressed 








Figure 30: Temporal profiling of discrete synaptic populations reveals biomarkers of 
ageing and vulnerability. A. Biomarkers of ageing: example temporal expression profiles 
of proteins demonstrating a steady up- or down-regulation during ageing. B. Biomarkers of 
vulnerability: example clusters displaying late stage increases or decreases in temporal 
protein expression. All graphs were generated in BioLayout Express3D (r=0.95) and display 
the mean protein expression across the timecourse in occipital and hippocampal synaptic 
isolates. C&D. Venn diagrams indicating subtraction of candidates. Proteins 
demonstrating equivalent spatiotemporal profiles in both occipital cortex and hippocampal 
synapses (shown at intersection) were not considered to be regulators of differential regional 
synaptic vulnerability and were subtracted from further analysis.  
 
 
5.3.4 Recapitulation of candidate protein expression promotes 
aberrant synaptic phenotypes in vivo. 
Although we had characterized spatiotemporal alterations occurring in populations of 
differentially vulnerable synapses on a global scale, it remained unclear whether the 
regional divergence in expression of individual candidate proteins may be capable of 
actively regulating synaptic vulnerability. We reasoned that candidates likely 
modulating alterations in the stability of the synapse, particularly at old age, would 
exhibit unequivocal regional temporal profiles.  Proteins with corresponding regional 
expression at the young and mid-age time-points followed by a significant 
demarcation in expression at old age were selected as potential regulators of synaptic 
vulnerability – these particular expression profiles correlate with previous reports of 
significant alterations in synapse electrophysiological properties and morphometry in 
the aged rhesus monkey hippocampus (1, 25). With characterization of the 241 
filtered proteins (Fig. 31A), we identified 8 candidates (CYC1, UQCRC1, WDR1, 
ROCK2, CAPZA2, OGDH, RCN2, CDH2) that displayed the archetypal regional 
spatiotemporal expression profile (Fig. 31B). Interestingly, all candidates 
demonstrated a significant reduction in expression in the old age hippocampal 
synapses versus the occipital cortex at the equivalent time point. To examine whether 
this reduction in candidate protein expression in the aged hippocampus was 
contributing to the vulnerability status of synaptic compartments in vivo, we utilized 
a molecular genetic approach at the Drosophila larval neuromuscular junction (NMJ) 
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to assess the regulatory role of individual candidates at the synapse. The larval NMJ 
is an excellent model system to unravel the molecular mechanisms underpinning 
synaptic structure, function and plasticity (26). Fundamental mammalian biological 
and neurological pathways demonstrate conservation in Drosophila and recent 
evidence has indicated that up to 75% of human disease related genes exhibit a 
functional ortholog in the fruit fly (27). Larval NMJs harbour glutamatergic synaptic 
boutons with contiguous invaginated post-synaptic membranes (sub-synaptic 
reticulum (SSR)) (28, 29), which display significant homology to those found in the 
mammalian central nervous system. Neurotransmission between these connections 
has the propensity to invoke plastic modifications (26, 28, 30), providing 
physiologically relevant mechanistic insights into proteins regulating the structure 
and function of the synapse in mammalian cognition (30). 
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Figure 31: Identification of potential candidates capable of modulating synaptic 
vulnerability during ageing. A. Heat map displaying average normalized abundance values 
of 241 differentially expressed candidates associated with synaptic vulnerability. Blue 
indicates low expression and red high expression. YH - young hippocampus; MH – mid-age 
hippocampus; OH – old hippocampus; YO – young occipital; MO – mid-age occipital; OO – 
old age occipital. B. Identification of proteins that may have the propensity to modulate 
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regional synaptic vulnerability. Graphs represent temporal expression profiles of identified 
candidates. Note the similar expression profiles through young and mid-age in both resistant 
and vulnerable synaptic compartments followed by significant divergence in expression at 
old age. All graphs display the ratio of candidate protein expression against the young age. 
Hippocampus temporal protein expression - purple; occipital cortex temporal protein 
expression - grey. 
 
 
Recapitulation of hippocampal candidate protein expression at the larval NMJ was 
achieved using the UAS/Gal4 system, promoting tissue specific expression of the 
selected transgenes under control of the elav-Gal4 driver (see Table 3 for Drosophila 
orthologs). Pan-neuronal expression of the RNAi constructs (v9180; v40466; 
v22851; 28797; v100773; 34101; v30690; v36166) resulted in viable larva from all 
crosses with the exception of CAPZA2 (v100773), which demonstrated lethality at 
the first instar stage of development. Phenotypic assessments of muscle 12/13 NMJs 
in third instar larva harboring RNAi-mediated selective knock-down of single 
candidates revealed perturbations in multiple morphological parameters associated 
with the stability of the synaptic architecture (Fig. 32A-C). Bouton volume appeared 
significantly altered in 3 candidate lines: WDR1 (v22851), RCN2 (v30690) and 
CDH2 (v36166). Contrary to RCN2 and CDH2 knock-down, reductions in WDR1 
protein expression demonstrated a global decrease in bouton volume (p<0.01) 
coupled with an increase in bouton number and NMJ arborization (Fig. 32A&B), 
likely due to the regulatory role of WDR1 signalling in the organization of the actin 
cytoskeleton (31). Conversely, selective targeting of RCN2 and CDH2 produced 
morphologically distinct but quantitatively similar phenotypes, with volumetric 
enlargement of boutons (p<0.01) alongside a reduction in bouton number. 
Furthermore, numerous candidate lines (WDR1, OGDH, RCN2, CDH2) 
demonstrated a significant loss of distinguishable type Ib (big) boutons (Fig. 
32A&C) and perturbed SSR architecture (represented by DLG staining). Disruptions 
in SSR expression are apparent at type Is (small) boutons, with multiple candidates 
displaying a lack of (UQCRC1, WDR1, RCN2), or fragmented (OGDH, CDH2), 
DLG staining (Fig. 32A) suggesting aberrant alterations in synaptic function. The 
morphological vicissitudes in multiple parameters with selective knock-down of 
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individual candidates suggests that these proteins may be essential to homeostatic 
regulation of the synaptic compartment. Thus these data represent a physiologically 
relevant paradigm demonstrating that reductions in the expression of these 
candidates in the NHP hippocampus may promote selective synaptic vulnerability 





Figure 32: Identified candidates regulate the synaptic milieu at the Drosophila 
neuromuscular junction. A. Representative confocal images of muscle 12 NMJs, labelled 
with anti-HRP and anti-DLG. Knock-down of candidates CYC1, UQCRC1, WDR1, OGDH, 
RCN2 and CDH2 with RNAi demonstrates significant perturbations in the synaptic 
architecture. B. Graphs represent quantification of control and candidate line bouton volume 
(µm). WDR1 (**p = 0.0094, n=3), RCN2 (**p = 0.0033, n=3) and CDH2 (**p = 0.0024, 
n=3) indicate significant alterations in bouton volume. C. Graphs indicate the number of 
distinguishable type Ib glutamatergic boutons in control and candidate knock-down lines. 
WDR1 (**p = 0.0067, n=3), OGDH (**p = 0.0011, n=3), RCN2 (***p = 0.0004, n=3) and 
CDH2 (***p = 0.0006, n=3) demonstrate significant reductions in the number of type Ib 
boutons. All lines used the elav-Gal4 driver system. NMJs imaged at 63x. Scale bar = 10µm, 
n=8. Statistical analyses utilized unpaired two-tailed Student’s t-test (** p = <0.01; *** p = 
<0.001; **** p = <0.0001).  
 
5.3.5 Selective inhibition of the TGFβ1 cascade rescues synaptic 
phenotypes. 
Despite presenting a number of novel candidates that have the propensity to alter 
synaptic morphometry, it is unlikely that the expression of single proteins solely 
regulate regional synapse vulnerability during mammalian brain ageing. Instead, it is 
probable that multiple cellular and molecular pathways up- and downstream of the 
identified candidates converge to regulate age-dependent alterations in synaptic 
structure and function. By employing Ingenuity Pathway Analysis (IPA) software, 
we sought to identify a common upstream ‘master regulator’ that may be modulating 
the reduction in expression of the 8 identified candidates simultaneously. The IPA 
upstream analysis function highlighted that the majority of our candidates (ROCK2, 
CAPZA2, CYC1, CDH2, OGDH, RCN2) appeared to sit downstream of TGFβ1 
(transforming growth factor beta 1) in the hierarchical cellular signalling cascade. 
With further examination we established that this particular pathway appeared to be 
activated in aged hippocampal synapses, promoting concomitant downregulation of 
our candidate proteins (Fig. 33). Interestingly, occipital cortex synapses of the 
equivalent age exhibited differential regulation of this pathway, with TGFβ1 
showing significant inhibition (data not shown) and our candidate proteins 
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demonstrating stable expression. Thus, there are suggestions that the activation status 
of TGFβ1 signalling in discrete populations of synapses may be contributing to 
differential synaptic vulnerability. To establish whether activation of the TGFβ1 
cascade was enhancing the synaptic phenotypes described at the Drosophila NMJ 
(Fig. 32A-C), we pharmacologically manipulated expression levels with a TGFβ1 
selective inhibitor (LY364947, Tocris). Inhibition of TGFβ1 with 2mM LY364947 
paralleled with RNAi mediated knock-down of the candidates CDH2 and RCN2 
conferred synaptic protection, with no significant differences in bouton volume 
detected between control and treated lines (Fig. 33A&B). In conjunction, treatment 
with the TGFβ1 inhibitor significantly rescued the number of type Ib glutamatergic 
boutons in both the RCN2 and CDH2 RNAi lines and promoted restoration of SSR 
architecture (Fig. 33A&C). Furthermore, NMJ arborisation appeared to be reinstated 
with RCN2 and CDH2 treated lines with branching and NMJ structure demonstrating 
morphological similitude with controls (Fig. 33A). No developmental defects were 
observed with LY364947 treatment and larva pupated and eclosed concurrently with 
corresponding control lines suggesting that there were no off-target effects. 
Moreover, control human patient synaptosomes demonstrated conserved reductions 
in RCN2 and CDH2 expression during ageing, highlighting the physiological 
relevance of the results described (Fig. 34). Taken together, the data demonstrate that 
the inherent vulnerability of aged hippocampal synapses may be mediated by 





Figure 33: Pharmacological inhibition of the upstream master regulator TGFβ1 
rescues synaptic phenotypes. A. Ingenuity Pathway Analysis (IPA) software highlighted 
TGFβ1 as a common upstream regulator to 6 candidates that have the propensity to 
significantly alter synaptic morphometry. The TGFβ1 signalling cascade displays significant 
activation in vulnerable hippocampal synaptic populations at old age promoting reductions 
in candidate expression. Positive z-scores indicate activation (orange) and negative z-scores 
indicate inhibition (blue); green represents downregulation relative to the expression in 
young animals. B&D. Representative confocal images of Drosophila third instar larva 
muscle 12 NMJs in control (left), candidate knock-down (middle) and candidate knock-
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down treated with 2mM of the selective TGFβ1 inhibitor LY364947. Note the loss of 
stereotypic NMJ structure, bouton morphology and patterned DLG staining with both RCN2 
and CDH2 RNAi lines (middle panels). RCN2 and CDH2 RNAi lines treated with 2mM 
LY364947 demonstrate amelioration of synaptic phenotypes (right panels). C&E. Bar charts 
displaying inhibition of TGFβ1 with 2mM LY364947 promotes rescue of multiple 
morphological parameters. Treatment revealed a significant reduction in mean bouton 
volume in both RCN2 (*p = 0.0244) and CDH2 (*p = 0.0274) RNAi lines versus untreated, 
restoring volume to control levels. In conjunction, treated lines displayed a significant 
increase in the number of distinguishable type Ib boutons versus untreated lines (RCN2: 
***p=0.0008; CDH2: *p=0.0105). All lines used the elav-Gal4 driver system. NMJs imaged 
at 63x. Scale bar = 10µm, n=3. Unpaired two-tailed Student’s t-test (* p = <0.05; ** p = 




Figure 34: Reductions in RCN2 and CDH2 protein expression is conserved in ageing 
human patient synapses. A. Actin loading control for control human patient hippocampal 
synaptosomes. Quantification reveals no significant difference in total protein between age 
groups. B. Western blot displaying RCN2 protein expression in young, mid-age and old 
human patient hippocampal synaptosomes. Quantification demonstrates reductions in RCN2 
expression during the ageing timecourse. C. Western blot displaying CDH2 protein 
expression in young, mid-age and old human patient hippocampal synaptosomes. 
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Quantification shows a significant decrease in CDH2 expression at the old age time point. 
Bar charts represent average age-group protein expression quantified by fluorescence 
emission. YH - young hippocampus; MH – mid-age hippocampus; OH – old hippocampus. 


























The molecular mechanisms governing the age-dependent decline of selected synaptic 
populations remain elusive and studies are only now beginning to focus on how 
protein pathways may synergistically or hierarchically drive this phenomenon. Here, 
we demonstrate that differential synaptic vulnerability is dictated by regional 
divergence in protein expression. Temporal proteomic profiling of anatomically 
distinct brain regions from the non-human primate revealed discrete and dynamic 
alterations in the synaptic proteome, which appear unequivocally conserved in 
human patients. Utilising in silico and molecular genetic tools, we confirmed that the 
TGFβ1 signalling cascade demonstrates activation in aged hippocampal synapses, 
however the corresponding pathway appears inhibited in resistant synapses. 
Recapitulation of TGFβ1 activation by genetic manipulation of several downstream 
effector molecules demonstrated significant perturbations in the synaptic architecture 
in vivo. Furthermore, pharmacological inhibition of TGFβ1 ameliorated synaptic 
phenotypes thus affirming that enhanced transduction of TGFβ1 signalling may be 
modulating regional synaptic vulnerability during mammalian ageing.  
 
 
5.4.1 Candidate proteins regulating age-dependent selective synaptic 
vulnerability. 
The identification of fundamental biochemical pathways orchestrating selective 
synaptic vulnerability is imperative for the development of neuroprotective 
strategies. The current investigation suggests there is scope to detect inherent 
protective modulators leading to the amelioration of synaptic dysfunction. Of 
particular relevance are the numerous novel candidates identified, all of which have 
the propensity to regulate the synaptic milieu in vivo. The subcellular localisation 
and functional specialisation of these proteins is wide-ranging (CYC1 – 
mitochondria; UQCRC1 – mitochondria; WDR1 – cytoplasmic/cytoskeletal; ROCK2 
- cytoplasmic/cytoskeletal; CAPZA2 – cytoskeletal; OGDH – mitochondria; RCN2 – 
endoplasmic reticulum; CDH2 – pre- and post-synaptic membranes), likely reflecting 
convergence of numerous biochemical pathways required for homeostatic regulation 
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of the synaptic compartment. Indeed, alterations in mitochondrial function (32), the 
cytoskeletal architecture (33) and calcium buffering via the endoplasmic reticulum 
(ER) machinery have all been widely implicated in age-dependent synaptic demise 
(34, 35).  
 
Of particular interest are the candidates reticulocalbin 2 (RCN2) and cadherin 2 
(CDH2), as upstream pharmacological intervention promoted significant 
amelioration of the associated synaptic phenotypes at the Drosophila NMJ. RCN2 is 
a known EF-hand calcium-binding protein (36) with strict localisation to the ER-
lumen (37) and has previously been associated with numerous neurological diseases, 
including absence epilepsy (38) and multiple sclerosis (39). In addition, fibroblasts 
derived from elderly human patients have reported significant reductions in RCN2 
expression suggesting the protein may be relevant to the cellular alterations 
underpinning senescence (40). Furthermore, recent experimental evidence has 
demonstrated that RCN2 directly interacts with the mitochondrial sideroflexin 
(SFXN) protein family in human patients (41), which we have shown to be α-
synuclein dependent regulators of the synaptic architecture in vivo (42). Taken 
together, the data indicate that this particular protein may play a role in mediating 
age-related synaptic demise via disruptions in calcium-dependent signalling at the 
ER-mitochondrial axis. Further investigations into RCN2 signal transduction and 
mitochondrial effector molecules may aid in determining the pathophysiological role 
of the ER and its associated mitochondrial complexes and how these may modulate 
synaptic stability during ageing and disease. 
 
In addition to RCN2, we also demonstrated phenotypic rescue of the CDH2 
misexpression Drosophila line. CDH2, or N-cadherin, is a cell adhesion molecule, 
acting as synaptic ‘glue’ to ensure appropriate recognition and connectivity of the 
pre- and post-synaptic membranes (43, 44). The hippocampus exhibits clustering of 
CDH2 protein within the active zones of excitatory synapses (45) and appears to 
modulate synaptic plasticity, synaptic vesicle docking and recycling, post-synaptic 
density stabilisation and dendritic spine morphology in vitro (46). Interestingly, 
expression of CDH2 is required for the induction of long-term potentiation (LTP) 
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suggesting homeostatic control of the protein is essential to both the structural 
integrity and functional activity of the synapse (47). Indeed, reductions in neuronal 
CDH2 expression promoted aberrant pre- and post-synaptic organisation at the 
Drosophila NMJ suggesting perturbed synaptic functions via impairments in 
activity-dependent morphological remodelling - processes which are believed to 
widely contribute to age-related cognitive decline.  
 
 
5.4.2 The TGFβ1 signalling cascade: a synaptic-microglial 
intersection? 
Despite the 8 candidates displaying significant diversity in localisation and function 
at the synapse, surprisingly, 6 proteins demonstrated a common upstream regulator: 
TGFβ1. Intriguingly, TGFβ1 is not constitutively expressed in neurons, but displays 
robust levels of expression in microglia (Fig. 35A) suggesting that regional synaptic 
vulnerability may be mediated by microglial signalling. Indeed, recent investigations 
have reported age- and region-dependent microglial diversity at the transcriptome 
level, with indications that hippocampal microglia exhibit compromised function 
with advancing age (48). In conjunction, immunohistochemical techniques have 
revealed that microglial populations in aged NHP models and human patients appear 
to display a dystrophic morphology (49). In conjunction with this senescent 
phenotype, there is abundant evidence to suggest that microglia become 
hypersensitive or ‘primed’ resulting in prolonged pro-inflammatory activation in 
response to homeostatic alterations (50, 51), which may functionally contribute to 
age-related neuronal alterations via modifications in cytokine signalling and 
immuno-surveillance (52). Furthermore, investigations into the pathogenic role of 
microglia have documented chronic over-expression of TGFβ1 in multiple 
neurodegenerative diseases, including Alzheimer’s disease (AD), frontotemporal 
dementia (FTD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) 
(53, 54), illustrating that this pathway may be contributing to numerous age-related 





Figure 35: Regional synaptic vulnerability is regulated by the microglia. A. Bar chart 
displaying TGFβ1 transcript expression in isolated hippocampal microglia and hippocampal 
homogenate. The homogenate exhibits relatively little TGFβ1 expression versus the isolated 
microglia (unpaired two-tailed student’s t-tests, p = 0.0009). B&C. Summary of synaptic-
microglial interactions and regulation of the cellular milieu during ageing. Young adult 
microglia (B.) demonstrate ramified morphology and inhibition of the TGFβ1 signalling 
cascade, promoting homeostatic regulation of the subcellular machinery within the synaptic 
compartment. Intracellular processes are illustrated in the black box. Conversely, resident 
microglia in an aged brain (C.) display a dystrophic, primed phenotype. Activation of the 
TGFβ1 signalling cascade, by binding of TGFβ1 to the TGFβ1 synaptic receptor, promotes 
injurious events within the synaptic terminal facilitating synapse instability. Orange colour 
represents dendritic arbour with synaptic terminals; pale blue indicates microglia; white 




Based upon this evidence, it is perhaps unsurprising that our data have described 
microglial TGFβ1 signalling as a fundamental modulator of regional synaptic 
vulnerability during ageing. Of course, microglia and synapses are not mutually 
exclusive entities and there is a requirement for a dynamic and bi-directional 
relationship to enable homeostatic control of the cellular milieu however, this critical 
intersection appears to be potentiating age-dependent instability in the hippocampal 
synaptic architecture. Despite the wealth of data presented in this study, the cause-
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consequence relationship underpinning selective synaptic vulnerability remains 
unresolved. It is unclear whether i) disruptions in synaptic proteostasis precede 
aberrant microglial TGFβ1 signalling or ii) microglia are the primary effectors and 
activation of TGFβ1 signalling facilitates synaptic dysfunction. However, we may 
speculate that the latter appears to be the most compelling hypothesis as restoration 
of upstream microglial signalling promotes a full rescue of the synapse in multiple 
models of synaptic ageing (Fig. 35B&C). Correspondingly, supporting our proposed 
hypothesis are the pioneering heterochronic parabiosis studies by Villeda et al, 2011 
(55), who describe TGFβ1 as a pro-ageing cytokine underpinning hippocampal-
dependent cognition. In agreement with the current study, experimental procedures 
inhibiting TGFβ1 (and other microglial-regulated immunomodulatory factors) 
rescued neurogenesis and concomitant learning deficits in aged mice. Thus, the 
microglial-synaptic axis appears to be a fundamental intersection that requires a fine-
tuned equilibrium to maintain selective synaptic integrity during advancing age. 
 
Cumulatively, our data provide a comprehensive insight into the regional 
heterogeneity of synaptic ageing and how proteostatic alterations may dictate 
selective synaptic vulnerability in the primate. Identification of the microglial 
cytokine TGFβ1 as a master regulator of hippocampal synapse structure and function 
is indicative of a highly dynamic cohesive cellular network that requires symbiotic 
modulation for optimal neuronal function during advancing age. Despite this, the 
implicit role of the TGFβ1 cascade in regional synaptic vulnerability is not 
unequivocal. It remains unclear whether activation of TGFβ1 signalling is uniquely 
maladaptive to selected synaptic populations or whether discrete target tissues 
demonstrate varied allostatic loads. Furthermore, a significant chasm in scientific 
knowledge concerning microglial-synaptic interactions during advancing age persists 
and this must be addressed before we can fully appreciate the functional 







Chapter 6. Proteomic profiling of differentially vulnerable 
synaptic populations in the ageing human patient 
6.1 Introduction 
Despite erudite research efforts many of the causative mechanisms driving human 
neurodegenerative disease manifestation and progression remain to be elucidated. It 
has been well established that advancing age is the single largest risk factor for the 
development and diagnosis of a neurodegenerative disease, with Alzheimer’s disease 
(AD) being the most prevalent condition (251). AD has a destructive impact on the 
patient’s capacity to function independently paralleled with significant cognitive and 
behavioural alterations (2, 3) reflecting the gross pathological alterations occurring 
within the intricate cortical structures of the brain (116). Due to the prevalence, 
severity and devastating consequences of AD, research focus has been directed 
towards unravelling the causative mechanisms of the disease; however, there has 
been relatively little emphasis on the correlates of normal healthy brain ageing in the 
human patient and the impact that advancing age has on the cortical cellular 
architecture in the absence of pathogenic processes. It has become increasingly 
evident that normal ageing has the propensity to promote progressive cognitive 
impairment with a multitude of aged individuals exhibiting selective reductions in 
executive function, short-term memory capacity and retention of novel information 
(3-5). The clinical symptomology described is common to both the very early stages 
of AD and advancing age suggesting age-related cognitive impairment and the early 
pathologic processes occurring in AD may demonstrate a convergence of analogous 
biochemical cascades. To appreciate the complex intersection of human advancing 
age and AD pathogenesis, it is essential that the field characterises neuronal 
biochemical alterations that may be regarded as ‘normal’ and those that may act as 
pathogenic precursors to the development of neurodegenerative diseases. Without a 
comprehensive understanding of the perturbed pathways governing age-related 
alterations in the neuronal milieu, there are limited possibilities for the development 
of successful strategies that promote cognitive health in the human patient. 
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As outlined in Chapters 1&5, synapses are particularly vulnerable during advancing 
age and discrete neuroanatomical regions demonstrate selective susceptibility to 
insult. It is well established that the hippocampal synaptic architecture displays 
particular vulnerability to a wide range of insults during advancing age (4, 5, 93), 
whereas synapses resident to the occipital cortex exhibit resistance to age-related 
alterations (3, 94, 116-121, 224, 225). Despite this, there are relatively few studies 
investigating the molecular correlates bolstering selective synaptic vulnerability, 
particularly in human tissues.  
 
Here, in what appears to be the first investigation exploring the temporal molecular 
alterations occurring in neuroanatomically distinct populations of synapses during 
the human lifespan, we describe data supporting the notion that local alterations in 
the regional synaptic proteome may facilitate synaptic vulnerability during ageing. 
Comparative proteomic profiling of hippocampal and occipital cortex synapses 
revealed regional divergence in protein expression, promoting the identification of 
25 novel candidates that may be associated with synaptic vulnerability during 
advancing age in the human patient. A number of the identified candidates clustered 
into the TGFβ1 hierarchical signalling cascade, which exhibited differential 
activation in the hippocampus and occipital cortex at old age. The data support our 
previous observations in Chapter 5 and suggest that the activation status of the 
TGFβ1 pathway may mediate the age-dependent vulnerability of hippocampal 












6.2.1 Human patient samples 
Human patient samples were obtained from the Edinburgh Brain Bank. All tissues 
were classified as controls due to the absence of gross pathological hallmarks and 
neurological disease. Human tissues were assigned to equivalent age groups: young 
(18-25 years), mid-age (40-50 years) or old age (70+ years), with 4 samples per time 
point. Use of human tissue for post-mortem studies was reviewed and approved by 
the Edinburgh Brain Bank ethics committee. The Edinburgh Brain Bank is a Medical 
Research Council funded facility with research ethics committee approval 
(11/ES/0022).  
 
6.2.2 Synaptosomal preparations 
Regional synaptosomal preparations were performed on the human patient young, 
mid-age and old hippocampal and occipital cortex samples using the methods 
described in Chapter 2, section 2.3. 
 
6.2.3 Protein concentration assay 
Protein concentration of individual patient samples and pooled regional samples was 
determined utilizing the methods described in Chapter 2, section 2.5. 
 
6.2.4 Label-free proteomics 
Human patient regional synaptosomal preparations were extracted in SDT lysis 
buffer containing 100 mM Tris-HCl (pH 7.6) and 4% (W/V) sodium dodecyl sulfate 
(VWR). For efficient protein extraction, lysates were freeze–thawed and 
homogenized in SDT buffer several times. Protein concentrations were then 
determined using BCA assay.  
 
The following mass spectrometry analyses were performed by the FingerPrints 
proteomic facility at the University of Dundee. Aliquots (200 µg) of each 
synaptosomal preparation were processed through FASP (filter-aided sample 
preparation) involving buffer exchange to 8 M urea and alkylation with 50 mM 
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iodoacetamide prior to a double digestion with trypsin (Roche, sequencing grade), 
initially for 4 h, then overnight at 30 °C. Trypsin-digested peptides were separated 
using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system with the 
column oven set to 35 °C. Technical replicates (3 × ∼1 µg) of each sample were 
loaded at a constant flow of 5 µL/min onto a trapping cartridge (PepMap100, C18, 
5µm, 100Å 0.3 x  5 mm; (Thermo Scientific, San Jose, CA) using 2% Acetonitrile, 
0.1 % formic acid. After trap enrichment, peptides were separated on a peptide CSH, 
1.7µm, 130Å, 75µm x 250mm C18 column (Waters Corp, Milford, MA) with the 
following gradient: t=0 min, 2 % B; t=6, 2 % B; t=20, 8 % B; t=110, 24 % B; t=135, 
37 % B where solvent A is water with 0.1 % formic acid and solvent B is 80% 
acetonitrile with 0.1% formic acid, with a constant flow of 260 nL/min. The HPLC 
system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-
Orbitrap Velos Pro, Thermo Scientific) via a nanoelectrospray ion source (Thermo 
Scientific). The spray voltage was set to 2.2 kV, and the temperature of the heated 
capillary was set to 200 °C. Full-scan MS survey spectra (m/z 335–1800) in profile 
mode were acquired in the Orbitrap with a resolution of 60$000 after accumulation of 
1$000$000 ions. A lock mass of 445.120$024 was enabled for survey scans to improve 
mass accuracy. The 15 most intense peptide ions from the preview scan in the 
Orbitrap were fragmented by collision-induced dissociation (normalized collision 
energy, 35%; activation Q, 0.250; and activation time, 10 ms) in the LTQ after the 
accumulation of 10$000 ions. Dynamic exclusion parameters were set as follows: 
repeat count, 1; repeat duration, 30 s; exclusion list size, 500; exclusion duration, 45 
s; exclusion mass width, plus/minus 10 ppm (relative to reference mass). Maximal 
filling times were 10 ms for the full scans and 100 ms for the MS/MS scans. 
Precursor ion charge state screening was enabled, and all unassigned charge states as 
well as singly charged species were rejected. Data were acquired using Xcalibur 
software. 
 
The following analyses described were performed by Laura Graham at the Roslin 
Institute. Raw proteomic data were imported into Progenesis for characterization and 
analysis of relative ion abundance. 2D representations of MS/MS output were 
created for each sample and these were aligned to determine similar features 
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(average alignment score >88%). Following alignment, data was filtered by retention 
time with features detected below 11.81 minutes and above 134.37 minutes 
discarded to correct for elution variability. The runs were grouped according to age 
and brain region and Statistical P values were automatically generated in Progenesis 
software through a 1 way ANOVA on the ArcSinh transform of the normalized data. 
 
Peptides were filtered by the following criteria: power <0.8, fold change >1.2, 
p>0.05 and the remaining data were exported from Progenesis for identification of 
individual peptide sequences using the IPI-homo sapiens database via Mascot Search 
Engine (V2.3.2). Enzyme specificity was set to that of trypsin, allowing for cleavage 
N-terminal to proline residues and between aspartic acid and proline residues. Other 
parameters used were as follows. (i) Variable modifications: methionine oxidation, 
methionine dioxidation, protein N-acetylation, gln → pyro-glu. (ii) Fixed 
modifications: cysteine carbamidomethylation. (iii) MS/MS tolerance: FTMS- 10 
ppm, ITMS- 0.6 Da. (iv) Minimum peptide length: 6. (v) Maximum missed 
cleavages: 2. (vi) False discovery rate: 1%. A cutoff score of >34 was used based on 
Mascot probability threshold of 0.05 that the observed hit is a random event. As an 
indication of identification certainty, the false discovery rate for peptide matches 
above identity threshold was set at 1%.  
 
Identified proteins were re-imported into Progenesis for further processing. Proteins 
were subject to stringent filtering parameters to eliminate those which had <2 unique 
peptides, <1.2 fold change between age groups and p>0.05 to obtain the proteins 
which demonstrated the largest significant variation in expression over the ageing 
time course in each brain region. 
 
6.2.5 Biolayout Express3D 
Proteomic data was dissected using the complex pattern recognition software, 
Biolayout Express3D (159). The software allows visualization of molecular networks 
by applying Markov clustering algorithms to raw proteomic data (MCL 2.2). All 
graphs were clustered using Pearson correlation r=0.97. Clusters of interest 
indicating age-dependent alterations included those that demonstrated a steady up- or 
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down-regulation or a late stage up- or late stage down-regulation during the 
timecourse of ageing. Proteins from clusters with analogous expression profiles 
underwent a subtractive process – candidates appearing in both the resistant and 
vulnerable clusters, altered in the same manner, were unlikely to regulate synaptic 
vulnerability during ageing. These candidates were eliminated as modulators of 
synaptic vulnerability.  
 
6.2.6 Ingenuity Pathway Analysis 
IPA analyses were performed as previously described (157). See methods section 2.9 
for details on the parameters utilized for experimental analysis.  
 
6.2.7 Quantitative Fluorescent Western Blotting 
See Chapter 2, section 2.10 for a detailed methodological overview. All antibodies 















6.3.1 Temporal proteomic profiling of anatomically distinct synaptic 
isolates from the human patient brain. 
As highlighted in chapters 1 and 5, discrete neuroanatomical brain regions harbour 
differential vulnerabilities to insult and degeneration during advancing age. Despite 
concerted efforts to characterise the age-dependent patterned morphological 
alterations occurring in neuronal subpopulations, few investigations have examined 
the temporal biochemical cascades that may facilitate susceptibility or resistance to 
injurious stimuli in the human patient. To investigate the regional temporal 
molecular alterations occurring in human synapses during normal healthy ageing, we 
purified and characterised crude synaptosomes from two differentially vulnerable 
brain regions (occipital cortex and hippocampus) at 3 time points (young adult, mid-
age, old). Quantitative label-free proteomic analyses identified >1570 proteins in 
both regions across the time-course, revealing dynamic divergences in synaptic 
protein expression. Remarkably, over 1000 proteins were altered by greater than 
20% in both the hippocampus and occipital cortex, demonstrating the significant age-
dependent biochemical adaptations occurring in discrete synaptic populations (Fig. 
36A&B). Purity of regional synaptic preparations was assessed utilising PANTHER 
Gene Ontology bioinformatics software. Input of the 1574 identified proteins from 
the proteomic data indicated significant enrichment of postsynaptic membranes 
suggesting relative purity of the synaptosomal preparations (Fig. 36C). Additionally, 
to determine the veracity of the proteomic data we employed quantitative fluorescent 
western blotting. Corresponding protein expression trends were observed in the 
human tissue preparations as indicated by the proteomics for the proteins citrate 
synthase (Fig. 37C&D) and ROCK2 (Fig. 37E&F). Collectively, the data indicate the 
relative purity of the synaptic preparations and suggest the proteomic data is 






Figure 36: Spatiotemporal characterisation of regional synaptic proteomes in the 
human patient. A&B. Venn diagrams demonstrating regional characterization of the 
synaptic proteome. Proteins were identified and filtered in Progenesis using the following 
criteria: p>0.05, <1.2 fold change across the timecourse and 1 unique peptide to obtain the 
proteins that demonstrate the largest alterations during normal healthy ageing in human 
patients. Number of proteins up- or down-regulated by >1.2 fold change during ageing, is 
indicated at the middle intersection. These filtered proteins were utilized for all analyses. C. 
PANTHER GO-Slim cellular component enrichment analysis of the temporal hippocampal 
and occipital cortex proteomic data. Table indicates enrichment of the postsynaptic 
membrane suggesting relative purity of preparations. Fold-enrichment values greater than 1 
denote overrepresentation of category in dataset. 
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Figure 37: Validation of human regional synaptic alterations with quantitative 
fluorescent western blotting. A. βIII-tubulin loading control demonstrating equal loading 
between individual patients and between regions. B. Graph displays no significant difference 
in βIII-tubulin expression between pooled samples. C-F. Upper bar charts display the 
proteomic average normalised expression values of the proteins citrate synathase (C.) and 
ROCK2 (E.) in regional synapses during ageing. Lower bar charts demonstrate sample 
protein expression quantified by the fluorescent western blots shown. Proteomic and sample 
expression of both citrate synthase (D.) and ROCK2 (F.) follow the same trend thereby 
providing validation of the proteomic data. Y1-3 = young adult individual human patient 
synaptic samples; M1-3 = mid-age adult individual human patient synaptic samples; O1-3 = 
old adult individual human patient synaptic samples. YH = young patient pooled 
hippocampal synapses; MH = mid-age patient pooled hippocampal synapses; OH = old 
patient pooled hippocampal synapses; YO = young patient pooled occipital cortex synapses; 
MO = mid-age pooled occipital cortex synapses; OO = old patient pooled occipital cortex 
synapses. Statistical analysis was performed using an unpaired two-tailed Student’s t-test. 
 
 
6.3.2 Regional heterogeneity of the human synaptic proteome during 
normal healthy ageing 
To examine whether synapses from differentially vulnerable brain regions aged in a 
similar manner, we utilized the objective network visualisation software Biolayout 
Express3D (www.biolayout.org) to generate brain regional principal component 
analysis correlation graphs demonstrating relative age-dependent similarities (Fig. 
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38). Examination of these networks verified the presence of distinct region-
dependent clustering profiles. Interestingly, the graph representing the temporal 
timecourse of hippocampal synaptic ageing demonstrates division into 2 discrete 
networks, indicating age-dependent heterogeneity. Fragmentation suggests that the 
aged hippocampal synapses possess discrete protein expression profiles (Fig. 38A) 
versus the young and mid-age synaptic isolates, which may contribute to the 
vulnerability status of synaptic compartments at this particular age. Though the 
resistant occipital cortex synapses also demonstrate a fragmented profile (Fig. 38B), 
it appears that mid-age synaptic isolates exhibit reduced equivalence with the young 
and old time points. The salient similarities in protein expression between the young 
and old occipital cortex synaptic populations may confer resistance to insult during 
advancing age. The data provide indications that isolated human synaptic 
populations age in a region-dependent manner and these unique alterations may 
dictate potential vulnerability of synapses during advancing age. 
   
 
Figure 38:  Human synaptic ageing is regionally heterogeneous. Unbiased sample-sample 
correlation analysis generated from BioLayout Express3D software. Nodes signify individual 
samples and edges reflect the strength of correlation of expression. YH = young patient 
pooled hippocampal synapses; MH = mid-age patient pooled hippocampal synapses; OH = 
old patient pooled hippocampal synapses; YO = young patient pooled occipital cortex 
synapses; MO = mid-age pooled occipital cortex synapses; OO = old patient pooled 
occipital cortex synapses. All graphs clustered using Pearson r=0.98. 
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6.3.3 Regional profiling of hippocampal and occipital cortex 
synapses reveals protein expression profiles associated with synaptic 
vulnerability 
In conjunction with the principal component analyses, to dissect region-specific age-
dependent synaptic alterations further, we generated network graphs of the regional 
timecourse proteomic data, again utilising Biolayout Express3D (159). The software 
applies unbiased Markov clustering algorithms to the input data and groups proteins 
displaying similar expression trends. This allows visualisation of spatiotemporal 
profiles promoting the identification of physiological cascades altered within the 
dataset. Graphs were constructed utilizing regional differentially expressed proteins 
(altered >20%) through the timecourse of ageing (see Fig. 36A&B) providing 40-50 
clusters per region. Interestingly, in contrast to the principal component analyses, 
both the hippocampal and occipital cortex timecourse data exhibit one large 
interconnected network (Fig. 39), though there is a marked increase in fragmentation 
in the hippocampal synapses (Fig. 39A). This appears to be in agreement with the 
principal component analysis correlation graphs and is likely reflective of the 
heterogeneity in protein expression between the young, mid-age and old 
hippocampal synaptic populations (see Fig. 38A). Conversely, the occipital cortex 
timecourse displays a single network with little fragmentation (Fig. 39B), suggesting 
that a multitude of proteins may harbour similar protein expression profiles despite 
the reported heterogeneity between age groups (Fig. 38B). Although the networks 
display subtle demarcations between hippocampal and occipital cortex temporal 
synaptic protein expression, the data indicate that resistant and vulnerable brain 




Figure 39: Vulnerable and resistant synaptic populations exhibit subtle alterations in 
protein clustering. Regional protein-protein correlation networks displaying proteins 
significantly altered through the timecourse of ageing in human patient hippocampal and 
occipital cortex synapses. Nodes signify individual proteins and edges reflect the strength of 
correlation of expression. Colours represent clusters of proteins that are grouped together 
based on their expression profiles. All graphs clustered using Pearson r=0.97. 
 
 
As highlighted in chapter 5, there appears to be a divergent spectrum of synaptic 
vulnerability upon which the occipital cortex opposes the hippocampus. By utilising 
2 contrasting brain regions demonstrating disparate profiles of ageing, we aimed to 
identify potential regulators of synaptic vulnerability with comparison of analogous 
protein expression profiles. Clusters displaying particular expression trends of 
interest were selected from both the occipital cortex and hippocampus synaptic 
timecourse using Biolayout Express3D (Fig. 40A&B). Those exhibiting steady up- or 
down-regulation protein expression profiles during the timecourse were considered 
as potential biomarkers of normal healthy ageing due to the predictable age-
dependent tractability of those candidates (Fig. 40A). Conversely, proteins 
displaying late-stage increases or decreases in expression were regarded as potential 
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biomarkers of synaptic vulnerability as the abrupt expression changes observed in 
the old synaptic populations likely reflected acute alterations disrupting homeostasis 
at the synapse (Fig. 40B). In order to identify candidates that may be regulating 
regional synaptic vulnerability during ageing, proteins from occipital and 
hippocampal clusters with analogous expression profiles were subject to a 
subtractive process. Proteins demonstrating equivalent spatiotemporal profiles in 
both occipital cortex and hippocampal synapses were not considered to be regulators 
of differential regional synaptic vulnerability and filtered from the data prior to 
further analysis (Fig. 40C&D). Upon subtraction of proteins exhibiting analogous 
expression profiles, there remained 583 differentially expressed proteins that we 














Figure 40:!Temporal profiling of discrete synaptic populations reveals biomarkers of 
human synaptic ageing and vulnerability. A. Biomarkers of ageing: example temporal 
expression profiles of proteins demonstrating a steady up- or down-regulation during ageing. 
B. Biomarkers of vulnerability: example clusters displaying late stage increases or decreases 
in temporal protein expression. All graphs were generated in BioLayout Express3D (r=0.97) 
and display the mean protein expression across the timecourse in occipital and hippocampal 
synaptic isolates. C&D. Venn diagrams indicating subtraction of candidates. Proteins 
demonstrating equivalent spatiotemporal profiles in both occipital cortex and hippocampal 
synapses (shown at intersection) were not considered to be regulators of differential regional 
synaptic vulnerability and were subtracted from further analysis. 
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6.3.4 Activation of the TGFβ1 signalling cascade modulates 
candidates associated with synaptic vulnerability 
Despite characterizing the global spatiotemporal changes occurring in differentially 
vulnerable synaptic populations, it remained unclear whether divergence in 
expression of individual candidate proteins may be capable of actively regulating 
synaptic vulnerability. To elucidate regional regulators of synaptic vulnerability 
during advancing age, we initially mapped the individual temporal expression 
profiles of the 583 candidates identified by the Biolayout Express3D analyses using 
Python Jupyter Notebook (see Appendix 4). We sought to identify candidate proteins 
demonstrating corresponding regional expression at the young and mid-age time-
points followed by a significant demarcation in expression at old age – these 
particular candidates were considered potential regulators of synaptic vulnerability 
due to the reasoning outlined in Chapter 5, section 5.3.4. Additionally, we aimed to 
replicate the methodological parameters utilized for the analysis in Chapter 5 to 
facilitate direct comparisons of the ageing NHP and human regional timecourse data 
and delineate whether similar candidates may be modulating regional synaptic 
ageing between species. Upon tracking of the 583 candidates, we identified 25 
proteins that displayed the archetypal spatiotemporal expression profile (Fig. 41). 





Figure 41:! Candidate proteins associated with regional differential synaptic 
vulnerability during advancing age. Graphs display the temporal expression profiles of the 
25 candidates identified by Biolayout Express3D analyses. Data is displayed as a ratio of 
candidate protein expression against the young age. Note the similar expression profiles 
through young and mid-age in both resistant and vulnerable synaptic compartments followed 
by significant divergence in expression at old age. Hippocampal temporal protein expression 
- blue; occipital cortex temporal protein expression – green; red lines indicate 20% change. 
Graphs constructed using Python Jupyter Notebook.!
!
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Though the 25 candidates did not include those identified in Chapter 5, by 
employing Ingenuity Pathway Analysis (IPA) software, we sought to identify 
whether the aged NHP and human hippocampal synapses harboured a common 
upstream regulator that may be globally modulating the expression of proteins 
associated with increased synaptic vulnerability (Fig. 31&41). Indeed, the IPA 
upstream analysis function highlighted that 11 of our candidates identified from the 
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human data (Fig. 41) also sit downstream of TGFβ1 in the hierarchical cellular 
signalling cascade (Fig. 42), and, similar to the NHP data, this particular pathway 
appeared to be activated in aged hippocampal synapses (Fig. 42A). Interestingly, 
occipital cortex synapses of the equivalent age exhibited differential regulation of 
this pathway, with TGFβ1 showing significant inhibition (Fig. 42B). Activation 
status of the TGFβ1 signalling cascade appears to mediate the regional expression of 
selected protein candidates (APOA1, SLC7A5, CDC42EP4, IGKC, CD99, STMN3, 
HCN2, PPT1, FKBP4, HEBP1, PDAP1) in aged humans suggesting that TGFβ1 may 
be an important biochemical substrate contributing to differential synaptic 




Figure 42: Activation status of the TGFβ1 signalling cascade modulates differential 
synaptic vulnerability in the aged human patient. A. The TGFβ1 signalling cascade 
displays significant activation in vulnerable hippocampal synaptic populations at old age 
promoting concomitant alterations in downstream candidate expression. The candidates 
APOA1, SLC7A5, CDC42EP4, IGKC, CD99, STMN3 are displayed at the bottom of the 
cascade. B. TGFβ1 signalling demonstrates significant inhibition in resistant occipital cortex 
synapses at old age, which modulates the expression of selected candidates downstream. The 
candidates HCN2, PPT1, FKBP4, HEBP1, PDAP1 are displayed at the bottom of the 
network. Positive z-scores indicate activation (orange) and negative z-scores indicate 
inhibition (blue); green represents downregulation relative to the expression in young 




The molecular mechanisms governing the selective vulnerability of discrete synaptic 
populations in the human patient during advancing age remain unresolved. In what 
appears to be the first investigation exploring the molecular alterations occurring in 
neuroanatomically distinct populations of synapses during the human lifespan, we 
describe data supporting the notion that local alterations in the regional synaptic 
proteome may facilitate synaptic vulnerability during ageing. Comparative proteomic 
profiling of hippocampal (age-vulnerable) and occipital cortex (age-resistant) 
synapses demonstrated regional divergence in protein expression, revealing novel 
candidates that may be capable of actively regulating synaptic stability during 
advancing age in the human patient. A number of the identified candidates clustered 
into the TGFβ1 hierarchical signalling cascade, which exhibited differential 
activation in the hippocampus and occipital cortex at old age. The data support our 
previous observations in Chapter 5 and suggest that the activation status of the 
TGFβ1 pathway may mediate the age-dependent vulnerability of hippocampal 
synapses in human patients as well as rhesus macaques. 
 
Though we have identified similar activation of the TGFβ1 hierarchical signalling 
cascade to the NHP in both the aged human hippocampus and occipital cortex, we 
were unable to determine whether experimental manipulation of the 11 candidates 
associated with this pathway promoted aberrant synaptic phenotypes in vivo. 
However, previous studies have established that misexpression of APOA1, SLC7A5, 
CDC42EP4, IGKC and CD99 correlate with perturbations in the synaptic-microglial 
axis and may facilitate pro-inflammatory states, increasing the risk of AD or 
dementia development (252-258). Thus, it is likely that TGFβ1 is an important 
modulator of selective synaptic vulnerability due to conserved regional activation of 
the pathway across multiple primate species during advancing age and the reported 
downstream candidate associations with synaptic dysfunction. Although discussed in 
length in Chapter 5, section 5.4.2, holistic investigations exploring the effect of 
TGFβ1 expression on synaptic structure, function and cognitive status during normal 
healthy ageing may provide increased mechanistic insights into the biochemical 
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substrates orchestrating selective synaptic vulnerability and enable identification of 
appropriate modulatory candidates for therapeutic intervention. Elucidation of such 
mechanisms will be imperative for the development of strategies promoting 
cognitive health in human patients.  
 
The use of human patient tissue is fundamental for the extrication of the molecular 
mediators promoting age-related cognitive decline and neurodegenerative diseases. 
Though a precious and enlightening resource, significant challenges present when 
utilising human samples, particularly in biochemical studies. Investigations 
examining post-mortem preservation of the cortical molecular milieu describe 
several interfering variables that appear to affect protein integrity, expression and 
post-translational modifications, including cause of death, duration between death 
and cadaver refrigeration – as well as refrigeration temperature and post-mortem 
interval (259, 260). The post-mortem interval is typically reported in studies utilising 
human tissue and unless significantly extended (>50 hours) accounts for relatively 
little degradation at the protein level, providing tissue has been preserved and stored 
correctly (260). However, the time between death and refrigeration of the body has 
been demonstrated to have a profound impact on protein integrity, with marked 
degradation occurring at temperatures >1°C (259). Though we report patient post-
mortem intervals of <50 hours, and appropriate tissue storage at -80°C, the duration 
period between death and refrigeration remains elusive. Whilst we attempted to 
dilute sample-sample variability by pooling human patient tissues by age and region, 
uncontrolled post-mortem factors may have impacted upon the quality of the 
proteomic data presented.  
 
Although inter-patient variability may be substantial due to epigenetic modifications 
facilitated by dietary, health and environmental factors, in addition to the post-
mortem aspects described above, it is incredibly significant to the trajectory of 
ageing and cognitive capacity. It is well established that only selected individuals 
develop age-related cognitive decline thus assessing the variability in biochemical 
profiles between patients may enable the elucidation of biomarkers relevant to the 
manifestation of synaptic dysfunction and concomitant cognitive impairment. Whilst 
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we describe a study assessing the global alterations commonly occurring in pooled 
human regional synaptic populations, investigations delineating how the differential 
expression of discrete molecular substrates between patients may modulate cognitive 
capacity are fundamental to our understanding of selective synaptic dysfunction 
during advancing age.  
 
Despite the caveats, we describe a novel dataset documenting the age- and region-
dependent alterations occurring in the human patient brain. This comprehensive 
comparative proteomic profiling has provided unique insights into how differential 
synaptic vulnerability may be modulated by the TGFβ1 signalling cascade, which 
may have wide implications for the field of neurodegenerative diseases. Furthermore, 
the generation of a dynamic temporal synaptic map provides an important resource 
that we may further compare disease processes to, allowing elucidation of 
biochemical alterations that may be regarded as pathogenic.  
!
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Chapter 7. General discussion 
 
 
7.1 Overview of results 
The data presented in this thesis provide a comprehensive insight into the dynamic 
spatiotemporal regulation of the synaptic compartment during normal healthy ageing. 
Utilising a methodological workflow developed for such analyses, we describe 
several novel comparative studies documenting the biochemical alterations occurring 
in both discrete mitochondrial and synaptic populations during advancing age. 
Though our initial investigation focused on the mitochondrial molecular milieu at a 
static time point, we demonstrate that mitochondria harbour discrete proteomes 
dependent upon subcellular localisation. Additionally, recapitulation of the synaptic 
mitochondrial proteome has the propensity to promote perturbations in the 
presynaptic terminal, suggesting that the dynamic divergence in subcellular 
mitochondrial protein expression may modulate the stability of the synapse. Indeed, 
with spatiotemporal characterisation of the rodent synaptic and non-synaptic 
mitochondrial proteomes, we report significant age- and compartmental-specific 
alterations in protein expression, which appear to mediate the structural and 
functional properties of the synapse during ageing. Together these data indicate that 
proteostatic regulation of the synaptic mitochondrial proteome is vital for the 
sustained architectural integrity of the cortical synapse during advancing age.  
 
In addition to examining the temporal biochemical regulation of isolated organellar 
subpopulations, we also characterised the global molecular changes occurring in 
differentially vulnerable synaptic populations in the NHP and human patient during 
normal healthy ageing. Comparative proteomic profiling of hippocampal and 
occipital cortical synapses revealed novel modulators of synaptic stability as well as 
mechanistic pathways regulating the selective vulnerability of discrete synaptic 
populations. We demonstrate that expression of the upstream regulator TGFβ1 
modulates synaptic vulnerability and pharmacological manipulation of the protein 
ameliorates age-associated synaptic phenotypes. Remarkably, TGFβ1 appears to be a 
conserved regulator of regional synaptic stability in both the ageing NHP and human 
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patient, suggesting that the candidate may warrant further investigation as a potential 
therapeutic target for age-related cognitive decline.  
  
Collectively, this thesis provides the first molecular insights into differential 
proteostatic regulation of the synaptic compartment during ageing and how discrete 
alterations in protein expression may dictate vulnerability. Elucidation of the TGFβ1 
signalling cascade as a conserved mechanistic regulator of differential synaptic 
vulnerability during advancing age provides insights into the dynamic age-dependent 
modulation of the synaptic-microglial axis, which may be of paramount importance 
with regards to preservation of the synaptic milieu. Furthermore, the generation of 
species-specific temporal synaptic fingerprints provides a novel and essential 
resource that we may further compare disease processes to, allowing elucidation of 
biochemical alterations that may be regarded as pathogenic.  
 
 
7.2 Rodents: a representative model of human ageing? 
Although we have utilised rodents as a convenient experimental model of synaptic 
ageing in Chapters 3&4, recent reports have indicated that the temporal regulation of 
gene expression in the mouse cortex during advancing age is not well conserved in 
higher order mammals (138). Indeed, with comparative protein profiling of the 
mouse, rhesus macaque and human synaptic ageing datasets presented in this thesis 
(Chapters 4, 5 & 6), we demonstrate significant divergence in temporal protein 
expression in mouse cortical synapses during advancing age (Fig. 43), suggesting 
that rodent models may not faithfully recapitulate the dynamic biochemical 
alterations occurring in primate synapses during ageing. Indeed, with comparison of 
rhesus macaque and human synaptic ageing, we reveal significant similitude in 
temporal protein expression (Fig. 43), indicating that conserved regulation of the 
synaptic proteome may be unique to primate species. It appears likely that the 
differential biochemical regulation of the primate synaptic milieu is due to 
evolutionary divergence of the cortex as opposed to species-specific differences in 
maximal lifespan, as ageing of NHP and human synapses indicate analogous 
temporal protein expression alterations despite significantly varied biological ages. 
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Though the evidence appears to support the notion that ageing primate synapses may 
demonstrate discrete modulatory mechanisms during advancing age, some 
discrepancies between the primate and rodent datasets may also exist due to the use 
of varied populations of synapses and biochemical isolation methods (please refer to 
Chapters 4, 5 and 6 for methodological details). Although the modifications in 
methodological parameters between the rodent, NHP and human patient datasets is 
an important consideration, the results described correlate with previously reported 
cross-species transcriptomic ageing data (138), suggesting that this analysis may be a 
reliable representation of species-specific synaptic protein expression during 
advancing age.  
 
Accordingly, the preferential use of rodents in brain ageing and neurodegenerative 
disease studies may be hindering the detection of viable and translatable functional 
mediators that facilitate synaptic and/or neuronal vulnerability in the human patient. 
For the development of successful therapeutics that promote cognitive health, it is 
imperative that models with enhanced translational value are utilised. Without such 
investigations, it is unlikely that rodent models will provide unequivocal delineations 






Figure 43: Temporal regulation of proteins commonly identified in mouse, rhesus 
macaque and human synapses. A. Venn diagram middle intersection displays the 502 
commonly identified proteins in the mouse, rhesus macaque and human patient synaptic 
ageing analyses. B. Heat map exhibits the temporal expression profiles of the 502 proteins 
during ageing in the mouse, rhesus macaque and human patient. Protein expression values 
were log2 transformed and analysed by hierarchical clustering. Note the differential 
expression of proteins in the mouse synaptic ageing timecourse versus the primates. Red 
represents age-related upregulation of the protein; blue denotes age-related downregulation 
of the candidate. YS = young synaptic; MS = mid-age synaptic; OS = old synaptic. Input 
data: mouse = synaptic mitochondrial ageing (Chapter 4); rhesus macaque = hippocampal 
synaptic ageing (Chapter 5); human  = hippocampal synaptic ageing (Chapter 6).  
 
 
7.3 Further studies 
Whilst we have provided several novel comprehensive analyses of synaptic ageing 
throughout this thesis, there were, of course, time constraints preventing further 
investigations into the data. As highlighted in Chapter 4, we experienced numerous 
issues with the mouse samples, including at the proteomic and biochemical level, 
which resulted in reduced time for quantification and analysis of the data using the 
systematic approach we had planned. We had initially isolated synaptic and non-
synaptic mitochondria from the cortices of 4-week-old mice harbouring the 
neuroprotective slow wallerian degeneration (Wlds) mutation, in order to delineate 
the inherent molecular mediators that may be conferring synaptic protection. Despite 
obtaining the proteomic data from the mutant mouse model, we were unable to 
perform an isolated analysis directly comparing the age-matched wild-type and Wlds 
mice. These data would have provided an additional dimension to the analysis, 
enabling examination of the spatiotemporal expression of protective functional 
mediators in the wild-type mouse and further observing whether alterations in the 
expression of these candidates modulates increased synaptic vulnerability during 
advancing age. Furthermore, we had planned to perform in vivo experiments 
recapitulating the expression of potentially neuroprotective candidates in an attempt 
to rescue age-induced synaptic phenotypes in Drosophila models. These studies may 
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offer mechanistic insights into the molecular mediators facilitating synaptic 
protection and provide novel candidates that may be regarded as therapeutic targets 
for age-related neurological diseases where synapse loss is particularly problematic. 
However, as highlighted above, whether these results will be translatable to the 
human patient remains to be seen.  
 
7.4 Conclusions 
Here, we have provided the first comprehensive analyses describing the dynamic 
proteostatic regulation of discrete mitochondrial and synaptic populations during 
normal healthy ageing. We demonstrate that the trajectory of ageing appears to 
display significant malleability suggesting that strategic interventions may prevent 
age-related cognitive decline and associated neurodegenerative diseases. Further 
investigations examining the molecular correlates of age-dependent synaptic 
vulnerability in physiologically relevant models will prove valuable in elucidating 
the mechanistic cascades attenuating the structure and function of the synapse. 
Without a comprehensive understanding of the perturbed pathways governing 
synaptic demise during advancing age, there are limited possibilities for the 
development of efficacious therapeutic targets promoting cognitive health.!
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ABSTRACT
Introduction: Proteomic techniques offer insights into the molecular perturbations occurring in mus-
cular-dystrophies (MD). Revisiting published datasets can highlight conserved downstream molecular
alterations, which may be worth re-assessing to determine whether their experimental manipulation is
capable of modulating disease severity.
Areas covered: Here, we review the MD literature, highlighting conserved molecular insights warrant-
ing mechanistic investigation for therapeutic potential. We also describe a workflow currently proving
effective for efficient identification of biomarkers & therapeutic targets in other neurodegenerative
conditions, upon which future MD proteomic investigations could be modelled.
Expert commentary: Studying disease models can be useful for identifying biomarkers and model
specific degenerative cascades, but rarely offer translatable mechanistic insights into disease pathology.
Conversely, direct analysis of human samples undergoing degeneration presents challenges derived
from complex chronic degenerative molecular processes. This requires a carefully planed & reproducible
experimental paradigm accounting for patient selection through to grouping by disease severity and
ending with proteomic data filtering and processing.
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The muscular dystrophies (MDs) are a superfamily of heritable
heterogeneous disorders that exhibit similar clinical and
pathological features in those affected [1–6]. It is estimated
that MDs affect as many as 1 in 6200 people worldwide and
costs exceed $1 billion per year in the United States alone [5].
To date, there are upward of 50 discrete diseases, each of
which is defined by a distinct genetic mutation and can be
inherited as autosomal dominant, autosomal recessive,
X-linked or, in rare cases, may develop sporadically [2,5].
Patients commonly present with progressive weakness in the
appendicular, axial, and maxillofacial muscles but the age of
onset, severity of disease, and concomitant complications vary
dramatically between individuals [1,4–7]. The distribution of
muscle weakness often promotes distinction between the
particular types of disease [1]. As such, MDs have been cate-
gorized into various groups based upon clinical and molecular
observations; these include but are not limited to Duchenne
muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1),
facioscapulohumeral muscular dystrophy (FSHD), limb-girdle
muscular dystrophy (LGMD), Emery–Dreifuss muscular dystro-
phy (EDMD), and collagen VI myopathies.
Recent advances in molecular genetics have promoted
further understanding of the mechanisms governing the var-
ied types of MDs. Studies have identified over 30 causative
genes [1–3] that are involved in the pathogenesis of these
diseases (DMD: 1 gene; FSHD: 2 genes; LGMD: 25 genes;
EDMD: 6 genes; collagen VI: 3 genes); most of which appear
to be protein coding. Localization studies of MD-related can-
didates indicate perturbations may occur in the skeletal mus-
cle sarcolemma, nuclear membrane, extracellular matrix, inter
mediate filament network, and sarcomere [1,3,8]. Despite this,
the functions, pathways, and downstream targets of these
proteins remain to be elucidated. For efficacious therapeutic
targeting of MDs, it is imperative that research focuses on the
downstream networks of each particular mutation to assess
where intervention may restore cellular homeostasis. Prot
eomic technologies are well equipped to examine such pro-
cesses and various laboratories have begun utilizing these
techniques for identification of biomarkers and novel remedial
candidates in MDs.
In this review, we will outline the relative complexities of
studying MDs and how these may be addressed by utilizing
modern proteomic approaches. We aim to discuss the current
knowledge concerning the most common MD – DMD and some
of the less prevalent forms including DM1, FSHD, LGMD, EDMD,
and collagen VI myopathies. Here, we summarize proteomic-
derived advancements in our understanding of these conditions
to date and, where possible and/or appropriate, highlight con-
served downstream molecular perturbations which may prove
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DMD is the most common dystrophy and (to date) the most
thoroughly investigated using proteomic methodologies.
DMD is a recessive X-linked disease, characterized by muscle
degeneration and premature death, typically by the age of
20–30 years. With an incidence of approximately 11–28/
100,000 males, DMD is one of the most common and severe
types of MD [8]. The cause of DMD is a mutation in the
dystrophin gene, leading to an absence of the cytoskeletal
protein, dystrophin [9], and subsequent weakening of the
structural integrity of muscle cells. The majority of therapeutic
approaches for DMD have focused on restoring dystrophin
production by modulation of RNA using antisense oligonu-
cleotides [10]. The development of alternative and/or comple-
mentary therapeutic strategies to target modifiers of DMD
(reviewed by Vo and McNally, 2015 [11]) or the consequence
of downstream pathology [12] appears to be emerging areas
of research. For work in this area to progress, however, a
detailed understanding of the molecules and pathways
involved in DMD is required.
2.2. DM1
DM1 typically manifests in early adulthood and is classified as
a multisystemic neuromuscular disease [5,13] It is the second
most prevalent dystrophy, but most prevalent adult-onset MD
affecting up to 1 in 8000 individuals worldwide [14]. The
disease displays an autosomal dominant mode of inheritance
and patients often present with highly heterogeneous symp-
toms including clinical myotonia, progressive muscular weak-
ness, cardiac arrhythmia, visual disturbances, and insulin
resistance [5,14]. These diverse phenotypes are caused by a
large expansion of the (CTG)n trinucleotide repeat in the 3!
untranslated region of the dystrophia myotonica protein
kinase gene on chromosome 19q13.3 [5,13,15]. Patients with
substantial amplifications of these CTG repeats demonstrate
more severe phenotypes and often present with symptoms at
a much earlier age, promoting a diminished life span [14,15].
Broadly speaking, the clinical diversity of DM1 phenotypes
appears to stem from the sequestration of mutant RNA tran-
scripts encoded by the CTG expansion [13,15]. These tran-
scripts accumulate within the nuclei of various tissues and
promote perturbations in the pathways that regulate altera-
tive splicing programs. Mis-splicing of numerous genes has
been experimentally observed in DM1 patient tissues and
mutant cell lines suggesting that patient phenotypes may be
attributed to the aberrant expression of muscle-specific Cl!
channels, cardiac troponin T, insulin receptors, and the sarco-
plasmic Ca2+ ATPases [13,15–17]. Although alternative splicing
appears to demonstrate some involvement within the devel-
opment and pathogenesis of DM1, there remains a lack in
understanding of how mechanistic pathways could be thera-
peutically targeted to ameliorate disease progression.
2.3. FSHD
FSHD is the third most prevalent of the MDs and is an auto-
somal dominant disease with variable penetrance [18,19].
Typically, as the name suggests, patients present with weak-
ness in the maxillofacial muscles and shoulder girdle, which
subsequently progresses to affect the pelvis and lower extre-
mities [18–20]. The onset, progression, and severity of FSHD
are highly variable between and within families and patients
can range from asymptomatic to critical [19]. Unlike other
MDs, FSHD usually emerges in adulthood with diagnosis typi-
cally occurring in the second or third decade [1,19,20].
However, there are reports of patients presenting with early
FSHD symptoms in their 60s and 70s [18–20], highlighting the
heterogeneity of the disease.
The clinical variability of FSHD likely stems from the muta-
tion the patient is harboring. The most common form of the
disease, FSHD1, is the result of a contraction of microsatellite
repeats in the D4Z4 element located on the 4q35 subtelo-
meric region on chromosome 4 [6,18–21]. Patients typically
present with 1–10 D4Z4 repeats whereas the general popula-
tion demonstrate 11–100 [6,18–21]. Correlations between the
repeat size and clinical severity of patients have been reported
with those harboring 1–3 copies often more severe than
individuals with 8–10 copies [18,19]. Evidence suggests that
this reduction in D4Z4 copies induces chromatin remodeling
promoting cellular toxicity and degeneration in skeletal mus-
cle [20]. Although there are no obvious mutations in any
protein-coding gene, it has been proposed that there may
be erroneous activation of the DUX4, FRG1, FRG2, and ANT1
genes that are located centromeric of the D4Z4 array [18,20].
Little is currently known about the molecular cascades that are
responsible for the clinical manifestation of FSHD due to the
challenging nature of the disease; thus, the identification of
therapeutic targets remains in its infancy. Systematic analyses
utilizing ‘-omics’ data will be invaluable in the field in order to
establish biomarkers of disease and efficacious treatments for
FSHD patients.
2.4. LGMDs
LGMDs are a group of inherited diseases characterized by
progressive weakness and wasting of shoulder and pelvic
girdle muscles. Broadly, there are 2 subcategories of LGMD:
those which display a dominant manner of inheritance,
termed LGMD1 (upward of 8 subtypes), and those which are
recessive in nature, LGMD2 (with approximately 20 subtypes)
[22]. The overall frequency of LGMDs is 20–40/100,000 indivi-
duals [23] with clinical onset typically occurring during the
second decade of life [22] The most extensively studied sub-
types of the disease include LGMD2A, LGMD2B, and LGMD1B
and the molecular genetics underpinning these conditions are
now beginning to be unraveled. Recent studies have sug-
gested that LGMD2A may be caused by mutations in cal-
pain-3 [24] which promotes the loss of autocatalytic function
within skeletal muscle, stimulating fiber degeneration and
atrophy [25]. Although there are indications that calpain-3 is
involved in the pathophysiology of LGMD2A, the function of




























the protein is still to be established, providing complexities in
experimental design and interpretation.
LGMD2B is also believed to be caused by mutations in a
calcium-handling protein [26]. Patients presenting with
LGMD2B demonstrate mutations in the dysferlin (DYSF) gene
[27], which encodes a membrane-associated protein localized
to the sarcolemma. Dysferlin has been noted for its capacity to
aid in membrane regeneration and impairments in its function
appear to stimulate myonecrosis due to increased calcium
influx in skeletal muscle. These pathological processes are
thought to lead to the characteristic shoulder and pelvic girdle
weakness [28] LGMD1B, like subtypes of EDMD, is caused by
mutations in the lamin A/C (LMNA) gene [29,30] Mutations in
this gene result in a diverse range of phenotypes often with
muscular and/or cardiac involvement; however, it is not clear
how LMNA contributes to these clinical manifestations.
Studying the molecular pathways involved downstream of
LGMD mutations is especially challenging due to the hetero-
geneity of genetic mutations, complex clinical diagnosis, and
availability of human samples.
2.5. EDMD
EDMD affects 1 in 100,000 males [31] and is characterized by
scapulohumeroperoneal muscle weakness, joint contractures,
and cardiac defects that include arrhythmias and dilated car-
diomyopathy [32]. Onset of EDMD is typically seen during
childhood or early adolescence [33] and is caused by muta-
tions in various genes that are localized to the nuclear envel-
ope [34]. Commonly, the disease is X-linked recessive and is
associated with mutations in the emerin (EMD) gene, which
consequently causes the truncation of emerin proteins (in
around two-thirds of patients). However, multiple subtypes
mediated by a range of genetic mutations in the autosomes
also exist (for more information, see Pillers & Bergen [35]). As
discussed in Section 2.4, a degree of homology exists between
LGMD1B and autosomal dominant EDMD due to both sub-
types demonstrating mutations in the LMNA gene. Although it
is poorly understood how mutations in lamin A/C contribute
to the LGMD phenotype, EDMD is believed to be caused by
single amino acid substitutions that result in destabilization of
the protein promoting nuclear fragility [36]. Less prevalent
autosomal dominant forms of the disease have demonstrated
loss of function mutations in the nesprin-1 (SYNE1 gene) and
nesprin-2 (SYNE2 gene) proteins (OMIM no. 310300) fostering
perturbations in nuclear architecture [37].
2.6. Collagen VI myopathies
Collagen VI is a ubiquitously expressed extracellular matrix
protein (ECM) composed of threefolded chains that form
dimers and tetramers. In muscle, the collagen VI network sur-
rounds the basement membrane transferring mechanical and
biochemical signals from the ECM to the fiber [38]. Mutations in
any of these genes can cause dysfunction in the microfibrilar
network in the ECM of muscle, skin, and tendons leading to
muscle weakness, joint laxity, contractures, and respiratory
compromise [39]. Dominant and recessive mutations in
collagen VI are often associated with the COL6A1, COL6A2,
and COL6S3 genes and lead to two types of MD: Ullrich con-
gential muscular dystrophy (UCMD) and Bethlem myopathy
(BM) [40–42]. These diseases are relatively rare with an esti-
mated prevalence of 0.1 in 100,000 and 0.5 in 100,000, respec-
tively [43]. UCMD is an autosomal recessive disorder, typically
presenting at birth, with infants demonstrating hypotonia and
congenital hip dislocation. The majority of patients do not
reach the major motor milestones and struggle to walk inde-
pendently. Accompanying the motor symptoms is severe
respiratory problems that require intervention during the first
or second decade of life [44]. BM is phenotypically milder than
UCMD with patients demonstrating a near normal life span
[42,45]. Despite this, it is estimated that 50% of individuals
require ambulatory assistance after the age of 50 due to the
progressive deterioration of muscle and joint integrity [46]. For
a comprehensive review, see Lampe and Bushby [43].
3. Unraveling downstream dystrophic cascades
through proteomic investigations
As highlighted in Sections 2.1–2.6, there are numerous MD
variants aside from the most well-known DMD, caused by a
wide range of associated genetic mutations. There are cur-
rently no treatments that ameliorate the neuromuscular phe-
notype and molecular pathology of any of these diseases [2].
Although several clinical trials for novel therapeutics are in
progress, there remains a lack of understanding of the basic
molecular biology underpinning these diseases. To identify
efficacious pharmacologic targets, it is imperative that the
field utilizes modern ‘-omic’ technologies to examine the path-
ways and processes that are perturbed and how these may
regulate downstream pathology. This will facilitate a broader
understanding of the molecular mechanisms governing mus-
cle development, stability, and pathogenesis and will ulti-
mately enable data-driven interventions that will benefit
patients significantly.
As many as 50 discrete diseases fall under the umbrella of
the dystrophies but at the time of writing this manuscript,
there are only around 26 published proteomic investigations
carried out on dystrophy patient or model systems. Of these,
19 studies are focused on the most prevalent and widely
known DMD (Supplementary Table 1 [15,18,20,21,39,81–83])
whilst the remaining 8 surround the other less pervasive forms
described above (DM1, FSHD, LGMD, EDMD, and collagen VI
myopathies; Supplementary Table 3).
3.1. The search for differentially expressed proteins in
DMD versus control tissues
To date, approximately 19 separate publications from several
different research groups have utilized unbiased quantitative
proteomics technologies to identify differentially expressed
proteins in models of DMD compared to control subjects. All
but one of these studies were conducted in vivo, with dia-
phragm, cardiac, and various skeletal muscles being the most
popular tissue source. Whilst the vast majority of these studies
have utilized the mdx mouse model of DMD, material from




























DMD patients [47,48] as well as the spontaneous golden
retriever muscular dystrophy model [49] have also been inves-
tigated (summarized in Supplementary Table 1 [47–49,54–
56,71–74,91–98]). Though these experiments have generated
a wealth of information, there are several potential issues that
may hamper the translation of findings when the data sets are
considered in isolation. For these reasons, the focus of discus-
sion in the following section will be on proteins that were
consistently changed in expression across three or more of the
separate proteomic comparisons listed in Supplementary
Table 1. This approach also limits the pool of useable studies.
For example, although Ge et al. may have carried out the first
of these proteomic studies in 2003, we are unable to include
their results in our comparative analysis as the data sets are
not freely available [50]. Review of these data sets revealed 34
proteins that met these criteria and are summarized in
Supplementary Table 2 [49–50,54–56,71–74,92–95,97–100].
3.1.1. Increased expression of structural proteins in DMD
The type III intermediate filament proteins, desmin and vimen-
tin, were consistently increased across 8 and 15 comparisons
of DMD tissues, respectively. Considered as a hallmark of
developing myotubes [51], the high expression of both pro-
teins had previously been documented in regenerating muscle
fibers from different neuromuscular diseases, including DMD
[52,53]. Other structural proteins were also consistently
increased in DMD tissue across multiple proteomic compari-
sons, including beta-tubulin, lamin A/C, lamin B1, and spectrin
alpha chain, as well as proteins associated with protein assem-
bly (e.g. elongation protein, protein disulfide-isomerase A3)
(Supplementary Table 2). One possible explanation for this
apparent structural reorganization is that it may represent an
attempted compensatory response to stabilize the weakened
cytoskeleton [54]. It is interesting to note that increased levels
of desmin were also detected in a proteomics study of the
mildly affected (and thus, non-regenerating) extraocular mus-
cle (EOM) from the mdx mouse [55], lending support to this
notion. The possibility, however, that the changes in structural
proteins may merely depict the ongoing process of cellular
degeneration and/or fibrosis must also be considered [56].
3.1.2. Cellular stress responses in DMD
Several proteins associated with a cell stress response were
elevated in multiple proteomic studies of DMD tissue
(Supplementary Table 2), including the heat shock proteins
90, 70, 71, and 78 kDa glucose protein (also known as heat
shock 70 kDa protein 5). Thought to represent a molecular
response to cell stress, the increased expression of heat shock
proteins correlates well with their known involvement in dys-
trophin-deficient muscles [57].
Increased expression of oxidative stress markers including
hemopexin and glutathione-S-transferase (GST) was detected
across several different proteomic studies of DMD (Supple
mentary Table 2). Glutathione metabolism is clearly dysregulated
in dystrophic muscle [58,59], but the cause and functional con-
sequences of this are unclear. While one report has proposed a
model in which altered glutathione metabolism represents an
adaptive and attempted compensatory response to oxidative
stress [58], others argue that the dysregulation of this pathway
may actually be the cause of increased oxidative stress in DMD
[59,60]. Reports of GST activity levels in DMD are also contra-
dictory. While one report demonstrated a marked reduction of
GST activity in muscle from DMD patients [59], a study of the
chicken model of DMD demonstrated a reduction of activity [61].
Though the biochemical studies above detail the differen-
tial expression of several key players in the glutathione meta-
bolism pathway, as well as the activity of GST, the actual
protein expression levels of GST have not yet been verified
at the biochemical level. Given that elevated levels of GST
were detected in four separate proteomic studies of DMD
(Supplementary Table 2), it would seem there is an opportu-
nity to examine this further and to determine whether it is
possible to alter the capacity of DMD cells to respond to
oxidative stress by manipulating GST expression and activity.
3.1.3. Increased membrane permeability in DMD
Increased membrane permeability is a hallmark of DMD and
though theories exist about what may cause this (reviewed by
Allen and Whitehead [62]), including contraction-induced tears
due to fragility of the already weakened membrane, oxidative
damage to membranes, or altered regulation of calcium ion
channels, the precise mechanisms remain elusive. An increased
level of serum albumin was detected across 10 separate
proteomic comparisons of DMD versus control tissues
(Supplementary Table 2) and likely reflects the increased mem-
brane permeability of the target tissue [56]. Indeed, damage-
induced disruption of muscle fiber membranes is commonly
associated with an influx of extracellular components, contain-
ing albumin, into the muscle [63] and has previously been
detected at the histological level in DMD muscles too [64,65].
Parvalbumin, on the other hand, was reduced across eight
separate proteomics studies and was one of only two proteins
showing a consistent decrease across the multiple proteomic
comparisons of DMD and control tissues (Supplementary
Table 2). In contrast, a separate proteomics-based biomarker
discovery project detected increased parvalbumin levels in
mdx mouse sera [66], possibly indicating that the reduction
of parvalbumin in DMD tissues may be a result of parvalbumin
leaking out into the extracellular space rather than an intra-
cellular-controlled mechanism. Reduced levels of parvalbumin
in DMD muscle have also been reported previously from
biochemical studies [67,68] and have been implicated in the
‘Ca2+ overload theory,’ proposed as a leading mechanism of
cellular degeneration in DMD (reviewed by Vallejo-
Illarramendi et al. [69]). Potential consequences of Ca2+ over-
load were also detected in multiple proteomic comparisons,
including an increased expression of the Ca2+-binding protein
troponin C (three comparisons) and increased expression of
the Ca2+-effector proteins, annexin 2 (eight comparisons), and
annexin 5 (six comparisons) (Supplementary Table 2). Does the
influx of albumin, another Ca2+-binding protein, also contri-
bute to Ca2+ overload mechanisms in DMD tissues?
3.1.4. Immune cells may contribute to the proteome of
DMD tissues
A prominent feature of DMD muscle is the presence of an
obvious immune response, though the functional conse-
quences of this are still a matter of debate [70]. Several




























types of immune cells have been shown to infiltrate mouse
and human DMD muscle, including macrophages, eosinophils,
natural killer T cells, CD4+, and CD8+ T cells [70]. Whilst pro-
teomics comparisons may have revealed insights into the
molecular response to this influx (e.g. increased levels of
leukocyte elastase inhibitor A (Supplementary Table 2)), it is
important to consider that each of these immune cell types
could potentially contribute a unique repertoire of proteins –
quite different from the muscle itself – and would thus skew
the proteomic profile of the sample. Western blot verification
of differential protein expression from total protein extracts
appears to have been common practice but few studies of this
nature have also provided histological analysis of the same
proteins, meaning that any changes in protein expression that
are related to tissue heterogeneity would likely be
unattributed.
3.1.5. Proteomic insights into the differential vulnerability
of muscles in DMD
Of note is that there are a large number of proteins (50+)
detected across the studies of the proteomic investigations
(summarized in Supplementary Table 1) that showed contra-
dictory patterns of expression in different comparisons (i.e.
increased in expression in one or more proteomic compari-
sons but decreased in others). Examples of such proteins are
GAPDH, various myosin chains, creatine kinase, glycogen
phosphorylase, myoglobin, and adenylate kinase (also identi-
fied in [71]). As alluded to previously, changes in the levels of
some of these proteins could be ‘false positives,’ arising from
variations in disease models, tissue heterogeneity, or tissue
sampling techniques. There is also the possibility, however,
that some of these differences may be useful for determining
which constitutive and/or adaptive molecular pathways con-
tribute to the differential vulnerability of different muscles
in DMD.
Two of the proteomics studies listed in Supplementary
Table 1 specifically aimed to shed light on the molecular path-
ways that determine how vulnerable a particular muscle type is
to an absence of dystrophin. A 2-dimensional difference in gel
electrophoresis-based quantitative proteomics comparison of
the mildly affected EOM from mdx and control mice revealed
differential expression of just seven proteins [55]. The authors
highlight how these results are a stark contrast to previous 2D-
gel-based comparisons of the severely affected diaphragm
muscle, where between 20 and 35 differentially expressed pro-
teins were detected [72,73]. This suggests that there is a mini-
mal perturbation of molecular pathways in the EOM muscle and
perhaps also implies that adaptive molecular pathways may not
extend far beyond a straightforward upregulation of the dys-
trophin homolog, utrophin [55].
A later study from the same group – in which the proteome
of the soleus (SOL), extensor digitorum longus (EDL), flexor
digitorum brevis (FDB), and interosseous (INT) muscles from
the mdx mouse was quantitatively compared with control
mice – also found differences between the number of differ-
entially expressed proteins across different muscle types [74]
(see Supplementary Table 1). The histological analysis revealed
a higher degree of hypertrophy and central nucleation (a
hallmark of muscle fiber regeneration) in the SOL and EDL
muscles compared to INT and FDB. This clearly does not
consistently correlate with the degree of differential protein
expression, however, since just 5 proteins were differentially
expressed in the INT but 19 were differentially expressed in
FDB (i.e. more than the number detected in the EDL muscle;
Supplementary Table 1). Notwithstanding the potential limita-
tions of 2D-gel-based quantitative proteomic comparisons,
these findings serve to highlight the importance of consider-
ing results from multiple tissue types before drawing general-
izable mechanistic conclusions about DMD.
3.1.6. Temporal proteomic studies of DMD
Several proteomic studies aimed to identify temporal changes
during disease progression in DMD mouse models. These
studies provide insights into the longer term secondary mole-
cular changes that occur during disease progression in mdx
mouse hindlimb muscle [71], cardiac muscle [75], tibialis ante-
rior [76], and diaphragm [77].
Some potentially interesting differences were detected in
aged hearts from mdx mice, including a reduction of lamin A/
C, vimentin, and annexin [75], that were both undetected in
the other aging studies and contrast with findings from var-
ious DMD versus control comparisons (Supplementary
Table 2). Though the authors were unable to verify the reduc-
tion of lamin A/C and vimentin by Western blot, reduced
levels of annexin were confirmed. In addition, while the
expression level of the developmentally regulated protein,
myosin light chain 2, was consistently increased in mdx
mouse hindlimb muscle at 1, 3, and 6 months of age com-
pared to age-matched controls [71], the levels in aged mdx
mouse hearts appear reduced compared to controls [75]. It is
clearly not possible to draw direct comparisons between the
various studies because of differences in the age of the tissue
being compared, but it would be interesting in the future to
determine whether the differential expression of such candi-
dates offers insights into mechanisms underlying the differen-
tial vulnerability of muscles in DMD.
3.2. Proteomic insights into other MDs
In recent years, several studies utilizing proteomics have
appeared in the literature surrounding these less prevalent
MDs with the aim of enhancing our understanding of the
molecular mechanisms underlying the downstream effects of
the causative mutations. The majority of these investigations
have employed human patient muscle tissue for comparative
characterization of protein expression versus controls, in an
attempt to distinguish groups of dysregulated proteins in
various MD subtypes. This has allowed the generation of lists
of differentially expressed proteins, providing indications of
the biological functions and pathways involved in the patho-
genesis of various MDs. However, there is a requirement for
larger numbers of well-executed studies to dissect cause/con-
sequence relationships and determine which alterations may
reflect conserved responses in the range of diseases.
The complexity of the genetic background of each disease
as well as the limited availability of human donors provides
challenges. Currently, there are only seven proteomic-based
studies focusing on the diseases discussed in Section 2 above,




























most of which have utilized 2D gels, followed by mass spectro-
metry (MS) analysis. Selected reports discussed here have
attempted to discern the commonalities and differences in
protein expression between genetic variants of particular
MDs as well as between diseases using these techniques (see
Supplementary Tables 3 and 4 for a summary).
3.2.1. DM1
There is only one readily available publication employing
proteomic techniques in an attempt to identify the molecular
cascades which are perturbed downstream of the causative
genetic insult in DM1. Hernández-Hernández and colleagues
[15] utilized a 2D-gel-based proteomic analysis on DM1 trans-
genic mice with 45 kb of human genomic DNA originally
cloned from a patient with DM1 [78,79]. Here, they identify
potential alterations in post-synapsin I (SYN1) translational
modifications and elements of RAB3a and its downstream
cascades. Various RAB alterations have been associated with
other neurodegenerative conditions including retinopthaies
[80], suggesting the possibility of conserved mechanistic cas-
cades across multiple apparently unrelated neurodegenerative
conditions. However, this study is limited by its choice of
controls, depth of coverage granted by the use of 2D gels
and lacks clarity in terms of identification of sample type used
for the experiments.
3.2.2. FSHD
At present, there are three proteomic studies attempting to
address distinct molecular alterations that may be specifically
associated with FSHD. An early study performed by Celegato
et al. [18] utilized 2 dimensional electrophoresis (2-DE), high
performance liquid chromatography–MS, and transcriptomic
methods to characterize deltoideus muscle protein expression
in groups of patients (aged 8–69 years) with varying D4Z4
repeat lengths. The group identified a common profile of
proteins associated with FSHD, independent of repeat size,
suggesting proteins associated with glycolysis, the tricar-
boxylic acid cycle, and protein synthesis (particularly, elonga-
tion factor Tu) are upregulated in patient versus control
samples; conversely, detoxification and degradation proteins
(SOD, PRDX2) and actin isoforms are downregulated in FSHD
patients. Proteins involved in muscle differentiation also
appeared to demonstrate differential expression between
FSHD patient groups and controls: these included COP9,
HSP27, alpha-crystallin B, phosphoglycerate mutase, creatine
kinase, and myosin heavy-chain proteins. Upon further analy-
sis, the study identified a conserved upstream regulator –
MyoD, levels of which were shown to be consistently reduced
in patients. The authors hypothesized that defects in MyoD
signaling promoted the failure of regeneration of fast glycoly-
tic muscle fibers after episodes of mechanical stress, leading to
a progressive increase in slow oxidative fibers, promoting
weakness and dystrophy in FSHD patient muscle.
In a similar study by Laoudj-Chenivesse et al. [21], 2-DE
proteomics coupled with MS also identified alterations in the
detoxification and oxidative stress machinery in FSHD patient
muscle biopsies. The specimens were obtained from the del-
toideus and quadriceps muscles and included a range of
individuals (aged 17–66 years), all demonstrating various
D4Z4 repeat lengths. Although there appear to be overlaps
in the pathways detected between the Laoudj-Chenivesse
et al. [21] study and the work performed by Celegato et al.
[18], the directionality of the protein expression alterations
contrasts. For instance, Celegato et al. [18] report the down-
regulation of proteins associated with detoxification pro-
cesses, whereas Laoudj-Chenivesse et al. [21] demonstrate a
significant upregulation of these cascades (proteins include
SOD1 and GST). Due to the reported upregulation of oxidative
stress markers, the Laoudj-Chenivesse et al. [21] study focused
on the potential impact of mitochondrial dysfunction on mus-
cle fiber integrity that was hypothesized to be regulated by
increased ANT1 expression – a gene neighboring the D4Z4
repeat locus.
The final study concerning FSHD has provided another per-
spective on the molecular pathogenesis of the disease. Tassin
et al. [20] utilized patient-derived myoblasts (n = 2) and gel-free
shotgun proteomics (2DLC–MS/MS) to characterize atrophic
and disorganized FSHD myotubes versus control cells. In total,
336 proteins were quantified from the quadriceps-derived myo-
blasts with the study illustrating that myosin heavy and light
chain (MYH8, MYH3, MYH7; MYL1, MYL6B) and caveolar pro-
teins appeared dysregulated in primary FSHD cells. The authors
highlighted caveolin-3 (CAV3) and its associated networks as
potentially perturbed in FSHD promoting the reduction of myo-
genic differentiation in skeletal muscle. CAV3 mutations have
previously been documented in other neuromuscular diseases,
including LGMD1 and LGMD2B, which may suggest that caveo-
lin dysregulation is a consequence of myotube degeneration as
opposed to an upstream regulator of FSHD.
3.2.3. Molecular overlaps across multiple dystrophies
There is a requirement for further comparative studies in order to
elucidate how these membrane micro-domains may play a role
in pathogenesis. One such study by De La Torre et al. [81]
similarly documented an impairment in myotube differentiation
in LGMD2B patient muscle biopsies. This comparative investiga-
tion focused on differentially expressed proteins between
LGMD2A, LGMD2B, FSHD, and control triceps and quadriceps
muscle using 2-DE and MALDI–TOF MS. The authors provided
details on 17 conserved proteins that appear altered in all the
neuromuscular diseases characterized versus the control sam-
ples. These proteins displayed involvement in energy metabo-
lism, themyofibril, andmuscle development and repair, agreeing
with the previously discussed manuscripts studying FSHD. Much
like the Celegato et al. investigation [18], the group shows altera-
tions in themuscle fiber distribution with a significant increase in
slow-twitch fibers. These remodeling events appear to be occur-
ring in numerous neuromuscular diseases and track with disease
progression. The authors also elaborated to include proteins that
demonstrated alterations specifically in LGMD2B patients. These
14 candidates exhibited similar functional categories to those 17
that were conserved through the neuromuscular diseases exam-
ined. Although in the De La Torre et al. study [81] these proteins
appeared to demonstrate unique alterations in LGMD2B
patients, upon further inspection of the literature, there are
indications that several of these candidates have been discussed
in a range of neuromuscular diseases including collagen VI




























myopathies (De Palma et al. [39]), FSHD (Celegato et al. [18]), and
Duchenne MD (see Supplementary Table 4).
Considerable overlaps exist between investigations examin-
ing FSHD and LGMD subtypes, which may be due to the
upstream regulators of disease or the conserved downstream
processes of muscle degeneration. Magagnotti et al. [82] also
noted similar pathways may be disrupted in EDMD with
patients harboring mutations in the LMNA gene, namely
LGMD1B. 2-DE proteomics, MALDI–TOF MS, and in silico ana-
lyses of patient fibroblasts suggested that proteins regulating
cytoskeletal/structural organization were less abundant in indi-
viduals with a diagnosed laminopathy. Conversely, and in keep-
ing with the Laoudj-Chenivesse et al. FSHD study [21], oxidative
stress markers appeared enriched in patient cells versus con-
trols. Despite Magagnotti et al. [82] utilizing groups of patients
with general myopathies as an internal control to assess specific
protein alterations in laminopathies, it is clear from examination
of multiple published data sets that several of these candidates
have been reported to be differentially expressed in other
neuromuscular diseases (see Supplementary Table 4 [18,20–
21,39,49,54–56,72–74,81–83,92–94,99]).
Suggestions of skeletal muscle remodeling in MDs are fre-
quently referenced in the literature due to the dynamic altera-
tions in proteins involved in myofibrillar architecture and
cytoskeletal integrity (Celegato et al. [18], Tassin et al. [20], De
La Torre et al. [81], Magagnotti et al. [82] – see Supplementary
Tables 2 and 4). De Palma et al. [83] also proposed that in
LGMD2B patients, there was a redistribution of muscle fiber
type as proteins involved in oxidative phosphorylation were
increased and those associated with anaerobic metabolism
decreased versus control samples. In accordance with the altera-
tions in expression of bioenergetic candidates, myosin light-
chain isoforms were also differentially expressed in the
LGMD2B patients’ quadriceps muscle, suggesting functional
impairments in contractile velocity and force may be due to
increased numbers of slow-twitch fibers.
A further study conducted by the same authors (De Palma et al.
[39]) focused on the collagen VI myopathies: UCMD and BM (see
Section 2.6). Human quadriceps muscle biopsies from BM (n = 8),
UCMD (n = 4), and control (n = 2) patients revealed bioenergetics
pathways were altered in both BM and UCMD individuals versus
healthy samples. The downregulation of the hexosamine biosyn-
thetic pathway (HBP) was highlighted as a key driver of BM and
UCMD progression due to associations with protein homeostasis
in the endoplasmic reticulum and unfolded protein response
systems. Although this reduction in the HBP and glycosylation
appeared conserved between the collagen VI MDs, the down-
streambiochemical alterations in UCMD and BMdisplayed unique
properties, likely reflecting the differences in disease severity. In
BM patient samples, the authors suggest that the muscle protein
quality control system is sustained by metabolic adaptation. This
allows the cells’ energy requirements to be met and the cata-
strophic consequences of the ER protein misfolding response to
diminish. In contrast, UCMD patients demonstrate disruption in
this pathway and the compensatory-layered mechanism, likely
leading to lipotoxicity and cellular apoptosis. Interestingly, other
MDs such as spinal muscular atrophy (SMA) demonstrate pertur-
bations in proteostasis with ubiquitin homeostasis defects influ-
encing neuromuscular pathology [84] (see Section 2.1).
3.2.4. In silico analysis suggests proteomic studies are
highlighting downstream consequences of degenerative
cascades
Although the appearance of common themes in the MD field
may permit enhanced understanding of the molecular pathol-
ogy of the various diseases, it may also be a great hindrance.
The proteomic studies discussed examined groups of hetero-
geneous conditions caused by numerous discrete genetic
mutations that all encode for different proteins, pathways,
and processes (see Section 2). Thus, the emergence of these
conserved changes in cytoskeletal and bioenergetic families
throughout various neuromuscular disorders suggests that
these alterations are likely a downstream consequence of
causal upstream perturbations. Many alterations are likely an
adaptive response to ongoing myofibril degeneration – a
process occurring in all MDs discussed. In fact, with in silico
analysis of the proteins identified in Supplementary Table 4,
there are clear indications that a substantial number of these
candidates may be involved in downstream degenerative cas-
cades occurring in a wide range of tissues – not merely
myofibrils (Figure 1(a)). Alterations in expression of upward
of 15 of these proteins have been associated with Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, and motor
neuron disease in published manuscripts (Figure 1(b)), illus-
trating likely late-stage consequences of cellular dysregulation.
Thus, it is probable that these candidates do not represent
viable therapeutic targets or biomarkers for MDs. Despite this,
vimentin is consistently identified as upregulated throughout
the different MD studies. Interestingly, vimentin also appears
to lie upstream of the majority of the candidates identified by
the investigations reviewed here (Figure 1(c)). These observa-
tions may warrant further analyses into what lies further
upstream of vimentin and how this may be potentially pro-
moting dysregulation selectively within the myofibrillar archi-
tecture. However, in order to successfully elucidate the
upstream regulators of various MDs, there are several consid-
erations that require attention before experimentation.
Fortunately, the field is now in the position to successfully
draw on lessons learned from other fields (such as SMA),
where considered applications of proteomic techniques have
yielded tangible gains (Figure 2).
4. Future directions in dystrophy research through
proteomic investigations
The data sets reviewed in Section 3 provide novel and valuable
insights into the molecular pathways that may be disrupted in
MDs. The search for conserved and uniquemolecular alterations in
MD variants has begun to shed light on the downstreampathways
affected by these discrete mutations. Despite this, the current
studies demonstrate some shortcomings in proteomic experimen-
tal design and data analysis that should be addressed.
4.1. Tissue selection and characterization
The investigations discussed in this review appear to focus on
static stages of disease in a variety of animal model or pooled
patient samples. This is a fundamental flaw whilst attempting to




























elucidate biomarkers of disease progression because this
approach does not account for the numerous variables that may
have influenced the data acquired. Primarily, there appears to be
an oversimplification of proteomic investigations, leading to the
loss of potentially relevant information thatmay indicate howMDs
are regulated. Commonly, the studies report two-way compari-
sons of pooled samples: disease versus control patients; however,
the patient cohorts vary significantly. Within the MD pooled
patient (and animal model) samples, authors include tissues
from a variety of muscles, ages, clinical severities, and genetic
mutations – promoting substantial heterogeneity and preventing
the possibility of also running a variable-matched control sample.
It is now well established that different tissues and even various
anatomical regions of the same tissue sample (e.g. proximal versus
distal) do not display uniformity in protein expression [85]. Thus,
pooling or comparing numerous biopsies from awide selection of
skeletal muscles and cellular populations will only hamper the
identification of proteins regulating pathogenesis.
In contrast to the majority of studies conducted on other
MDs, the vast majority of proteomic investigations into DMD
have utilized tissue from the mdx mouse and whilst two
proteomics studies of DMD patients have been conducted,
one utilized serum [47] and the other analyzed urine [48].
These sources can certainly be useful for identifying easily
accessible biomarkers of disease as demonstrated by
Coenen-Stass and colleagues’ [86] innovative identification of
peripherally accessible biomarkers which demonstrate
response to therapeutic attempts in mdx mice. However,
such peripherally accessible samples do not necessarily offer
easily translatable mechanistic insights into disease pathology.
For example, while one protein may appear elevated in the
serum of DMD patients, its expression in the primary tissue
(i.e. muscle) could be entirely the opposite. In order to deter-
mine that alterations in protein expression are due to the
presence of disease, the same ages, sexes, and clinical seve-
rities of patients, as well as muscle, and, ideally, the same
portion of muscle, must be utilized in the pooled MD and
control samples. Furthermore, in order to understand disease
mechanisms, it is imperative that protein expression in indivi-
duals without the condition is characterized so analogous
alterations can be eliminated as pathogenic.
4.1.1. Characterization of protein expression profiles
throughout disease progression
The degenerative process displays complex and dynamic spa-
tiotemporal molecular profiles, which demonstrate variability
Figure 1. Pathways analysis of conserved overlaps in Muscular Dystrophies. (a) Top canonical pathways bar chart highlighting the main disrupted cascades in
multiple MD subtypes (data from supplementary table 4). By combining data from several proteomic studies we are able to identify pathways such as multiple Rho-
related cascades or ‘Clathrin-mediated endocytosis signalling’ which were not specifically reported to be disrupted in these studies. (b) Network highlighting how
candidates identified in multiple MD proteomic studies interact with other neuronal/neuromuscular diseases. Alzheimer’s, Parkinson’s, Huntington’s and X-linked
hereditary diseases demonstrate similar protein expression alterations suggesting these proteins may be involved in downstream degenerative cascades. (c) Top
identified network in IPA generated from MD candidates. Vimentin (VIM) appears as a central hub of the network impacting to multiple downstream proteins. Lines
in blue indicate VIM interactions with other proteins with a conserved change in multiple datasets. (b–c) All proteins listed in supplementary table 4 were included
in the IPA analysis. Candidates with reported quantitative values in >2 studies and demonstrating consistent alterations (up-/or down-regulation) across >50% of
these studies were considered for the IPA statistical testing. These proteins were assigned an arbitrary fold-change value of +2 or !2 respectively, for the generation
of IPA data. Red = up-regulation; green = down-regulation; grey = proteins not considered for statistical analysis. Dotted lines indicate direct interactions; dashed lines,
indirect interactions. (Full color available online).




























throughout disease progression dependent upon the
upstream genetic mutation. Fluctuations in protein expression
throughout the disease course indicate tissue-specific cas-
cades, with differing biochemical alterations often occurring
in neighboring populations of cells [87]. These varying protein
expression profiles often reflect the vulnerability status of
particular cellular clusters that display an enhanced response
to insult. In order to determine how alterations in protein
expression may modulate cellular and tissue vulnerability, it
is important to track candidate alterations through the time
course of MDs – from early presymptomatic time points to
end-stage disease. There is abundant evidence to suggest that
alterations in causative upstream molecular cascades begin
long before the onset of detectable pathology [84]. From our
own studies, we have observed significant up/downregulation
of numerous proteins during the early stages of disease but at
later time points, protein expression is quite the contrary [87].
Therefore, focusing on the early stages of disease may provide
an enhanced understanding of the molecular mechanisms
governing muscle degeneration and offer a viable data source
for the identification of novel drug targets. Additionally, a
comparison of multiple disease variants (i.e. Duchenne vs.
Becker–Kiener dystrophinopathy) with differing severity may
also offer more tenable insights into potential upstream mod-
erating and/or regulating molecular cascades.
4.1.2. Proteomic techniques
The availability of modern proteomic techniques is beginning
to direct the field away from 2D gels. Tools such as label-free
proteomics as well as labeled approaches including isobaric
tags for relative and/or absolute quantitation (iTRAQ) or tan-
dem mass tagging enable a more comprehensive character-
ization of the molecular alterations occurring throughout
disease progression. Label-free techniques enable compara-
tive analyses of multiple samples with low concentrations of
protein extracts [87,88], which may be beneficial when work-
ing with precious resources such as human patient samples.
These techniques enable analysis with a little as 3–5 µg of
material for injection into an orbitrap. There are of course
limitations with the existing tools such as limited dynamic
range, compression of ratios calculated for tagged samples,
and even something as basic as coverage of the proteome
when compared to more established transcriptomics. Whilst
transcriptomics may be ahead of proteomics in coverage and
usability, it is protein and not RNA which are the ultimate
effector molecules and the two do not necessarily correlate
well [89]. Therefore, continued developments for the field of
proteomics in software (such as Progenesis) that allow the
processing and analysis of complex timecourse profiles and/
or comparisons, facilitate improved methodologies in the MD
field.
4.1.3. Data analysis
Filtering and refining of proteomic data is absolutely essential.
There remains a requirement for laboratories to follow stan-
dardized criteria in order to provide more reliable and com-
parable analyses in publications. For example, posttrans
lational modifications (PTM) and distinct isoforms should be
reported (if known), as they may be a source of contradictions
Figure 2. Experimental design and workflow. Description of the experimental
planning and process ranging from ‘Tissue Sampling’ to ‘Validation’ of the data
produced by proteomic techniques. The combination of the selection of specific
model/muscle type/time-point of disease progression, high-throughput proteo-
mic technique, strict data filtering and unbiased bioinformatics analyses fol-
lowed by validation are basic steps to follow. We encourage future proteomic
studies to consider this workflow in order to produce good quality data to aid in
elucidating the mechanisms regulating muscle degeneration.




























in the data shown. If the technique/software/database for the
identification of protein used is not able to distinguish
between protein isoform/PTM, strict filtering should be
applied to avoid low-quality identifications. The re-reporting
of published data sets without reanalysis has the potential to
propagate erroneous conclusions throughout published litera-
ture within the field. Investigators should also utilize available
software for in silico analyses. These tools enable unbiased
comprehension of the pathways and processes that may be
altered within the samples analyzed. It has become increas-
ingly clear that discrepancies exist in the data reported by
investigators and this affects the outputs from independent
pathway analyses (see Supplementary Tables 2 and 4 and
Figure 1).
5. Five-year perspective on advancements in MD
research
The relatively recent advances in proteomic tools and techni-
ques (as discussed in Section 4), coupled with the broad range
of disparate mutations leading to multiple forms of dystrophy
with varying prevalence, have (to date) severely impeded a
coherent approach to the molecular characterization of the
downstream molecular cascades regulating the vulnerability
of distinct muscle populations and the progression of indivi-
dual disease variants. We have outlined various experimental
obstacles in Section 4, which require attention before con-
ducting proteomic experiments (Figure 2).
There is clearly scope for future work in this area, using
modern approaches such as iTRAQ or label-free MS, to quan-
titatively compare the proteome of MD muscles that show
differential vulnerability. Indeed, recent publications examin-
ing other neurodegenerative conditions such as the childhood
motor neurone disease SMA have taken a concerted proteo-
mic molecular genetic approach to identify regulators path-
ways and therapeutic targets [84]. Here, the authors applied
iTRAQ proteomics to vulnerable neuronal populations in a
SMA murine model to identify differentially expressed pro-
teins. Selected candidates were examined for their ability to
regulate neuronal stability in multiple small animal model
systems including Drosophila and zebrafish before scaling
back up to murine systems providing a complete rescue of
the neuromuscular system. As a result, the authors have pub-
lished the most effective non-survival motor neuron replace-
ment therapy to date. The samples and models exist within
the dystrophy field to allow the replication of such proven
target-rich workflows to be implemented to inform novel
(non-replacement-based) therapeutic interventions for the
dystrophies.
6. Expert commentary
Current proteomic studies regarding inherited MDs are unra-
veling common/specific disrupted pathways in terms of the
molecular constituents altered, but these candidates are not
necessarily altered in a consistent manner due to the nature of
the investigations/experimental design employed. Though
they provide a window for a better understanding of the
process of degeneration, some issues should be addressed in
future work. The development of novel proteomics, such as
label-free techniques, facilitates a more complex experimental
design where factors such as tissue-specific vulnerability and
disease stages may be taken into account. This will allow
researchers to distinguish between early and late responses
of the specific mutations causing MDs and a more accurate
mapping of the dynamic processes taking place in the muscle.
Moreover, the production of animal and cellular models that
faithfully recapitulate the disease phenotype seen in patients
will also help for a more comprehensive characterization of
the molecular changes taking place throughout disease pro-
gression than can later be correlated to human disease. As
there are currently no effective therapeutics for the dystro-
phies, the field is reminiscent of where the SMA field was
10 years ago, i.e. gene replacement therapy is on the extreme
horizon, but the tools and techniques are available to make
some tangible headway into our understanding of the disease
processes underpinning the condition leading to the identifi-
cation of novel potential non-gene replacement therapeutics
along the way [84,87].
Key issues
! Proteomics is a powerful tool for the identification of bio-
markers and therapeutic targets.
! Investigators must endeavour to utilise strict and standar-
dised methodologies for comparison of control and disease
tissues.
! If identified candidates are enzymes or have a role in meta-
bolic processes, ex vivo biochemical or in vivo reporter
assays (in model organisms i.e. Drosophila) should be per-
formed to determine if detection of altered abundance
correlates with altered activity/function.
! Studies should utilise western blotting and immunohisto-
chemical analysis, as well as multiple model organisms for
validation of candidate relevance to human physiological
alterations and to assess their ability to moderate disease
processes in vivo.
! Such candidates should be assessed for their ability to
moderate disease processes in vivo and in multiple organ-
sims (i.e. Drosphila/Zebrafish/Rodents) in order to confirm
relevance in a species/model independent manner.
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Graphs display the temporal expression profiles of the 451 candidates identified by 
the Biolayout Express3D analyses. Schematics were constructed using Python Jupyter 
Notebook. All graphs display the ratio of candidate protein expression against the 
young age. Synaptic mitochondrial temporal protein expression - blue; non-synaptic 

































Graphics demonstrate the presence of polymer smears (indicated by arrows) in the 
young synaptic mitochondrial sample (top) and difficulty with protein identification 









Graphs display the temporal expression profiles of the 583 candidates identified by 
the Biolayout Express3D analyses. Schematics were constructed using Python Jupyter 
Notebook. All graphs display the ratio of candidate protein expression against the 
young age. Hippocampal temporal protein expression - blue; occipital cortex 
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